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The anaplastic lymphoma kinase (ALK) is a single chain transmembrane receptor tyrosine
kinase that belongs to the insulin receptor superfamily. Other members of this superfamily
include the insulin receptor (IR), type I insulin-like growth factor receptor (IGF-IR), and the
leukocyte tyrosine kinase. The common structural finding among these tyrosine kinases is the
YXXXYY motif present within their respective tyrosine kinase domains. Binding of its
ligands causes ALK receptor homodimerization and protein kinase activation. ALK has been
previously shown to play a significant role during early developmental stages. In human
embryos, the expression of ALK is mainly seen in the nervous system but it decreases at
birth. A variety of structural rearrangements have been identified in the ALK gene, such as
mutations, overexpression, and translocations, often leading to the production of oncogenic
proteins found in several different types of human cancers, such as nucleophosmin-anaplastic
lymphoma kinase-expressing anaplastic large-cell lymphoma (NPM-ALK+ ALCL). The
oncogenic potential of NPM-ALK has been demonstrated by several studies using in vitro
assays as well as transgenic mouse models.
NPM-ALK+ ALCL is an aggressive subset of T-cell lymphoma that predominantly occurs
in children and young adults. It comprises approximately 85% of ALK+ ALCL cases and is
characterized by the translocation t(2;5)(p23;q35) that leads to the fusion between the NPM
gene on chromosome 5q35 and the ALK gene on chromosome 2p23 generating the NPMALK oncogene, which encodes the expression of NPM-ALK chimeric tyrosine kinase. NPM-
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ALK induces lymphomagenic effects through the formation of the constitutively activated
NPM-ALK/NPM-ALK homodimers, which phosphorylate/activate downstream survivalpromoting proteins including JAK/STAT, PI3K/AKT, and MAP kinase. NPM-ALK resides
in the cytoplasm; nonetheless, it is also capable of forming the wild type NPM/NPM-ALK
heterodimers that translocate to the nucleus through the nuclear localization signal site
present in wild type NPM.
IGF-IR is a homodimeric protein that is composed of two extracellular α and two
transmembranous β subunits connected by disulfide bonds. Similar to ALK, its expression
plays an important role during early developmental stages. Mouse models have confirmed
the importance of IGF-IR in prenatal and postnatal growth through its interactions with the
growth hormone. The result of activation of IGF-IR during these stages is survival and
proliferation of cells resulting in developmental growth of tissues such as skeletal and cardiac
muscles. It also plays a critical role during growth of the mammary gland during pregnancy
and lactation. It has been previously shown that Igf1r null mice develop generalized organ
hypoplasia, such as developmental delays in bone ossification, abnormalities in the central
nervous system, and they prematurely die because of underdevelopment of their lungs that
leads to respiratory failure. Recently, it has been shown that IGF-IR overexpression
significantly contributes to the establishment and progression of different types of cancer and
to the emergence of therapeutic resistance. These effects have been extensively investigated
in solid tumors including breast, prostate, lung, ovary, skin, and soft tissue cancers.
We have recently demonstrated that, compared with normal human T lymphocytes and
reactive lymphoid tissues, the expression and activation of IGF-IR are remarkably
upregulated in NPM-ALK+ ALCL. We also demonstrated that IGF-IR physically associates
and directly interacts with NPM-ALK. Nonetheless, the exact mechanisms for the up-
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regulation of IGF-IR and NPM-ALK in this lymphoma are not fully characterized. We
hypothesized that multilevel deregulation of survival mechanisms contributes to aberrant
NPM-ALK and IGF-IR expression, which supports the survival and progression of NPMALK+ ALCL.
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1.1. NPM-ALK+ T-cell anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is a high-grade non-Hodgkin’s T-cell lymphoma
that was originally described as universally expressing the tumor necrosis factor receptor
CD30/Ki-1 [1, 2]. Morphological features typically include large anaplastic cells with
abundant cytoplasm and distinct, often “horse-shoe” shaped, nuclei [3]. However, it is agreed
now that ALCL is a misnomer as it is not unusual for this lymphoma to represent in the form
of small lymphoma cells without notable anaplastic features. ALCL constitutes 3 to 5% of
adult malignant lymphomas and comprises 10 to 30% of malignant lymphomas in children
and young adults [3, 4]. The lymphoma is slightly more predominant in males. ALCL usually
presents as a widespread stage III/IV neoplasm, with a rapidly progressive course. It is
considered an aggressive type of lymphoma because patients typically present with B
symptoms (fever, weight loss, and night sweats), generalized lymphadenopathy, and frequent
extranodal involvement [1].
Approximately 60-80% of ALCL cases harbor an aberration involving the anaplastic
lymphoma kinase (ALK) gene that encodes the expression of the ALK protein (ALK+
ALCL). The expression of ALK holds prognostic significance as ALK- ALCL patients show
a much reduced 5-year survival rate compared to ALK+ ALCL patients [5, 6]. Although
several chromosomal translocations involving ALK have been identified in ALK+ ALCL,
approximately 85% of these lymphomas are characterized by the translocation
t(2;5)(p23;q35) that generates the fusion between the NPM gene on chromosome 5q35 to the
ALK gene on 2p23 that forms the oncogenic fusion protein NPM-ALK, which is the defining
feature of NPM-ALK+ ALCL [1, 5-8]. Because NPM-ALK expression is the most common
and because cell lines have been developed only from the NPM-ALK+ variant, in this work
we will refer to this lymphoma as NPM-ALK+ ALCL.
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First-line treatment using doxorubicin-based polychemotherapy is encouraging in some
cases, in which 60-80% of NPM-ALK+ ALCL patients initially respond favorably, with a 5year relapse-free survival of 60%, and a 5-year overall survival of 70% [9, 10].
Anthracycline-based

chemotherapy

regimens,

including

CHOP

(cyclophosphamide,

doxorubicin, vincristine, and prednisone), have also provided favorable results. Radiation or
stem cell transplantation in combination with CHOP is oftentimes utilized in more advanced
cases, in which large localized masses are found [9, 10]. However, as many as 40% of these
patients relapse, develop resistance, and eventually die, suggesting the need for specific and
more effective therapeutics. Recently, selective ALK inhibitors have been developed;
nonetheless, most of these inhibitors have been tested in solid tumors, with the majority
being in lung cancer patients [11-14]. Notably, mutations of ALK have quickly developed in
some of the NPM-ALK+ ALCL patients that were treated with such inhibitors, indicating that
the battle against this aggressive lymphoma is far from over [15, 16].
1.2. NPM
1.2.1. Roles of NPM: NPM is a ubiquitously expressed RNA-binding nucleolar
phosphoprotein that is encoded by chromosome 5q35. It is believed to be involved in
regulating numerous processes that leads to maintaining cellular homeostasis. For instance, it
is involved in the transport of pre-ribosomal particles during ribosome biogenesis, response
to stress stimuli such as UV irradiation and hypoxia, the maintenance of genomic stability
through the control of chromosome segregation, and DNA-repair processes. Furthermore, it
is highly involved in gene transcription where it regulates chromatin condensation and
decondensation events [17].
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1.2.2. Structure of NPM: NPM protein has a molecular weight of approximately 38 kDa. The
numerous functions of NPM are largely attributed to the diversity of its structural
characteristics (Figure 1). The N-terminus contains a hydrophobic segment that is essential
for oligomerization and chaperone activity. Immediately following this segment are two
acidic stretches that are important for binding histones during DNA transcription processes
[17-19]. The ribonuclease activity stems from the middle portion of NPM, the region
between the two acidic domains. Finally, the C-terminal domain contains segments
comprising basic amino acids that are important for nucleic-acid binding. These basic regions
are followed by aromatic stretches, which house two tryptophan residues (288 and 290)
located within the nuclear-localization signal (NLS) that are required for nuclear localization
of the protein [17, 20]. In addition, NPM includes a nuclear-export signal (NES) that
mediates NPM’s ability to shuttle from the nucleus [21].
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FIGURE 1. Structure of NPM. Starting from the N-terminus, the protein contains one
hydrophobic segment that is involved in oligomerization as well as chaperone activity,
followed by two acidic stretches that are important for binding to histones. The central
portion between the two acidic domains is required for ribonuclease activity, together with
the C-terminus domain, which contains basic regions involved in nucleic-acid binding. The
basic clusters are followed by an aromatic stretch, which contains two tryptophan residues
(288 and 290) that are required for nucleolar localization of the protein. In addition, NPM
includes a nuclear-localization signal (NLS) and a nuclear-export signal (NES). Adapted
with permission from Macmillan Publishers Ltd on behalf of Cancer Research UK:
[Nature Reviews Cancer] (Grisendi S, Mecucci C, Falini B, Pandolfi PP.
Nucleophosmin and cancer. Nat Rev Cancer. 2006 Jul;6(7):493-505.), copyright 2006.
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1.3. ALK
1.3.1. Role of ALK: Physiologically, the expression of ALK is largely restricted to neuronal
tissues at early developmental stages, as indicated by the high expression of ALK mRNA in
the central nervous system (CNS) during mouse embryogenesis [22-24]. ALK expression
diminishes after birth, reaching minimal levels at 3 weeks of age, and subsequently
maintained at low levels during adult stages [22]. Based on these observations, it is believed
that ALK is a critical regulator of neuronal development and function of the CNS. For
example, it has been demonstrated that the ALK–IgG Fc hybrid protein, in which the
extracellular region of ALK is substituted with the mouse IgG Fc domain, induces neurite
differentiation and outgrowth of PC12 cells, mediated through the MAPK pathway [25]. In
addition, it has also been demonstrated that specific antibody-mediated inhibition of ALK
leads to prevention of the binding of the Src homology and collagen domain protein (Shc) to
ALK, which causes subsequent MAPK inactivation and decreased neuronal differentiation.
Similarly, inhibition of the ALK-activated MAPK pathway decreases neurite outgrowth,
further strengthening the idea that neuronal differentiation induced by ALK is mediated via
the MAPK pathway [26, 27]. In addition to Shc, the fibroblast growth factor receptor
substrate 2 (FRS2) has also been reported to be recruited to a novel non-consensus
phosphotyrosine site within ALK and contributes to ALK-induced neuronal differentiation
[27].
1.3.2. Structure of ALK: ALK is a receptor tyrosine kinase whose structure is highly
conserved within species, as well as within members of the insulin receptor superfamily,
especially in regards to their kinase domains. The common structural finding among these
tyrosine kinases is the YXXXYY (indicating a tyrosine (Y), followed by 3 non-tyrosine
amino acid residues, and then 2 additional tyrosine residues) motif present within their
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respective tyrosine kinase domains. It has been reported that the first tyrosine residue
(Tyr1278) within the YXXXYY motif is the principal site to become phosphorylated during the
autoactivation process of ALK [28, 29].
The ALK gene is located on chromosome 2p23 that encodes for a single chain
transmembrane receptor tyrosine kinase of 180 kDa (Figure 2). The extracellular portion of
ALK contains an N-terminal signal peptide followed by two MAM domains (meprin, A5
protein and receptor tyrosine phosphatase mu) that flank one LDLa domain (low-density
lipoprotein class A), followed by a glycine rich (G-rich) region. The N-terminus region is
capable of undergoing N-linked glycosylation, which increases the molecular weight of ALK
by 20kDa. Although the precise function of the LDLa domain is unknown, it has been
proposed as the ligand binding domain. Similarly, the function of the MAM domains remains
to be identified, however, they are thought to be involved in cell-to-cell interactions [30]. In
addition, the G-rich domains are believed to be required for ALK function, as point
mutations within this region render loss of ALK function [31]. The intracellular domain
(ICD) consists of a transmembrane (TM)-spanning segment that essentially connects the
extracellular region to the PTK domain; the ICD also contains ATP binding sites and putative
binding sites for various interacting proteins including insulin receptor substrate 1 (IRS-1),
Shc, phosphoinositide 3-kinase (PI3K) and phosphoinositide phospholipase C-gamma (PLCγ) distributed throughout [22, 23, 32].
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FIGURE 2. Structure of human ALK. The N-terminal region of ALK comprises two
MAM domains (amino acids 264–427 and 480–626), one LDLa domain (amino acids 453–
471), and a glycine rich (G-rich) region (amino acids 816–940). A transmembrane (TM)spanning segment connects the extracellular region with the protein tyrosine kinase domain containing intracellular region (amino acids 1116–1383). Adapted with permission from
PMC [Biochemical Journal] (Palmer RH, Vernersson E, Grabbe C, Hallberg B.
Anaplastic lymphoma kinase:signalling in development and disease. Biochem J. 2009
May 27;420(3):345-61.), copyright 2009.
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1.3.3. ALK and disease: Alterations involving ALK have been implicated in various diseases,
with the initial discovery of the NPM-ALK fusion protein in NPM-ALK+ ALCL in 1994 [33,
34]. In addition to NPM-ALK, other ALK fusion proteins have been identified in ALCL,
inflammatory myofibroblastic tumors, non-small cell lung cancer, diffuse large B-cell
lymphoma, and squamous cell carcinoma [35-38]. Recently, overexpression of ALK has
been reported to play a role in malignant transformation of cell lines and tumors, as well as
activating point mutations in ALK, as in the case of neuroblastoma [39-49].

1.4. NPM-ALK
1.4.1. NPM-ALK structure and function: The most distinguishable feature in NPM-ALK+
ALCL is the presence of the translocation t(2;5)(p23;q35) that generates the fusion between
the NPM gene on chromosome 5q35 to the ALK gene on 2p23 to form the chimeric oncogene
NPM-ALK, that encodes for NPM-ALK fusion protein [7] (Figure 3; upper panel). The
t(2;5)(p23;q35) translocation juxtaposes the N-terminal domain of the NPM gene (amino
acids 1-117) to the C-terminal domain of the ALK gene that codes for the entire cytoplasmic
region of the ALK protein. As a consequence, the ALK gene is under the control of the highly
active NPM promoter, which induces continual transcription of NPM-ALK gene and results
in the silencing of the ALK regulatory and promoter regions that normally suppress ALK
expression in normal lymphocytes. This leads to the constitutive activation of the NPM-ALK
protein because the oligomerization domain of NPM and activation of the kinase catalytic
domain of ALK are preserved.

Because the truncation of NPM during the translocation does not conserve its C-terminal
domain, the nuclear localization signals are absent in the chimeric protein. Similarly, the
extracellular and transmembrane regions of ALK are also not present, thereby rendering
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ALK entirely cytoplasmic. The NPM-ALK protein is able to form homodimers with other
NPM-ALK moieties or heterodimers by cross-linking with wild-type NPM. The formation of
homodimers results in the constitutive activation of the ALK tyrosine kinase domain
contained in the NPM-ALK fusion protein and the induction of downstream signaling via the
JAK/STAT3, MEK/ERK1/2, or the PI3K/AKT pathways (detailed in section 1.4.2). The
NPM/NPM-ALK heterodimers, on the other hand, translocate to the nucleus, primarily from
the ability of wild type NPM to translocate to the nucleus (Figure 3; lower panel). There is
considerable evidence suggesting that the nuclear localization of NPM-ALK is not required
for the development of lymphoma, and therefore, the biological consequences of nuclear
localization of NPM-ALK are not known [50, 51]. However, the importance of NPM in the
transforming abilities of NPM-ALK has been demonstrated through experiments in which
deletion of the NPM portion of the fusion protein abolishes transformation events; the
process of dimerization through NPM oligomerization domain essentially mimics ligand
binding and therefore, gives NPM-ALK its transforming abilities [52].

The oncogenic properties of NPM-ALK have been demonstrated in vitro in a variety of
cell types, such as mouse NIH-3T3 and Fr3T3, as well as Rat-1 cells, and several
hematopoietic cell lines such as the myeloid line 32Dcl3 and the lymphocytic cell line Ba/F3
[50-54]. Transformation occurs in primary mouse bone marrow cells retrovirally transduced
with NPM-ALK, which was reversed upon treatment with PI3K inhibitors [54]. In addition,
cells transfected with NPM-ALK are able to grow colonies in soft-agar, providing further
support for the transforming abilities of NPM-ALK. These properties have also been
demonstrated in vivo. For example, bone marrow expressing human NPM-ALK is able to
induce lymphoid malignancies in lethally irradiated mice [53, 55]. Furthermore, transgenic
mice expressing NPM-ALK under the control of the CD4 promoter develop CD30+ NPM-
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ALK+ T-cell lymphoma [56]. Of important note is that in all NPM-ALK transgenic mouse
models, significant numbers of tumors were plasma cell or B-cell neoplasms, strongly
suggesting that NPM-ALK is not the only factor contributing to the immunophenotypic,
pathophysiological, and clinical features as known in humans.
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FIGURE 3. The t(2;5)(p23;q35) translocation resulting in NPM-ALK fusion protein.
Upper panel, the t(2;5)(p23;q35) translocation juxtaposes the N-terminal domain of the NPM
gene (amino acids 1-117) to the C-terminal domain of the ALK gene that encodes the entire
cytoplasmic region of the ALK protein. The NPM-ALK fusion protein retains the
oligomerization domain with the metal binding region of NPM and the tyrosine kinase
domain and the cytoplasmic tail of ALK. Reprinted from Anaplastic Lymphoma Kinase:
Role in specific tumours, and development of small molecule inhibitors for cancer
therapy: Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic
Lymphoma Kinase: role in specific tumours, and development of small molecule
inhibitors for cancer therapy. Cancer Lett. 2010 Dec 28;299(2):81-94., with permission
from Elsevier. Lower panel, NPM-ALK is able to form homodimers with other NPM-ALK
moieties in the cytoplasm as well as heterodimers with wild type NPM that allow ALK to
translocate to the nucleus.
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1.4.2. NPM-ALK signaling: The predominant signaling system in the cell survival
mechanisms maintained by NPM-ALK is the signal transducer and activator of transcription
3 (STAT3) pathway either through Janus kinase-3 (JAK3)-dependent or independent
mechanisms [57-59]. NPM-ALK can directly phosphorylate STAT3 [60, 61] and/or activate
JAK3, which subsequently activates STAT3 [62] (Figure 4). Under normal circumstances,
the SH2-containing ubiquitously expressed tyrosine-specific protein phosphatase-1 (SHP1)
functions to inhibit ALK-mediated signaling by dephosphorylating ALK or its interacting
proteins, namely Src and JAK. In NPM-ALK+ ALCL, SHP1 is methylated, and therefore
loses its expression, resulting in the enhancement of STAT3 signaling. Phosphorylated
STAT3, in turn, translocates to the nucleus and up-regulates the expression of molecules
involved in anti-apoptotic mechanisms such as B cell leukemia/lymphoma 2 (Bcl-2), Bcl-xL,
and myeloid cell leukemia sequence 1 (Mcl-1), or key cell cycle regulators such as survivin,
cyclin D3, and C/EBPβ [58, 63, 64]. We have also demonstrated previously that STAT3
plays a direct role in upregulating the tissue inhibitor of metalloproteinase-1 (TIMP1) in
ALK+ ALCL, and that expression of TIMP1 is associated with high level of STAT3
activation in this disease [65]. Also, there has been evidence that STAT5, particularly
STAT5b, may act promote survival in NPM-ALK+ ALCL through the activation of JAK2
[66, 67]. In vitro and in vivo studies using anti-STAT5b inhibitors resulted in impairment of
NPM-ALK-induced cell transformation by inducing apoptosis. In contrast, it has also been
shown that STAT5a is epigenetically silenced in this lymphoma [68]. In this regard, STAT5a
acts as a tumor suppressor by reciprocally inhibiting NPM-ALK expression.
NPM-ALK also exerts proliferation signals through the activation of Ras, Raf-1,
MEK1/2, and ERK1/2 by the direct binding of IRS-1, Src, and Shc to the autophosphorylated
tyrosine residues located in the substrate-binding domain of ALK [7, 52] (Figure 4). This
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induces the interaction between the SHP2-Grb2 (growth factor receptor-bound protein 2) and
the ALK/Shc complex, which in turn enhances the phosphorylation of ERK1 and ERK2
through Src. Phosphorylation of ERK1 and ERK2 leads to the phosphorylation of the
mammalian target of rapamycin (mTOR), which stimulates protein translation, ribosome
biogenesis, and cap-dependent translation of mRNA [69]. In addition, NPM-ALK
phosphorylates JUN N-terminal kinase (JNK) that up-regulates the activity of certain
oncogenic transcription factors, such as AP1, which leads to uncontrolled proliferation due to
repression of p21 and subsequent upregulation of cyclins [70]. Lastly, PLC-γ directly binds
to ALK, catalyzes the conversion of diacylglycerol and inositol triphosphate, triggering the
release of Ca2+ from the endoplasmic reticulum (ER) to activate protein kinase C, leading to
cell cycle progression [54].
Survival signaling can also occur through the PI3K/AKT pathway primarily by eliciting
anti-apoptotic signals by NPM-ALK (Figure 4). NPM-ALK activates PI3K, which in turn
activates the serine/threonine kinase, AKT, and results in the enhancement of survival signals
by phosphorylating the cyclin-dependent kinase inhibitor p27 and increasing its proteosomal
degradation [71]. Activation of AKT also results in inhibition of the function of pro-apoptotic
proteins such as Bcl-2 antagonist of cell death (BAD) [72]. Concurrently, activated AKT
phosphorylates and deactivates the FOXO3a transcription factor, which sustains FOXO3a in
the cytoplasm, preventing its translocation to the nucleus and subsequent transcription of proapoptotic and cell cycle inhibitory genes [73]. This also leads to upregulation of cyclin D2,
which is involved in G1-S cell cycle progression. Furthermore, mTOR is also activated by
PI3K/AKT signaling through the induction of sonic hedgehog (SHH) expression. Binding of
SHH to its receptor, Patched (PTCH), activates Smoothened (SMO) co-receptor by Patched,
which results in activation of the GLI1 transcription factor and subsequently cyclin D2 [74].
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FIGURE 4. NPM-ALK and its downstream signaling pathways. The NPM-ALK fusion
protein is aberrantly expressed and activates canonical signaling pathways, including
Ras/Mek/Erk and PI3K/Akt cascades. The STAT3 signaling pathway has a central role in
NPM-ALK–mediated transformation. Adapted from Pathobiology of ALK+ anaplastic
large-cell lymphoma: Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell
lymphoma. Blood.2007 Oct 1;110(7):2259-67., Copyright 2007, with direct permission
from BLOOD.
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1.5. Overview of the insulin-like growth factor system
The insulin–like growth factor (IGF) system plays significant roles in both embryonic and
postnatal development as well as important functions in normal adult physiology. The IGF
system includes 4 receptors: insulin receptor (IR), type I insulin-like growth factor receptor
(IGF-IR), IGF-IIR, and the hybrid receptors (HR) consisting of one-half IR and one-half
IGF-IR. These receptors interact with at least three ligands: insulin, IGF-I, and IGF-II
(Figure 5). The IR, IGF-IR, and IGF-IIR have strongest binding affinity for their respective
ligand, whereas binding of insulin to IGF-IR and IGF-I to IR are approximately 100-fold
less. IGF-I and IGF-II signaling is mediated through IGF-IR; however, IGF-I has a 4-5-fold
higher binding affinity. The IGF system also includes 6 regulatory proteins known as IGF
binding proteins that regulate IGF signaling [75].
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FIGURE 5. Overview of IGF system. The IGF system consists of 4 receptors: IR, IGF-IR,
IGF-IIR, and HR. These receptors interact with at least three ligands: insulin, IGF-1, and
IGF-II. In addition, the IGF system also includes 6 regulatory proteins called IGF binding
proteins that regulate IGF signaling.
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1.6. IGF-I
IGF-I is a single chain peptide that shares 62% homology with IGF-II and 40% homology
with proinsulin [75]. Evidence shows that IGF-I is synthesized in a variety of tissues and
cultured cell types, suggesting that the protein may have autocrine and paracrine effector
functions, unlike insulin, which is stored within cells of a particular tissue (pancreas) and has
mainly autocrine effects [76-80]. Liver secretion of IGF-I is regulated by the growth
hormone (GH), which signals peripheral tissues to grow, whereas insulin is tightly regulated
by glucose uptake [79, 81, 82]. Therefore, insulin is primarily associated with inducing
metabolic effects, whereas IGF-I is essentially a growth factor and an anabolic agent.
IGF-I is the primary ligand for IGF-IR. There is increasing evidence that IGF-I might
provide a major link between IGF-IR and the development of cancers through its regulatory
effects on normal cell proliferation, differentiation, and apoptosis. Although most cancers do
not secrete IGF-I, high concentrations of circulating IGF-I in serum appear to contribute to
the growth, maintenance, and progression of cancers of the breast, lung, and colon [83-87].
For example, previous studies have demonstrated that colonic epithelium in acromegalic
patients is characterized by increased proliferation that is proportional to serum IGF-I levels
[88]. Also, in vitro and in vivo experiments showed that prostate cancer is mitogenically
responsive to IGF-I [84]. Several mouse models have shown reduced proliferation of
androgen-dependent prostate cancer cells in IGF-I deficient hosts relative to control hosts,
testifying to the strong mitogenic properties of IGF-I [89].
IGF-I appears to tightly control both positive and negative regulators of the cell cycle
primarily through the interaction with IGF-IR. It has been previously documented that IGF-I
increases cell proliferation by amplifying DNA synthesis and upregulating cyclin D1 mRNA
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expression, which allows entry into the S phase of the cell cycle. Using skeletal myoblasts, it
was demonstrated that the early effects of IGF-I during cell cycle progression are associated
with the stabilization of Rb1 phosphorylation, which is typical of proliferating cells.
Subsequently, upregulation of CDK4 and cyclin D1 gene expression further maintains Rb1
phosphorylation [83]. In another study using neocortical neural progenitor cells, in vitro
addition of IGF-I induced rapid increase in cyclin D1 and cyclin D3. This led to a further
increase in cyclin E, which also assists in the G1/S phase transition. Simultaneously,
observed decrease in CDK inhibitors p27 and p57 suggested that downregulation of negative
regulators of cell cycle also contributes to the mitogenesis induced by IGF-I. These effects
were further demonstrated in vivo, where injection of IGF-I led to increased DNA synthesis
and number of S phase cells, with simultaneous increase in phosphorylated/activated AKT,
cyclin D1, and cyclin E [90]. Endogenous blockade of IGF-I with an anti-IGF-I antibody led
to decreased DNA synthesis, upregulation of p27 and p57, as well as prevention of cyclin E
mRNA expression. Interestingly, it has been demonstrated that the effects exerted by IGF-I
are primarily induced through the PI3K/Akt pathway. Blocking this pathway, but not the
MAPK/Erk pathway, inhibited the mitogenic potential of IGF-I [90]. These data suggest that
the strong mitogenic potential of IGF-I is essentially mediated through IGF-IR.
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1.7. IGF-IR

1.7.1. IGF-IR structure and signaling: IGF-IR is a receptor tyrosine kinase consisting of two
identical α subunits and two identical β subunits that are connected by disulfide bonds to
form the functional homodimeric receptor complex. The α subunit is entirely extracellular
and contains a cysteine rich domain that forms the primary binding site for its ligands IGF-I
and, to a lesser affinity, IGF-II and insulin. The β subunit includes an extracellular domain, a
24-residue hydrophobic transmembrane domain, and a larger cytoplasmic region that shares
84% homology with the IR [91, 92]. Tyrosine 950 is the binding site for its substrates, IRS-1
and Shc, among others. The intracellular region of the β subunit contains an ATP binding site
at lysine 1003. It also contains a kinase domain encompassing the activation loop made up of
three critical tyrosine residues at positions 1131, 1135, and 1136 (form part of the YXXXYY
moiety), which become phosphorylated upon ligand binding. Residue 1136 is particularly
important in that it maintains the conformational stability of the β subunit. The C-terminus
domain contains several tyrosine and serine residues that are phosphorylated to probably
induce mitogenic effects, but how they actually contribute to normal and malignant IGF-IR
signaling is still not fully understood [92] (Figure 6).

Binding of IGF-IR to its ligands causes the phosphorylation of tyrosine residues located
in the intracellular portion of its β subunit. Once phosphorylated, tyrosine 950 provides a
docking site for its substrates IRS-1-4 and Shc proteins. Upon substrate binding, downstream
signaling is activated through PI3K/AKT, MAPK or STAT pathways and may stimulate
cancer cell growth in an autocrine/paracrine manner [93-95] (Figure 7).
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FIGURE 6. Structure of IGF-IR. IGF-IR is a transmembrane homodimeric receptor
tyrosine kinase that is composed of two identical extracellular α subunits and two identical
transmembranous β subunits connected by disulfide bridges. The α subunit contains a
cysteine rich domain where the ligand binds. The cytoplasmic regions of the β subunits
contain residues involved in the activation of IGF-IR. Y950 is the binding site for its primary
substrates IRS-1 and Shc; K1003 is the ATP binding domain; and Y1131, Y1135, and Y1136
make up the activation loop of the kinase domain, which is followed by the C-terminus.
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FIGURE 7. IGF-IR signaling. Binding of IGF-IR to its ligands causes the phosphorylation
of tyrosine residues present in the intracellular portion of its β subunit. Once phosphorylated,
Y950 provides a docking site for its substrates IRS-1-4 and Shc domain protein. Upon
substrate binding, downstream signaling is activated through PI3K/AKT, MAPK, or
JAK/STAT pathways. Adapted from Kojima S, Inahara M, Suzuki H, Ichikawa T,
Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int
J Urol. 2009 Feb;16(2):161-7. Copyright 2008 by JOHN WILEY AND SONS.
Reproduced with permission of JOHN WILEY AND SONS in the format Dissertation
via Copyright Clearance Center.
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1.7.2. Physiological and pathological roles of IGF-IR: Mouse models have signified the
importance of IGF-IR in prenatal and postnatal growth, especially in regards to genetic
imprinting. The outcome of activation of IGF-IR during these stages is survival and
proliferation of mitosis-competent cells resulting in growth of tissues such as skeletal and
cardiac muscles [76, 80, 96-99]. IGF-IR also plays roles related to the growth of mammary
gland during pregnancy and lactation. It has been previously shown that Igf1r null mice
develop generalized organ hypoplasia, including developmental delays in bone ossification
and abnormalities in the central nervous system [76, 80, 100-103]. During embryonic
development, the IGF-IR pathway is also involved in the development of limb buds. Mice
lacking the entire Igf1r gene typically exhibit dramatic reduction in body mass, testifying to
the strong growth-promoting effect of this receptor, and they die at birth due to severe
respiratory failure [100]. Mice carrying only one functional copy of Igf1r are normal, but
demonstrate ~45% decrease in their body mass [100].
Aberrant activation of the IGF-IR pathway is also strongly associated with initiating
cancer growth [86, 93, 96, 104-115]. Evidence in the last 20 years has emerged to support
that IGF-IR overexpression plays a significant role in the development and progression of
tumors, metastatic potential, and resistance to therapies. Studies have shown that IGF-IR
induces its oncogenic effects through the inhibition of apoptosis and induction of
transformation, metastasis, and angiogenesis. Moreso, it has been documented that IGF-IR
can induce ligand-independent tumor cell progression, a process that is highly reliant on the
level of expression of IGF-IR that deems it as constitutively active. In other words, exceeding
a certain threshold for IGF-IR expression results in the lack of need for exogenous ligand
stimulation. For example, treatment of RM11A cells (a murine breast cancer cell line with
high levels of IGF-IR) with exogenous IGF-I, IGF-II or serum did not enhance the
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proliferative/survival advantage [116]. On the other hand, the ability of RM11A cells
expressing low levels of IGF-IR to respond to IGF stimulation was found to be robust, most
likely to be due to the activation of the endogenous murine IGF-IR. Therefore, it was
proposed that high expression of IGF-IR results in constitutive activation of the IGF-IR
independent of the presence of ligands [116]. In addition, autoactivation of IGF-IR, when
expressed at sufficient levels, has previously been shown in cells lacking IGF-IR that have
been transfected with different levels of IGF-IR [117]. Furthermore, IGF-IR regulates
properties that cause the malignant cells to overcome anchorage-independent growth,
allowing them to acquire characteristics directly relevant to enduring detachment and
migration that are essential attributes for metastasis [118].
It has been shown that the number of IGF-IR molecules present in cells plays a key role
in its transforming properties [117, 119]. In fibroblasts, IGF-IR number needs to be greater
than 20,000 receptors per cell to enable mitogenesis after stimulation with IGF-I. Similarly,
in a pancreatic cell line, the observed increase in receptor number from 40,000 to 100,000
receptors/cell is in the range required to enable IGF-I-stimulated growth and therefore may
be of central importance for pancreatic tumor growth. Based on these findings, it is
concluded that only a small increment in the number of receptors per cell can induce the
transforming properties of IGF-IR in different types of tumors [117, 119].
In solid tumors, some studies for the role of the IGF system have been performed using
breast cancer cell lines, and found that one of the mechanisms that IGF-IR was activated both
in vitro and in vivo was through IGF-I: 1) serum IGF-I may act as a stimulatory molecule to
induce the proliferation of breast cancer cells in an endocrine manner and/or 2) stromal cells
that surround the tumorigenic cells serve as a paracrine stimulator of the mitogenic signal
[110, 120-123]. It has been demonstrated that there is hindrance of cell proliferation by
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cancer cells when IGF-IR activation is inhibited. One possible mechanism is the lack of
interaction of IGF-I with IGF-IR, which results in interrupting the signaling pathway. In
prostate cancer, IGF-I is believed to directly stimulate the androgen receptor (AR) via
crosstalk with IGF-IR on prostatic epithelial cells to induce its pathogenesis, progression, and
metastasis [124]. Similarly, the oncogenic effects of IGF-IR are documented in colon cancer.
IGF-IR is overexpressed in colon cancer, compared to normal colonic mucosa and IGFs in
colonic malignant mucosa are shown to exert their effects via the IGF-IR only [88, 114].
In contrast to the widely studied solid tumors, not many studies have been performed to
examine the role of IGF-IR in hematological neoplasms, and most of the studies have
focused on plasma cell myeloma [125, 126]. In addition, our lab has demonstrated the
contributions of IGF-IR signaling to the pathogenesis of other hematological neoplasms
including mantle cell lymphoma and chronic myeloid leukemia [127-130].
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Rationale, Hypothesis, and Specific Aims
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The scope of this project is to further current understanding of the pathobiology of NPMALK+ ALCL. Our findings may provide a framework that could be useful to tailor novel
selective and specific therapeutic strategies for NPM-ALK+ ALCL.
There has been substantial evidence supporting the importance of NPM-ALK in the
pathogenesis of NPM-ALK+ ALCL, highlighted in section 1.4.1. Oncogeneic effects are
induced by NPM-ALK interaction with several proteins that regulate cell survival and growth
[131]. Notably, the mechanisms leading to NPM-ALK overexpression and activation in this
neoplasm are still unclear. In this regard, we have recently shown that NPM-ALK is posttranscriptionally regulated by microRNA-96 [132].
Previous experiments performed in our lab demonstrated that IGF-IR is overexpressed in
NPM-ALK+ ALCL cell lines and primary tumors than normal human T lymphocytes and
reactive lymphoid tissues, which provide preliminary findings for this project [128] (Figure
8). Moreover, we found that novel reciprocal functional interactions exist between IGF-IR
and NPM-ALK. Our previous results suggest that the two kinases physically associate to
maintain their tyrosine phosphorylation and kinase activation levels. We demonstrated that
IGF-IR and NPM-ALK directly interact through a positive feedback loop that appears to
exist between NPM-ALK and IGF-IR through specific tyrosine (Y) residues, Y644 or Y664,
located within the C terminus of NPM-ALK that maintains NPM-ALK phosphorylation
status. A single mutation within Y644 or Y664 that changes these residues to phenylalanine
decreased substantially the association between IGF-IR and NPM-ALK and phosphorylation
levels, although not entirely [128] (Figure 9). Generation of a double mutation, NPMALKY644,664F, completely eliminated the association between IGF-IR and NPM-ALK, which
provides strong evidence to support a direct role of IGF-IR in maintaining the
phosphorylation status of NPM-ALK for the latter to subsequently activate/phosphorylate
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downstream proteins [113]. In addition, we have shown that IGF-IR can also maintain NPMALK protein stability; because specific targeting of IGF-IR by siRNA significantly decreased
NPM-ALK basal protein levels [127]. Based on its dual influence on NPM-ALK
phosphorylation and stability, IGF-IR most likely represents an important survival entity in
this lymphoma.
Reciprocally, NPM-ALK appears to play a crucial role in maintaining the
phosphorylation of IGF-IR at Y1131, and thereby sustains its downstream signaling. In
support of this idea, specific targeting of NPM-ALK by siRNA decreased IGF-IR
phosphorylation significantly [128]. However, NPM-ALK does not appear to contribute to
IGF-IR protein stability. Specific targeting of NPM-ALK by siRNA resulted in substantial
decrease of NPM-ALK protein, but changes in IGF-IR mRNA or protein expressions were
not observed, even over prolonged periods of time. These important observations suggest that
NPM-ALK does not contribute to IGF-IR overexpression, but mainly to its phosphorylation
and downstream signaling process [113] (Figure 10).
Because the mechanisms underlying the survival of NPM-ALK+ ALCL are not
completely understood, we hypothesized that multilevel deregulated mechanisms contribute
to aberrant expression of IGF-IR and NPM-ALK, which enhances the survival potential of
this aggressive lymphoma. To test this hypothesis, the following set of specific aims were
performed:
Specific Aim 1: Transcriptional regulation of IGF-IR.
a. Transcription factors: We identified novel transcription factors that regulate the
expression of IGF-IR and test their biological significance in NPM-ALK+ ALCL.
b. Gene amplification: IGF-IR gene amplification has been observed in different
types of cancers including malignant melanoma and breast and pancreatic
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cancers. We examined whether IGF-IR gene amplification exists in NPM-ALK+
ALCL.
Specific Aim 2: Posttranscriptional regulation of IGF-IR.
a. MicroRNA: We identified potential deregulated microRNAs that contribute to
IGF-IR upregulation and test their biological significance in NPM-ALK+ ALCL.
b. RNA stability: We tested whether IGF-IR mRNA decay rate contributes to upregulation of IGF-IR expression in NPM-ALK+ ALCL.
Specific Aim 3: Posttranslational regulation of NPM-ALK and IGF-IR.
a. SUMOylation:

We

examined

whether

SUMOylation

contributes

to

posttranslational stabilization of IGF-IR and NPM-ALK in NPM-ALK+ ALCL.
b. Deregulation of IGF-I: We examined whether NPM-ALK potentiates IGF-IR
signaling via upregulation of IGF-I expression.
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FIGURE 8. Expression of IGF-IR in NPM-ALK+ ALCL cell lines. Upper panel, WB
studies showed overexpression of IGF-IR protein in NPM-ALK+ ALCL cell lines. R− and P6
cell lines were used as negative and positive controls for the expression of IGF-IR,
respectively. It is important to note that the overexpression of IGF-IR in P6 cells has been
artificially over-induced and does not represent a physiologic level. RT-PCR shows the
presence of IGF-IR mRNA in the NPM-ALK+ ALCL cell lines as well as in the P6 cell line.
Although IGF-IRα mRNA is not detectable in R− cells, these cells appear to express very low
levels of IGF-IRβ mRNA. Quantitative flow cytometric analysis shows that the NPMALK+ ALCL cell lines express significantly higher levels of IGF-IR compared with normal
human T lymphocytes. Using flow cytometry, the estimated numbers of IGF-IR
molecules/cell are shown to be much more abundant in NPM-ALK+ ALCL cell lines
compared with normal human T-cells. Lower panel, immunohistochemical staining of ALK+
ALCL patient specimens illustrates that 89% and 86% of patient samples were positive for
IGF-IR and pIGF-IR expression, respectively. Patients 1 and 2 represent positive cases, and
patient 3 represents a negative case. Karpas 299 and R- were used as positive and negative
controls, respectively. Adapted by direct permission from BLOOD (Shi P, Lai R, Lin Q,
Iqbal AS, Young LC, Kwak LW, Ford RJ, Amin HM. IGF-IR tyrosine kinase interacts
with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell
lymphoma cells. Blood. 2009 Jul 9;114(2):360-70.), copyright 2009.
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FIGURE 9. Association and functional interactions between NPM-ALK and IGF-IR.
Upper panel, NPM-ALK and IGF-IR are physically associated through Y644 and Y664 of
NPM-ALK and Y950 of IGF-IR. Through this association, the phosphorylation and tyrosine
kinase activity of the two oncogenic proteins are maintained at high levels, and this leads to
up-regulation of the phosphorylation of the common downstream targets including STAT3,
AKT, and ERK. Such effects enhance the transformation, proliferation, and migration of
NPM-ALK+ T-cell lymphoma cells. In addition, the physical association between NPM-ALK
and IGF-IR, in the presence of Hsp90 (not shown), appears to sustain the stability of NPMALK protein. Lower panel, specific targeting of IGF-IR by siRNA significantly decreased
NPM-ALK protein expression levels over prolonged time; densitometric analysis of the IGFIR:β-actin and NPM-ALK:β-actin ratios are shown below the WB. Adapted with
permission from PMC [Neoplasia] (Shi B, Vishwamitra D, Granda JG, Whitton T, Shi
P, Amin HM. Molecular and functional characterizations of the association and
interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulinlike growth factor receptor. Neoplasia. 2013 Jun;15(6):669-83.), copyright 2013.
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FIGURE 10. NPM-ALK does not regulate IGF-IR expression. Upper panel, specific
targeting of NPM-ALK by siRNA significantly decreased NPM-ALK protein expression, but
changes in IGF-IR protein expression were not observed even after 96 h. Lower panel, no
change in IGF-IR mRNA expression was observed after sufficient knockdown of NPM-ALK
by siRNA.
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3.1. Transcriptional Regulation of IGF-IR
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3.1.1. Introduction
Deregulated expression, activation or inactivation of transcription factors plays critical roles
in tumorigenesis. Additionally, signaling via major oncogenic pathways is tightly controlled
through transcription factors that have the ability to regulate the expression of target genes
that are directly relevant to the corresponding oncogenic pathways, resulting in either
induction or inhibition of tumor formation and progression. Under physiological conditions,
genes are regulated by specific upstream transcriptional regulators, whereas in cancer cells,
aberrant activation or inactivation of these transcription factors leads to deregulated
expression of oncogenes or tumor suppressor genes that affect tumor development and
progression. Only a few transcription factors have been shown to bind the IGF-IR gene
promoter (15q26.3) and modulate its activity through stimulation or inhibition. These
transcription factors include Sp1, WT1, E2F1, STAT1, and EGR-1 [26-34].
Gene amplification is indicative of a copy number increase of a particular segment on a
chromosome. It is prevalent in some tumors and is associated with overexpression of the
amplified genes. The presence of IGF-IR gene amplification and its clinical relevance has
been investigated in a limited number of solid cancers including breast, lung, and
gastrointestinal stromal tumors (GISTs) [133-139]. Of these cancers, gene amplification was
detected only in small subgroups of patients with non-small cell lung cancer and GISTs
[134]. IGF-IR amplification correlated positively with high IGF-IR protein expression and
lymph node metastasis.
In this aim, we examined whether increased IGF-IR expression in NPM-ALK+ ALCL
may be explained by transcriptional aberrancies, such as deregulated transcription factors
and/or IGF-IR gene amplification.
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The following section is published in Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick
GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate
IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer. [accepted].
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3.1.2.1. Materials and Methods
Web-based transcription factor search algorithms – To identify transcription factors that
potentially bind the human IGF-IR gene promoter, 3 web-based transcription factor search
algorithms

were

searched:

Genomatix

(www.genomatix.de/),

(http://www.gene-regulation.com/pub/programs.html),

and

TFSearch

and
(we

MATCH
used

this

transcription factor search algorithm when we initiated the study, but we noticed that now it
has been removed and the website is not available for online support. Importantly, the
findings we obtained from TFSearch matched exactly the findings gathered from Genomatix
and MATCH).
Cell lines – Five NPM-ALK+ ALCL cell lines were used in this study: Karpas 299, SUP-M2,
SR-786, DEL, and SU-DHL-1 (DSMZ, Braunschweig, Germany). The R- cell line (mouse
3T3-like fibroblasts with targeted ablation of Igf1r gene; gift from Dr. Renato Baserga,
Thomas Jefferson University, Philadelphia, PA) was used as the host cell line for luciferase
assay studies (8). Normal human peripheral blood CD3+ pan-T lymphocytes were used in
some experiments (catalog number: PB009-1F; StemCell Technologies, Vancouver, BC,
Canada). In addition, Jurkat cells (ATCC, Manassas, VA) were used as a positive control for
the expression of Ik-1 and MZF1 [140, 141]. The T lymphocytes as well as the Jurkat and
NPM-ALK+ ALCL cell lines were maintained in Roswell Park Memorial Institute (RPMI)
1640 medium supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO),
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37°C in
humidified air with 5% CO2. Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% FBS was used to culture the R- under the same conditions.
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Antibodies – The following antibodies were used: pIGF-IRY1131 (3021), pALKY1604 (Y664 in
NPM-ALK; 3341), pAKTS473 (4051), and Ikaros (5443) (Cell Signaling Technology,
Danvers, MA); IRS-1 (ab40777), AKT (ab8805), NPM (ab52644), and MZF1 (ab64866)
(Abcam, Cambridge, MA); IGF-IR (396700; Life Technologies, Grand Island, NY); pIRS1S639 (sc-22300; Santa Cruz Biotechnology, Santa Cruz, CA); ALK (M719501-2; Dako,
Carpinteria, CA); c-Myc (631206, Clontech Laboratories, Mountain View, CA); IGF-I (05172; Millipore, Billerica, MA); and β-actin (A-5316; Sigma).
Western blotting – Cells were lysed using lysis buffer containing 25 mM HEPES (pH 7.7),
400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM PMSF, 2 mM
DTT, and phosphatase and protease inhibitor cocktails (Thermo Scientific, Rockford, IL).
Protein concentrations were measured using the Bio-Rad protein assay, and optical density
values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT).
Proteins (50 μg) were resolved by electrophoresis on 8% SDS-PAGE and then transferred to
PVDF membranes and probed with specific primary antibodies and then with appropriate
horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Waukesha, WI).
Proteins were detected using a chemiluminescence-based kit (Amersham Life Sciences,
Arlington Heights, IL).
In addition, a commercially available kit (Qproteome Tissue Kit, Qiagen, Valencia, CA)
was used to perform Western blot assay to measure Ik-1 and MZF1 protein levels in
formalin-fixed and paraffin-embedded (FFPE) tissue sections from NPM-ALK+ ALCL
patients (approval of the Institutional Review Board was obtained prior to performing human
tissue analysis). Briefly, tissue sections mounted on glass slides were examined and tumor
areas were identified and marked. Next, sections were deparaffinized, and tumor areas were
excised from the slides and transferred into 1.5-mL collection tubes. β-Mercaptoethanol (6
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µL) was admixed with the provided Extraction Buffer EXB Plus (94 μL) and then added to
the excised tissues. Tissue tubes were incubated on ice for 5 min and then the contents were
mixed by vortexing and incubated on a heating block at 100°C for 20 min. Using an oven
with rotators, samples were incubated at 80°C for 2 h with agitation at 750 rpm. After
incubation, tubes were cooled at 4°C for 1 min. The samples were centrifuged for 15 min at
14,000 g at 4°C. The supernatant containing the extracted proteins was collected. For
quantification of protein yield, the Bio-Rad assay was used as described above.
RNA extraction, cDNA synthesis, and relative quantitative PCR (qPCR) – Total RNA was
isolated and purified using the RNAeasy Mini Kit (Qiagen). Briefly, 1 × 106 cells were
collected by centrifugation at 200 g for 5 min, washed twice in phosphate-buffered saline
(PBS), and subjected to lysis and homogenization with Buffer RLT using QiaShredder spin
columns (Qiagen). Homogenized cells were re-suspended in an equal volume of 70% ethanol
and passed through the spin columns. Cells were then washed once using Buffer RW1 and
twice using Buffer RPE (Qiagen). Total RNA was collected upon elution with RNase-free
water. Optical density was detected using spectrophotometry (NanoDrop 2000, Thermo
Fisher Scientific, Waltham, MA).
cDNA synthesis was performed using the Superscript III RT protocol (Invitrogen,
Carlsbad, CA). Approximately 0.3 μg total RNA was used for reverse transcription. Briefly,
total RNA, oligo deoxy-thymine (dT), and deoxytrinucleotide triphosphate (dNTP) were
admixed, and the final volume was adjusted to 10 μL using RNase-free water. The RNA
mixture and primer were denatured at 65°C for 5 min and then placed on ice. The master
reaction mixture consisting of 10× cDNA synthesis buffer, 0.1 M DTT, RNaseOUT,
SuperscriptIII RT, MgCl2, and RNase-free H2O was prepared on ice and vortexed gently.
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Then, 10 μL of the reaction mixture was pipetted into each reaction tube on ice. Samples
were transferred to a thermal cycler preheated to the appropriate cDNA synthesis temperature
and incubated at 50°C for 60 min and then at 85°C for 5 min. Finally, 1.0 μL RNase H was
added and the samples were incubated at 37°C for 20 min to remove template RNA.
Relative qPCR was used to measure the levels of IGF-IR mRNA in NPM-ALK+ ALCL
cell lines after transfection with Ik-1 or MZF1 expression vectors (Open Biosystems,
Pittsburgh, PA) using reactions containing reverse-transcribed cDNA, IGF-IR primer/probe,
and Taqman Mastermix (Applied Biosystems, Grand Island, NY). 18S ribosomal RNA was
used as the endogenous control.
Transfection – Cells were transfected with Ik-1 or MZF1 expression plasmids using
electroporation and the Amaxa 4D Nucleofector System (solution SF, program CA-150;
Lonza, Walkersville, MD) and then incubated for 48 h. In some experiments, scrambled or
ALK siRNA (Dharmacon, Pittsburgh, PA) was transfected into NPM-ALK+ ALCL cell lines
by using the same approach.
Construction of the human IGF-IR gene promoter – Three different fragments of the
human IGF-IR gene promoter were amplified using genomic DNA (Promega, Madison, WI).
Briefly, 500 ng of genomic DNA was added to HotStarTaq plus Q solution additive mixture
(Qiagen) and subjected to Touchdown PCR. The PCR primers and amplification conditions
are shown in Table 1 and Table 2, respectively.
TABLE 1. Sequence of the primers used to construct the 3 fragments (F1, F2, and F3) of the human
IGF-IR gene promoter.
Primer Name

Sequence

F1 (Forward)

5’-CTC TCC TCG AGC CAC TCT GGG C-3’

F1 (Reverse)

5’-CAA GAC GTG CGG AGC GGA GC-3’

F2 (Forward)

5’-TCC GCA CGT CTT GGG GAA CC-3’
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F2 (Reverse)

5’-GCC CCG AAG TCC GGG TCA CA-3’

F3 (Forward)

5’-GAC TCC GCG TTT CTG CCC CTC-3’

F3 (Reverse)

5’-CTC CAC TCG TCG GCC AGA GC-3’

TABLE 2. The amplification conditions used in Touchdown PCR for the construction of 3 fragments
of the human IGF-IR gene promoter (∞: hold).
Phase 1

Step

Temperature Time

1

Denature

95°C

15 min

2

Denature

95°C

30 sec

3

Anneal

70°C

45 sec

-1.0°C*
4

Elongate

72°C

1 min

Repeat steps 2-4 (15 times)
Phase 2

Step

Temperature Time

5

Denature

95°C

30 sec

6

Anneal

60°C

45 sec

7

Elongate

72°C

1 min

Repeat steps 5-7 (25 times)
Termination

Step

Temperature Time

8

Elongate

72°C

5 min

9

Halt reaction

4°C

15 min

10

Hold

4°C

∞

*

Every time steps 2-4 were repeated, the annealing temperature was decreased by 1.0°C/cycle until
the estimated melting temperature was reached.

PCR products were run on 1.5% agarose gel, excised, and purified using the Qiaquick
Gel Extraction Kit (Qiagen). The PCR products were then subcloned at a 1:5 molar ratio into
the pGEM vector using the TA cloning system (Promega). The ligated products were
transformed using MaxEfficiency DH5α-competent cells (Invitrogen) overnight at 37°C, and
positive clones were selected and verified by PCR and direct DNA sequencing. Clones
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containing the correct insert were amplified in ampicillin containing Luria-Bertani (LB)
broth (Corning Costar, Corning, NY). Plasmids were isolated and purified using the Purelink
Quick Plasmid Miniprep Kit (Invitrogen). To construct reporter plasmids containing the
human IGF-IR gene promoter fragments, the pGEM plasmids and the PGL4.17 luciferase
vector (Promega) were subjected to restriction enzyme digestion using ZraI/SpeI (Promega)
and EcoICRI/NheI (New England Biolabs, Ipswich, MA). After digestion, DNA was ligated
at room temperature using T4 DNA ligase (Promega) and the PCR conditions shown in Table
3.
TABLE 3. PCR conditions used for DNA ligation for the construction of the human IGF-IR gene
promoter (∞: hold).
Temperature

Time

22°C

30 min

20°C

30 min

18°C

30 min

16°C

30 min

14°C

30 min

12°C

30 min

10°C

30 min

8°C

30 min

6°C

30 min

4°C

30 min

4°C

∞

Ligated products were confirmed by agarose gel electrophoresis and transformed using
DH5α-competent cells. Positive clones were selected, subjected to plasmid isolation and
purification using the Miniprep Kit, and verified by PCR and direct DNA sequencing.
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Site-directed mutagenesis and luciferase assay – Mutated human IGF-IR luciferase reporter
constructs were generated using the QuickChange II XL Site Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) and a set of primers depicted in Table 4.
TABLE 4. Sequences of the primers used to construct the 3 mutated fragments of human IGF-IR
luciferase reporter (F1, F2, and F3).
Primer Name

Sequence

F1 (Forward)

5’-CAA GAG CCC CAG CCG GGA GAA AGG GGA C-3’

F1 (Reverse)

5’-GTC CCC TTT CTC CCG GCT GGG GCT CTT G-3’

F2 (Forward)

5’-CAG AAA CGC GGA GCG CCG GCC ACC-3’

F2 (Reverse)

5’-GGT GGC CGG CGC TCC GCG TTT CTG-3’

F3 (Forward)

5’-GCC AGA GCG AGA GCG CCA AAT CCA GGA CAC-3’

F3 (Reverse)

5’-GTG TCC TGG ATT TGG CGC TCT CGC TCT GGC-3’

Luciferase assay – For luciferase assays, R- cells were transfected using Lipofectamine 2000
reagent. Briefly, 1 x 106 R- cells were seeded in 6-well plates. The following day, plasmids
were incubated in 100 µL OptiMEM media for 5 min at room temperature. Simultaneously, 7
µL lipofectamine was incubated in a separate tube. Then, the contents of the plasmid tubes
were added to the lipofectamine and incubated for 20 min at room temperature. Finally, the
plasmid mixtures were added to the corresponding plate wells containing the R- cells.
Luciferase assay was performed with the Dual Glo Luciferase Kit (Promega) after cotransfecting the R- cells with the reporter plasmids containing the wild-type or mutated IGFIR promoter fragments or NPM promoter (kind gift from Dr. Qishen Pang, Cincinnati
Children’s Hospital, Cincinnati, OH) along with Ik-1 or MZF1 expression plasmids using
Lipofectamine 2000 (Invitrogen) for 48 h. Cells were trypsinized, washed twice with sterile
PBS, and plated in a 96-well luminometer plate. An equal volume of Dual-Glo reagent was
added and incubated for 10 min for cell lysis to occur. Firefly luminescence readings were
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obtained using a plate reader (PolarStar Omega, BMGLabTech, Cary, NC). Finally, the
Dual-Glo Stop & Glo reagent was added and incubated for 10 min. Renilla luminescence
readings were obtained using the above methods.
Chromatin immunoprecipitation (ChIP) assay – Because NPM-ALK+ ALCL cells contain
low levels of endogenous Ik-1 and MZF1, expression plasmids containing full-length Ik-1 or
MZF1 were constructed by transferring the inserts into a c-Myc-tagged expression vector
(pCMV-Myc-N; Clontech). Briefly, the original expression vectors containing Ik-1 or MZF1
as well as pCMV-Myc-N were subjected to digestion using the restriction enzymes NotI/SalI
for Ik-1 or XhoI/ECORI for MZF1 (Promega). Digested products were verified by agarose
gel electrophoresis and then excised and ligated using the HD InFusion system (Clontech).
Ligated products were transformed using DH5α-component cells, and positive clones were
selected and verified by PCR.
ChIP assays were performed using the Pierce Agarose ChIP Kit (Thermo Scientific).
Briefly, at 48 h post-transfection, cells were cross-linked using 1% formaldehyde, and cell
pellets were lysed and re-suspended in a buffer containing 0.6 µL Micrococcal Nuclease
(ChIP grade) and subjected to sonication on ice (Output 6; six 15 sec pulses, followed by 45
sec rest periods; Sonic Dismembrator, model 100; Thermo Fisher Scientific). Five microliters
of digested chromatin was separated for the 10% input. The remaining sonicated samples
were immunoprecipitated overnight at 4°C on a rocking platform using the c-Myc-Tag
antibody and the provided plugged spin columns. Following overnight incubation, ChIPgrade Protein A/G Plus agarose beads were incubated for 2 h with the lysate at 4°C on a
rocking platform. The samples were then washed and reverse cross-linked at 65°C for 40
min. The immunoprecipitated samples and input were eluted in a buffer containing 5 M NaCl
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and 20 mg/mL Proteinase K. Finally, chromatin DNA was recovered and purified using the
DNA Clean-Up column and subjected to Touchdown PCR using HotStarTaq Master Mix and
Q solution and a set of primers shown in Table 5. PCR products were run on 1.5% agarose
gel.
TABLE 5. Sequences of the primers flanking potential binding sites (BS) of Ik-1 and MZF1 within
the human IGF-IR promoter used in the RT-PCR reactions following the ChIP assay.
Primer Name

Sequence

Ik-1 BS2 (Forward)

5’-CGG GGG CAT TGT TTT TGG AG-3’

Ik-1 BS2 (Reverse)

5’-CGG GTT CCC CAA GAC GTG-3’

Ik-1 BS3 (Forward)

5’-TCT TGT TTA CCA GC ATTA ACT CGC-3’

Ik-1 BS3 (Reverse)

5’-CCT CTC TCG AGT TCG CCT G-3’

Ik-1 BS4 (Forward)

5’-CGC CGC TTT GTG TGT GTC-3’

Ik-1 BS4 (Reverse)

5’-GCC GCC TCC TCC CTC A-3’

MZF1 BS2 (Forward)

5’-GCG GGG GCA TTG TTT TTG GA-3’

MZF1 BS2 (Reverse)

5’-CCG GGT TCC CCA AGA CGT G-3’

MZF1 BS3 (Forward)

5’-GCG CGT GTC TCT GTG TGC-3’

MZF1 BS3 (Reverse)

5’-GCG AGT TAA TGC TGG TAA ACA A-3’

MZF1 BS4 (Forward)

5’-GTG TGT GTC CTG GAT TTG GGA-3’

MZF1 BS4 (Reverse)

5’-GCA GAA ACG CGG AGT CAA AAT-3’

MZF1 BS5 (Forward)

5’-CGG CCC TTC GGA GTA TTG T-3’

MZF1 BS5 (Reverse)

5’-CAA GTC TCA AAC TCA GTC TTC G-3’

MTS assay – Cell viability was evaluated using a CellTiter 96 AQueous One Solution Cell
Proliferation

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-

2H-tetrazolium (MTS) assay kit (Promega). Cells were seeded in 96-well plates (1.0 × 104
cells/well) in 100 μL RPMI supplemented with 10% FBS. Twenty microliters of MTS
reagent were added, and the cells were incubated at 37°C in a humidified 5% CO2 chamber
for 4 h. Optical density measurements were obtained at 490 nm using an ELISA plate reader.
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BrdU assay – Cell proliferation was measured using a BrdU assay kit (ExAlpha Biologicals,
Shirley, MD). Briefly, 2.0 × 105 cells/mL were plated into a 96-well plate. BrdU (1:500
dilution) was added, and the plate was incubated for 24 h at 37°C. Cells were then fixed for
30 min at room temperature. After the cells were washed, anti-BrdU antibody was added for
1 h followed by peroxidase goat anti-mouse IgG conjugate (1:2000 dilution) for 30 min.
Next, the 3,3’,5,5’-tetramethylbenzidine peroxidase substrate was added, followed by
incubation for 30 min at room temperature in the dark. The acid Stop Solution was then
added and the plate was read at 450 nm using an ELISA plate reader.
Cell migration assay – Cell migration was analyzed using 24-well Transwell plates with
polycarbonate membranes (Corning Costar). Briefly, cells transfected with Ik-1 or MZF1 in
serum-free culture medium were loaded into the upper compartment, and 500 ng/mL IGF-I
(R&D Systems, Minneapolis, MN) in serum-free medium was loaded into the lower
compartment. As controls, non-transfected cells in serum-free medium were loaded into the
upper compartment with/without IGF-I added into the lower compartment. Plates were
incubated for 4 h at 37°C, and cells migrating through the membrane into the lower chamber
were counted using a particle counter and size analyzer (Beckman Coulter, Brea, CA).
Anchorage-independent colony formation assay – Methylcellulose (Methocult H4230;
StemCell Technologies) (3.0 mL) was added to 15-mL tubes. Empty vector- (EV-), Ik-1- or
MZF1-transfected cells were added in a 1:10 (v/v) ratio to the methylcellulose tubes and
mixed well by gentle inversion. One milliliter of the mix was divided into 24-well plates in
triplicate. Plates were placed in a humidified incubator at 37°C in 5% CO2 for 7 days. Then,
p-iodonitrotetrazolium violet was added for 24 h for staining. Colonies were visualized using
the AlphaImager system (Alpha Innotech Corporation, San Leandro, CA). In an additional
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experiment, SUP-M2 cells were incubated for 21 days, and the results were similar to those
of the shorter incubations.
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3.1.2.2. Results
Identification of the transcription factors Ikaros isoform-1 (Ik-1) and myeloid zinc finger 1
(MZF1) as capable to potentially bind with the IGF-IR gene promoter: The TFSearch,
MATCH, and Genomatix transcription factor search algorithms identified multiple potential
transcription factors. We elected to focus on Ik-1 and MZF1 because: their 1) matrix
similarity thresholds to bind with the IGF-IR gene promoter are > 0.9, which has been
predicted collectively by the 3 algorithms [the matrix similarity threshold represents the
quality of the match between the transcription factor binding sequence and arbitrary parts of
the promoter sequence, and is used to minimize false positive results] (Table 6); 2)
contribution to the transcriptional regulation of IGF-IR expression has not been previously
described; 3) role in the pathogenesis of NPM-ALK+ T-cell lymphoma is not known; and 4)
contribution to normal and abnormal hematopoiesis has been established by the transcription
factors [141-145].
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TABLE 6. Ik-1 and MZF1 can potentially bind with IGF-IR gene promoter. Three
online-based software search algorithms (Genomatix, MATCH, and TESearch) predicted
several transcription factors that could potentially bind with IGF-IR gene promoter. Ik-1 and
MZF1 were predicted by 3 and 2, respectively, of the 3 software algorithms, with the highest
probability of > 0.09.
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Expressions of Ik-1 and MZF1 are significantly decreased in NPM-ALK+ ALCL: Western
blotting was used to first analyze 4 NPM-ALK+ ALCL cell lines (Karpas 299, SR-786, SUPM2, and DEL) and normal human T lymphocytes for the expression of Ik-1 and MZF1. The
expression levels of Ik-1 and MZF1 were significantly decreased in the 4 cell lines compared
to the normal T lymphocytes (Figure 11A and 11B). Jurkat cells were used as positive
controls for the expression of Ik-1 and MZF1. Densitometric analysis of the expression of Ik1 and MZF1 relative to β-actin is shown (Figure 11C). In addition, examination of the
expression levels of Ik-1 and MZF1 in protein lysates extracted from 15 FFPE patient tissues
showed patterns of expression similar to cell lines. Ik-1 and MZF1 expressions were
decreased in 87% and 100% of the patient’s samples, respectively, compared to normal T
lymphocytes (Figure 11D). Densitometric analysis of the expression of Ik-1 and MZF1
relative to β-actin is shown (Figure 11E).
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FIGURE 11. The expression of Ik-1 and MZF1 is decreased in NPM-ALK+ ALCL cell
lines and human primary tumors. (A) WB shows that Ik-1 levels were lower in 4 NPMALK+ ALCL cell lines than in T lymphocytes. Jurkat cells were used as a positive control. βactin represents the level of proteins loaded in each lane. (B) Similarly, MZF1 levels were
lower in the lymphoma cell lines than in normal human T-cells. Jurkat cells served as a
positive control. β-actin reflects the level of proteins loaded in each lane. (C) Densitometric
analysis of the Ik-1/MZF1 Western blotting bands relative to the β-actin bands depicted in
(A) and (B) further demonstrated that the expression of these two transcription factors is
decreased in NPM-ALK+ ALCL cell lines vs. T-cells and positive control cell lines. (D)
Western blotting assay showing that the expression of Ik-1 and MZF1 were lower in ALK+
ALCL specimens from patients than in T lymphocytes. β-actin reflects the level of total
proteins loaded in each lane. Variability in β-actin levels is due to the poor quality of some of
the FFPE tumor sections. (E) Densitometric studies analyzing the Ik-1/MZF1:β-actin ratio of
the Western blotting bands shown in (D).
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Ik-1 and MZF1 bind the IGF-IR promoter and regulate its activity: To elucidate whether
Ik-1 and MZF1 can bind and regulate the IGF-IR gene promoter, a luciferase assay was
performed using 3 different fragments of the human IGF-IR promoter construct (F1: -682/137, F2: -137/+583, F3; +530/+1137; illustrated in Figure 12A and 12B) along with either
EV, Ik-1 or MZF1 expression plasmids. In addition, a second luciferase assay was performed
simultaneously using mutated versions of the promoter fragments that were sequentially
deleted at the corresponding binding sites. Ik-1 and MZF1 significantly decreased the
luciferase activity of the F1 and F2, but not the F3, regions of the human IGF-IR promoter
(Figure 12C). In contrast, Ik-1 and MZF1 did not decrease the luciferase activity of the
mutated forms of the IGF-IR promoter (Figure 12C). These results suggest that each of these
transcription factors can interact with binding sites located within the F1 and F2 regions, but
not the F3 region.
The 3 web-based transcription factor search algorithms also predicted 5 potential binding
sites for Ik-1 and 6 potential binding sites for MZF1 within the IGF-IR promoter (Figure
12A and 12B). To determine which of these sites is responsible for Ik-1 or MZF1
interactions with the IGF-IR promoter, a ChIP assay was performed. Because there are low
levels of endogenous Ik-1 and MZF1 in the cells, Karpas 299 and SR-786 cells were
transfected with Myc-tagged Ik-1 or MZF1 (c-Myc-Ik-1 or c-Myc-MZF1) expression
constructs or with empty vector (EV). Using a c-Myc antibody, the transcription factors were
immunoprecipitated and the sonicated chromatin was used to perform an RT-PCR analysis
using primers flanking the potential binding sites for Ik-1 and MZF1 within the human IGFIR promoter. The ChIP assay identified 2 binding sites (BS2 and BS4) for Ik-1 and 3 binding
sites for MZF1 (BS2, BS3, and BS4) (Figure 12D, 12E; the sites are depicted in 11A and
11B). The RT-PCR (2 different sets of primers were tried) showed nonspecific binding in the
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ChIP assay for Ik-1 BS1 and BS5, and for MZF1 BS1 and BS6 (data not shown). This
nonspecific binding could possibly be due to the instability of the primers to bind to and
amplify the extreme beginning and end of the IGF-IR gene promoter.
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FIGURE 12. Ik-1 and MZF1 interact with and bind to the IGF-IR gene promoter. (A)
The general structure of the IGF-IR gene promoter, including the transcription and
translation start sites is shown. The 3 PCR fragments used to perform the luciferase assay
(F1: -682/-137, F2: -137/+583, F3: +530/+1137) as well as 5 sites that could potentially bind
with Ik-1 are shown. *: 2 sites that were shown to bind with Ik-1 by the ChIP assay. (B) The
3 PCR fragments used to perform the luciferase assay and 6 sites that could potentially bind
with MZF1 are depicted. *: 3 sites that were confirmed by the ChIP assay as binding sites for
MZF1. (C) Luciferase assay performed in R- cells, which lack endogenous IGF-IR
expression, demonstrates that transfection of Ik-1 or MZF1 induced a marked decrease in
IGF-IR promoter activity at concomitantly transfected F1 and F2, but not at F3, of the IGFIR gene promoter (*: P < 0.05; **: P < 0.01; ***: P < 0.001 compared with EV).
Importantly, Ik-1 and MZF1 failed to induce their effects when F1 and F2 were mutated
(MT) at their potential binding sites. The results are shown as means ± SE of 3 consistent
experiments. (D) ChIP assay shows that Ik-1 binds with binding site 2 (BS2) and BS4 of the
IGF-IR gene promoter. As shown, controls including EV, IgG, input, and H2O worked
properly. The 2 binding sites are identified by an (*) in (A). (E) ChIP assay confirms that
MZF1 is capable of binding with the IGF-IR gene promoter at BS2, BS3, and BS4, which are
marked by an (*) in (B). Positive and negative controls worked properly.
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Ik-1 and MZF1 decrease IGF-IR mRNA and protein levels in NPM-ALK+ ALCL cells:
Next, we sought to explore the effects of up-regulating the expression of Ik-1 and MZF1 in
NPM-ALK+ ALCL cells. Sufficient transfection of Karpas 299, SUP-M2, and SR-786 cells
with Ik-1 or MZF1 expression plasmids resulted in a significant decrease in IGF-IR mRNA
expression (Figure 13A and 13B; Figure 13Cand 13D). In contrast, EV failed to elicit
similar effects. These effects resulted in significant decrease in IGF-IR protein levels, and
subsequently, its activated/phosphorylated form, pIGF-IR. Furthermore, Ik-1- and MZF1induced downregulation of IGF-IR was followed by decreases in several downstream
signaling proteins that are important for the IGF-IR signaling axis, such as pAKTSer437 and
pIRS-1Ser639 (Figure 13E). No significant changes were detected in total AKT levels, but
unexpectedly Ik-1 and MZF1 decreased total IRS-1 levels. When the IRS-1 gene promoter
sequence was analyzed using the 3 web-based transcription factor search algorithms, we
discovered that Ik-1 and MZF1 have the potential to bind to the IRS-1 gene promoter, which
may explain this unexpected finding.
The ectopic expression of Ik-1 and MZF1 resulted in significant decrease in NPM-ALK
and pNPM-ALK levels (Figure 13E). When we entered the NPM-ALK sequence into the
three web-based algorithms, we found that neither of these transcription factors have
potential binding sites within the NPM gene, which is where the promoter for NPM-ALK
resides. In addition, WB analysis failed to demonstrate changes in wild type NPM protein
after transfection of Ik-1 or MZF1, providing evidence that Ik-1 and MZF1 are not directly
regulating NPM-ALK (Figure 13E). Moreover, the luciferase activity of the full length NPM
promoter remained unchanged after transfection with Ik-1 or MZF1 (Figure 13F). These
observations allude to the possibility that the decrease NPM-ALK protein levels is most
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likely the result of decreases in IGF-IR, which is consistent with our previous results
showing that IGF-IR sustains the stability of NPM-ALK protein.
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FIGURE 13. Ik-1 and MZF1 decrease IGF-IR mRNA and protein expression and the
phosphorylation of downstream targets. (A) WB demonstrates increased expression levels
of Ik-1 and MZF1 proteins at 48 h after transfection into 3 NPM-ALK+ ALCL cell lines. βactin shows equal protein loading. (B) Densitometric studies illustrate the ratio of the Ik-1 or
MZF1 protein to β-actin. The ratios support increased expression of the corresponding
transfection factor after transfection. (C) Transfection of Ik-1 remarkably decreased IGF-IR
mRNA levels in Karpas 299, SUP-M2, and SR-786 cell lines (*: < 0.0001 compared with
EV). (D) Similarly, transfection of MZF1 induced a significant decrease in IGF-IR mRNA
levels (*: < 0.0001 compared with EV). The results depicted in (C) and (D) represent the
means ± SE of 3 experiments. (E) WB shows that transfection of Ik-1 and MZF1 into Karpas
299, SUP-M2, and SR-786 cell lines induced marked downregulation of IGF-IR protein,
which was also associated with decreased pIGF-IR levels. Moreover, the decrease in IGFIR/pIGF-IR expression levels was associated with decreased phosphorylation of important
IGF-IR targets including IRS-1, AKT, and NPM-ALK. Whereas the basal levels of AKT
remained unchanged, notable decrease in IRS-1 protein was observed. The 3 web-based
transcription factor search algorithms showed that Ik-1 and MZF1 could potentially bind with
the IRS-1 gene promoter. In contrast, searching these algorithms did not support potential
binding of Ik-1 or MZF1 and the NPM gene promoter, where the expression of NPM-ALK
protein is regulated at the transcriptional level. (F) In line with lack of potential
binding/interaction between Ik-1 or MZF1 and the NPM gene promoter, a luciferase assay
performed in R- cells shows that transfection of Ik-1 and MZF1 does not decrease the NPM
promoter activity. The results represent means ± SE of 3 consistent experiments.
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Ik-1 and MZF1 decrease the viability, proliferation, migration, and anchorageindependent colony formation of NPM-ALK+ ALCL cells: A series of cellular assays were
performed to test the biological impact of forced expression of Ik-1 and MZF1 in NPMALK+ ALCL. Transfection of Karpas 299, SUP-M2, and SR7-86 with Ik-1 or MZF1, but not
EV, decreased the cell viability of the NPM-ALK+ ALCL cells (Figure 14A and 14B). In
addition, cell proliferation was significantly reduced by the two transcription factors (Figure
14C and 14D). Furthermore, migration in response to IGF-I was significantly hindered in the
three cell lines (Figure 14E). Finally, Ik-1 and MZF1 abrogated the potential of NPM-ALK+
ALCL cells to form colonies in methylcellulose (Figure 14F and 14G).
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FIGURE 14. Transfection of Ik-1 and MZF1 decreases the viability, proliferation,
migration, and anchorage-independent colony formation of NPM-ALK+ ALCL cells.
(A) Compared with EV, transfection of Ik-1 was associated with significant decreases in the
viability of the NPM-ALK+ ALCL cells Karpas 299, SUP-M2, and SR-786 at 48 h after
transfection (*: P < 0.0001). (B) In a similar fashion, transfection of MZF1 into these cells
induced marked decreases in their viability (*: P < 0.0001). (C) Ik-1 significantly decreases
the proliferation of the NPM-ALK+ ALCL cell lines (*: P < 0.05; **: P < 0.01). (D) In
addition, transfection of MZF1 reduced the proliferation of these cells (*: P < 0.05; **: P <
0.01). (E) IGF-I stimulated the migration of Karpas 299, SUP-M2, and SR-786 cells.
Whereas this effect was profoundly reduced when cells were treated with IGF-I and
simultaneously transfected with Ik-1 or MZF1; transfection of EV failed to induce similar
effects (for Karpas 299, *: P < 0.0001 in IGF-I vs. IGF-I+Ik-1 and IGF-I+MZF1, †: P < 0.01
in IGF-I+EV [Ik-1] vs. IGF-I+Ik-1, ‡: P < 0.001 in IGF-I+EV [MZF1] vs. IGF-I+MZF1; for
SUP-M2, §: P < 0.05 in IGF-I vs. IGF-I+Ik-1, IGF-I+EV [Ik-1] vs. IGF-I+Ik-1 and IGFI+EV [MZF1] vs. IGF-I+MZF1, †: P < 0.01 in IGF-I vs. IGF-I+MZF1; for SR-786, *: P <
0.0001 in IGF-I vs. IGF-I+MZF1, IGF-I+EV [Ik-1] vs. IGF-I+Ik-1, and IGF-I+EV [MZF1]
vs. IGF-I+MZF1, ‡: P < 0.001 in IGF-I vs. IGF-I+Ik-1). (F) Ik-1 abrogated anchorageindependent colony formation of Karpas 299, SUP-M2, and SR-786 cells at 7 days after
transfection (*: P < 0.05; **: P < 0.01; ***: P < 0.001 compared with EV). The numbers of
the colonies are shown in the left panel, and representative examples from cells transfected
with EV or Ik-1 are shown in the right panel. (G) Furthermore, MZF1 halted NPM-ALK+
ALCL cells’ anchorage-independent colony formation in methylcellulose at 7 days after
transfection (*: P < 0.05; **: P < 0.01 compared with EV). The numbers of the colonies are
shown in the left panel, and representative examples from cells transfected with EV or MZF1
are shown in the right panel. Results illustrated in Fig. 14 are means ± SE of at least 3
consistent experiments.
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3.1.3. Transcriptional Regulation of IGF-IR: Gene Amplification
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3.1.3.1. Materials and Methods
Cell Lines – Five characterized NPM-ALK+ ALCL cell lines were used in this study
including Karpas 299, DEL, SUP-M2, SR-786, and SU-DHL-1. Normal T lymphocytes were
purchased from StemCell Technologies (Catalog # 70024, Vancouver, British Columbia).
Lymphoma cell lines and T lymphocytes were maintained in RPMI 1640 medium (HyClone,
South Logan, Utah) supplemented with 10% FBS, glutamine (2 mM), penicillin (100 U/ml),
and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber.
Cytospins – Cytospins were prepared from NPM-ALK+ ALCL cell lines and normal T
lymphocytes. Approximately 100,000 cells were suspended in RPMI medium and pipetted
into cytospin chambers. Cells were suspended onto slides using the following conditions: 700
rpm, high acceleration, for 5 min. Once completed, the slides were allowed to dry and fixed
immediately in ice cold 100% methanol (-20°C) for 5 min. Thereafter, slides were air dried
and stored in -20°C until FISH was performed.
Fluorescent in situ hybridization (FISH) – Human T lymphocytes and NPM-ALK+ T-cell
lymphoma cells (1 × 105 cells) suspended in RPMI were pipetted into cytospin chambers.
Cytospin slides were prepared (700 rpm at high 25 acceleration for 5 min). The cytospin
slides were fixed in ice cold 100% methanol, and stored at -20°C until FISH was performed.
We adopted a previously described approach to perform FISH assay and analysis [136]. The
SureFish probes and kit from Agilent Technologies were used. Briefly, 1.0 μL of IGF-IR
FISH probe (G100168R) and 1.0 μL of chromosome enumeration probe 15 (CEP15;
G100543G), which identify centromere 15, were mixed gently in Agilent FISH hybridization
buffer. Cytospin slides were prepared and placed in gradually increasing concentrations of
ethanol (70%, 85%, and 100%), each for 1 min at room temperature. After allowing the
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slides to dry, 5.0 μL of probe/hybridization buffer mixture were added to the slides, and
cover slips were applied. Hybridization was then accomplished by using the ThermoBrite
system (Abbott Molecular, Abbott Park, IL). The slides were first incubated at 78°C for 5
min to denature the DNA, and then incubated at 37°C for 24 h. Thereafter, cover slips were
removed and slides were placed and agitated in Wash buffer 1 (73°C) for 2 min.
Subsequently, slides were transferred and agitated at room temperature for 2 min in Wash
Buffer 2. The slides were air dried in the dark at room temperature, followed by pipetting
DAPI (1.0 μg/mL in PBS). DAPI was then removed, and slides were mounted with
ProlongGold antifade media (P36934, Invitrogen, Grand Island, NY) and viewed using the
FV1000 confocal microscope (Olympus America, Center Valley, PA).
FISH scoring was performed in 55 nonoverlapping nuclei per slide. The means of the
IGF1R gene and CEP15 copy numbers per cell, number of cells with two or fewer, three, and
four or more copies of IGF1R and CEP15 signals, and IGF1R-to-CEP15 ratio were obtained.
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3.1.3.2. Results
IGF-IR is not amplified in NPM-ALK+ ALCL cell lines: We analyzed IGF-IR gene probe
signal (red) and the chromosome 15 pericentromeric (CEP) probe signal (green) in
approximately 55 nonoverlapping nuclei in 5 NPM-ALK+ ALCL cell lines (Karpas 299, SR786, SUP-M2, SU-DHL-1, and DEL) and normal T lymphocytes prepared on cytospins by
FISH (Figure 15). Also, we measured the additional parameters that are listed in Figure 15.
While normal T lymphocytes IGF-IR copy number was approximately 2 copies/cell, the
median IGF-IR gene copy number in the cell lines was 3 copies/cell. However, the median
CEP15 gene copy number in the cell lines analyzed by FISH was 2.5 copies/cell.
Considering that the ratio between IGF-IR gene copy number-to-CEP15 gene copy number is
1.1, we conclude that there is no apparent IGF-IR gene amplification in NPM-ALK+ ALCL
cells.
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FIGURE 15. FISH analysis of IGF-IR gene (red signal) and chromosome enumeration
15 (green signal; CEP15), which detects centromere 15, copy numbers in normal human
T lymphocytes and NPM-ALK+ ALCL cell lines. FISH studies show no evidence to
support amplification of IGF-IR gene in NPM-ALK+ ALCL cells. As shown in the table, the
IGF-IR-to-CEP15 ratio was consistently < 2.0 in the T lymphocytes as well as in the NPMALK+ T-cell lymphoma cells.
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3.2. Discussion for Aim 1
In this aim, we show that previously unidentified defects in transcriptional machinery
contribute to the pathogenesis of NPM-ALK+ ALCL. Firstly, we found that, compared with
their expression in normal human T lymphocytes, the transcription factors Ik-1 and MZF1
are markedly decreased in NPM-ALK+ALCL cell lines and lymphoma tumors from patients.
Substantial evidence is provided to support that Ik-1 and MZF1 possess the ability to bind
specific sites residing within the IGF-IR gene promoter and inhibit its activity. In agreement
with these observations, ectopic expression of Ik-1 and MZF1 in NPM-ALK+ ALCL cells
causes remarkable downregulation of the expression of IGF-IR mRNA and protein. Also,
transfection of Ik-1 and MZF1 was associated with decreased cell viability, proliferation,
migration, and anchorage independent colony formation of NPM-ALK+ ALCL cells,
asserting the tumor suppressing impact of Ik-1 and MZF1 in this lymphoma. Secondly, we
failed to identify IGF-IR gene amplification in the lymphoma cells after measuring IGF-IR
gene and CEP15 pericentromeric gene copy numbers.
It has been previously shown that Ik-1 induces tumor-suppressing effects primarily in
hematopoietic cellular elements [146-148]; nonetheless, the contribution of MZF1 to
tumorigenesis is more diverse as it may induce oncogenic or tumor suppressor effects in
hematopoietic and non-hematopoietic cells [149-154]. The IGF-IR gene promoter is tightly
regulated during mammalian development, and during the embryonic and early postnatal
stages it induces the transcription of high levels of IGF-IR mRNA, which decreases to much
lower levels during growth [155]. The IGF-IR gene promoter is a TATA-less and CAAT-less
promoter, and like other structurally similar promoters, the IGF-IR promoter is GC-rich [156158]. The transcription of the IGF-IR gene is therefore initiated from an 11 basepair unique
site contained within an “initiator” motif similar to the ones present in the terminal
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deoxynucleotidyl transferase and adenovirus middle late gene promoters [157, 159, 160].
Although levels of expression of IGF-IR during physiological and pathological conditions
can be rigorously determined at the transcriptional level [161], relatively few transcription
factors have been shown to be capable of binding with and regulating the expression of the
IGF-IR gene promoter. The multiple GC boxes present in this promoter form potential
binding sites for members of the zinc-finger transcription factor family. In line with this
possibility, earlier studies using rat IGF-IR gene promoter showed that Sp1, a zinc-finger
transcription factor, binds with GC boxes located within the 5’-flanking region and one
homopurine/homopyrimidine motif (CT element) in the 5’-untranslated region of IGF-IR
gene promoter to enhance its activity [159, 162].
The IGF-IR gene promoter also includes cis-elements for members of the early growth
response family of zinc-finger proteins including the WT1 Wilms tumor suppressor, which,
in contrast with Sp1, downregulates the expression of IGF-IR [163, 164]. Indeed, increased
expression of WT1 protein was associated with a reciprocal decrease in the expression of
IGF-IR protein and receptor number in prostate cancer cells, and downregulation of WT1
increased IGF-IR expression in glioblastoma [165, 166]. Albeit less extensively studied,
E2F1 and EGR-1 are also implicated in the positive regulation, and STAT1 in the negative
regulation of IGF-IR gene expression [167-169]. In addition to the direct regulatory effects of
Sp1 and WT1, several studies have elucidated indirect contributions of oncogenic and tumor
suppressor proteins to the regulation of the IGF-IR gene expression through interactions with
these two transcription factors. In breast cancer, BRCA1 appears to suppress the IGF-IR
promoter activity, but there is no evidence to support BRCA1 binding and direct interactions
with the IGF-IR promoter. Instead, BRCA1 most likely suppresses the activity of the IGF-IR
promoter through the sequestration of Sp1 [170, 171].
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Similarly, in breast cancer cells, the estrogen receptor enhances IGF-IR gene promoter
activity via interactions with Sp1 and WT1 [172, 173]. Also, MCF7 breast cancer cells that
express caveolin-1 demonstrate much higher levels of IGF-IR gene promoter activity, and the
effects of caveolin-1 on the IGF-IR gene promoter were mediated through Sp1 [174].
Furthermore, the tumor suppressor transcription factor, Kruppel-like factor 6 (KLF6),
activates IGF-IR gene transcription through synergy with Sp1 [175]. Moreover, it was found
that wild-type p53 downregulates IGF-IR gene expression and mutated p53 enhances this
expression [176-178]. The regulatory mechanisms conferred by p53 also do not involve
specific binding with the IGF-IR gene promoter but seem to be mediated, at least partially,
by protein-protein interactions between p53 and Sp1.
We have also previously demonstrated that NPM-ALK and IGF-IR are physically
associated, and it appears that this physical association, through interactions with Hsp90,
enhances the stability of NPM-ALK protein [127]. In the current study, the decrease in IGFIR expression after Ik-1 and MZF1 transfection was also associated with pronounced
decrease in NPM-ALK basal protein levels. Although these results agree with our previous
observations, we sought to investigate whether Ik-1 or MZF1 is capable of regulating the
expression of NPM-ALK directly at the transcriptional level. The web-based transcription
factor search algorithms failed to predict potential binding sites between the NPM gene
promoter, where the transcription of the NPM-ALK chimeric oncogene is driven [34], and
either Ik-1 or MZF1. Furthermore, a luciferase assay using an NPM reporter construct
showed that transfection of Ik-1 and MZF1 does not affect NPM promoter activity or protein
levels. Therefore, our current results indicate that the decrease in NPM-ALK protein levels
occurs secondarily to Ik-1- and MZF-1-induced downregulation of IGF-IR protein
expression.

85
The Ik-1 and MZF1 transcription factors play physiological roles in the development of
normal hematopoiesis [142-145]. In the present work we describe for the first time in any
type of cancer cell the negative regulation of IGF-IR gene expression by Ik-1 and MZF1
transcription factors. Ik-1 regulates transcription by binding to specific consensus binding
sites (C/TGGGAA/T) within target promoters [179]. Similarly, MZF1’s 13 zinc fingers are
separated into 2 arms, and each arm has the ability to independently bind to specific binding
sites within the promoters of target genes: the first domain of fingers 1-4 (ZN 1-4) binds to
the sequence 5'-AGTGGGGA-3', and the second domain of fingers 5-13 (ZN 5-13) binds the
core sequence 5'-CGGGnGAGGGGGAA-3' [144]. Similar to other transcription factors that
bind with IGF-IR gene promoter, we found that Ik-1 and MZF1 possess the potential to bind
with sequences located both upstream and downstream of the transcription start site within
the 5'-flanking region as well as within the 5'-untranslated region. Specifically, potential
binding sites for Ik-1 are located at nucleotides -504/-491, -138/-125, +77/+90, +427/+440,
and +1011/+1024, and potential binding sites for MZF1 are located at nucleotides -504/-496,
-299/-291, -138/-130, +501/+514, +919/+928, and +1011/+1019 (binding sites confirmed by
ChIP are underlined). To our knowledge, these binding sites have not been previously
described to bind with any of the transcription factors that are known to regulate IGF-IR
gene. Among the previously described transcription factors, Sp1, E2F1, and EGR-1 showed a
greater net change in promoter activity at binding sites located downstream of the
transcription start site [162, 168, 169]. While this pattern was similar to Ik-1, MZF1
demonstrated a greater net change in IGF-IR promoter activity at binding sites located
upstream of the transcription start site, which resembles the inhibitory effects induced by
WT1 [163].
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Ik-1- and MZF1-induced downregulation of IGF-IR was associated with decreased levels
of its activated/phosphorylated form, pIGF-IR. These effects induced downregulation of the
phosphorylation levels of the molecular targets of IGF-IR including IRS-1, AKT, and
NPMALK. Whereas basal levels of AKT remained unchanged, the basal levels of IRS-1
decreased after transfection of Ik-1 and MZF1. To further analyze this unexpected finding,
we searched the web-based transcription factor algorithms and found that the IRS-1 gene
promoter contains sites that could potentially function as targets for Ik-1 and MZF1
transcriptional activity. It is important to mention that IRS-1 is also a downstream target of
NPM-ALK phosphorylation activity [52]. Although further analysis is required to support
this idea, we cannot completely rule out that Ik-1 and MZF1 act as tumor suppressors in this
lymphoma through targeting the expression of IGF-IR and IRS-1.
It is important, however, to emphasize that deregulated systems underlying the
pathogenesis of NPM-ALK+ ALCL are complex owing to the fact that they originate from
more than one defective regulatory mechanism [131]. Although our results provide strong
evidence that the aberrant decrease in the expression of Ik-1 and MZF1 transcription factors
contributes to upregulation of an important oncogenic protein, i.e., IGF-IR, we elected to
investigate whether other transcriptional mechanisms exist to further enhance IGF-IR
expression. Our experiments failed to support the presence of IGF-IR gene amplification, an
aberrant transcriptional mechanism, in NPM-ALK+ ALCL. IGF-IR gene amplification has
been previously reported in small subgroups of patients with solid tumors such as lung cancer
[136, 138]. To this end, our data suggest a model in which upregulation of IGF-IR in NPMALK+ ALCL results from defects in transcriptional mechanisms, which reflects the
complexity of survival signaling in this lymphoma.
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3.3. Posttranscriptional Regulation of IGF-IR
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3.3.1. Introduction
Modifications

of

mRNA

stability

and/or

translational

efficiency

through

the

posttranscriptional regulation of mRNAs are increasingly reported in cancer. MicroRNAs
(miRs) constitute a family of 19- to 24- noncoding nucleotide RNAs that regulate gene
expression posttranscriptionally through direct targeting of the 3’-UTR of the mRNA. There
has been substantial evidence indicating that miRs are aberrantly expressed in many human
cancers and may function as oncogenes or tumor suppressors; thus contributing significantly
to cancer development and progression [180, 181]. Recently, there have been a few studies
examining miRs that play a role in the pathogenesis of NPM-ALK+ ALCL [182-185]. In our
lab, we identified substantial decrease in basal expression levels of miR-96 and miR-26a in
NPM-ALK+ ALCL than normal human T lymphocytes [61, 132]. Importantly, we found that
miR-96 induces negative regulatory effects on the expression of NPM-ALK protein, and
miR-26a downregulates the expression of iNOS protein. However, the regulation of IGF-IR
by miRs in NPM-ALK+ ALCL has not been studied previously.

Another mechanism in which oncogenes, growth factors, cytokines, and cell-cycle
regulatory genes are regulated posttranscriptionally is by controlling the rate of their mRNA
turnover. In support of this view, mRNA turnover directly impacts signaling pathways that
are often overactive in cancer, suggesting an important posttranscriptional component in
regulating the expression of target mRNAs. In this aim, we hypothesized whether increased
IGF-IR expression may be explained by posttranscriptional aberrancies, such as deregulated
miRs and delayed mRNA turnover.
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3.3.2. Posttranscriptional Regulation of IGF-IR: MicroRNA

90
3.3.2.1. Materials and Methods
Microarray analysis – Total RNA isolation was performed using the Trizol reagent
(Invitrogen, Grand Island, NY). RNA labeling and hybridization on miR array chips were
performed as previously described [186]. Briefly, 5 μg of total RNA from each sample was
biotin-labeled by reverse transcription using 5′ biotin end-labeled random octomer oligo
primer. Hybridization of biotin-labeled cDNA was carried out on a miR array chip (MD
Anderson Cancer Center, Version 5.0), which contains 678 human miR genes in duplicate.
Hybridization signals were detected by biotin binding of a streptavidin–Alexa647 conjugate
by using an Axon GenePix 4000B scanner and the images were quantified by GenePix 6.0
software (Axon Instruments, Union City, CA).
Web-based software – In order to identify potential binding sites for miR-30a or miR-30d in
the

IGF-IR-3’-UTR,

3

web-based

(http://www.microrna.org/microrna/home.do),

algorithms
PicTar

were

used:

MiRANDA

(http://pictar.mdc-berlin.de),

and

TargetScan (http://www.targetscan.org).
Cell lines – Five NPM-ALK+ ALCL cell lines were used in this study including Karpas 299,
DEL, SUP-M2, SR-786, and SU-DHL-1 (DSMZ, Germany). Normal T lymphocytes were
purchased from StemCell Technologies (Catalog # 70024, Vancouver, British Columbia).
The R- cells (mouse 3T3-like fibroblasts with targeted ablation of Igf1r) were a generous gift
from Dr. R. Baserga (Thomas Jefferson University, Philadelphia, PA) and were used as the
host cell line for luciferase assay studies [100]. The lymphoma cell lines and normal T
lymphocytes were maintained in RPMI 1640 medium (HyClone, South Logan, Utah)
supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin (100
U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber.
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Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% FBS was used to
culture the R- cells under the same above conditions.
MiR isolation from formalin-fixed and paraffin embedded (FFPE) – miRs were extracted
from formalin-fixed, paraffin-embedded tissue sections prepared from tumor samples using
the High Pure FFPE RNA Micro Kit (Roche Applied Science, Indianapolis, IN). First, FFPE
tissue sections were marked for areas of interest and subjected to the following
deparaffinization conditions: xylene (2 changes, 10 min each), 100% ethanol (2 changes, 10
min each), and deionized water (1 change, until ready for tissue excision). Tissue areas were
excised using a blade and placed in microcentrifuge tubes. Tubes were spun to bring contents
to the bottom of the tube. To each sample, 100 µL Paraffin Tissue Lysis Buffer (provided in
kit), 16 µL 10% SDS, and 40 µL Proteinase K working solution were added. Samples were
vortexed and incubated in a 55°C water bath for 3 h. Next, 325 µL binding buffer was added
to each sample and transferred into the High Pure Filter tube attached to a 2mL collection
tube (provided in kit). Tubes were centrifuged 30 sec at 10,000 × g. Following centrifugation,
the flow through was discarded and samples were washed 2 times with 500 µL Wash buffer
working solution, then once again with 300 µL Wash buffer working solution. Finally, the
tubes were centrifuged at 13,000 × g for 1 min to dry the filter. The High Pure Tube was
placed in a clean 1.5 mL microcentrifuge tube and solution containing miRs were eluted 2
times with 20 µL nuclease-free water.
RNA extraction, cDNA synthesis, and quantitative real time PCR (qPCR) – Total RNA was
isolated and purified using RNAeasy Mini Kit (Qiagen, Valencia, CA). Briefly, 1-2 × 106
cells were collected by centrifugation at 200× g for 5 min, washed twice in sterile PBS, and
subjected to lysis and homogenization by RNA Lysis (RLT) buffer using QiaShredder spin
columns. Homogenized cells were resuspended in an equal volume of 70% ethanol and
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passed through provided spin columns. Two additional washing steps were performed with
appropriate buffers: Buffer RW1 and Buffer RPE. Total RNA was collected upon elution
with nuclease-free water. Optical density readings were read using DNA/Protein Analyzer
(Beckman Coulter, Fullerton, CA)
cDNA synthesis for IGF-IR was performed through a two-step procedure using
Superscript III RT protocol (Invitrogen, Carlsbad, CA). Approximately 0.3 μg total RNA was
used for reverse transcription. First, total RNA, oligo (dT), and dNTP mix were added to a
mixture that was adjusted to a final volume of 10 μL with nuclease-free water. This mixture
was denatured by incubating at 65°C for 5 min and then placed on ice. Second, a master
reaction mix consisting of 10× cDNA synthesis buffer, 0.1 DTT, RNaseOUT, SuperscriptIII
RT, MgCl2 and nuclease-free water was prepared on ice and vortexed gently. Approximately
10 μL of master mix was pipetted into each sample tube on ice bringing the final volume to
20 μL. The samples were then transferred to a thermal cycler preheated to the appropriate
cDNA synthesis temperature and incubated for 60 min at 50°C, then terminated at 85°C for 5
min. 1 μL of RNase H was added and samples were incubated at 37°C for 20 min to remove
template RNA.
cDNA synthesis for miR-30a and miR-30d was performed using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems). Briefly, 100 mM dNTPs (with dTTP),
MultiScribe™ Reverse Transcriptase (50 U/µL), 10× Reverse Transcription (RT) Buffer,
RNase Inhibitor (20 U/µL), and nuclease-free water was combined with total RNA in the
ratio of 7 µL RT master mix: 5 µL total RNA (300 ng/reaction). Samples were mixed gently
and centrifuged to bring the solution to the bottom of the tube. To each sample, 12 µL of the
master mix prepared above containing total RNA and 3 µL of 5× RT primer from each assay
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set was added into the corresponding RT reaction tube for a final volume of 15 μL/reaction.
The samples were vortexed, centrifuged briefly, and transcribed using the following PCR
conditions:
Table 7. PCR conditions for miRNA reverse transcription
Steps

Time

Temperature

Hold

30 min

16°C

Hold

30 min

42°C

Hold

5 min

85°C

Hold

∞

4°C

qPCR was used to quantitate the levels of IGF-IR mRNA in NPM-ALK+ ALCL cell lines
after transfection with miR-30a and miR-30d using the reverse transcribed cDNA, IGF-IR
gene expression assay primer/probe, and Taqman Mastermix (Applied Biosystems). The
primer/probe sets used were obtained from Applied Biosystems (sequences not provided by
the manufacturer). 18S ribosomal RNA was used as the endogenous control.
qPCR was used to examine the expression levels for miR-30a and miR-30d using the
reverse transcribed cDNA, miR-30a, miR-30d or RNU48 gene expression assay
primer/probe, and Taqman Mastermix (no AmpErase UNG) (Applied Biosystems). The
primer/probe sets used were obtained from Applied Biosystems (sequences not provided).
RNU48 was used as the endogenous control.
Transfection – Transfection of NPM-ALK, control mimic, miR-30a, miR-30d (Dharmacon)
or with vectors used to create stable cell lines was performed by electroporation using Amaxa
nucleofection system in 100 µL cuvettes (Lonza; Solution V, Program A-023) and thereafter,
cells were incubated for 48 h. For luciferase assays, R- cells were transfected using
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Lipofectamine 2000 reagent. Briefly, 1 × 106 R- cells were seeded in 6 well plates overnight.
The following day, plasmids were incubated in 100 μL Optimem media for 5 min at room
temperature. Simultaneously, 7 μL of Lipofectamine reagent was incubated in a separate
tube. Thereafter, the tubes containing plasmids and the tubes containing Lipofectamine
reagent were combined and incubated for a further 20 min at room temperature. Finally, the
mixture was added to the corresponding well in the 6 well plates containing R- cells and
incubated for 48 h.
Cloning of IGF-IR 3’-UTR – IGF-IR 3’-UTR luciferase plasmid containing miR-30 binding
site was constructed by the following approach: IGF-IR was amplified from genomic DNA
(50 ng) using the HotStar Taq Mastermix, primers and PCR conditions listed in Table 2.
Table 8. PCR conditions for WT IGF-IR 3’-UTR construction
Primer Name

Sequence

WT IGF-IR 3’-UTR Forward

5’-GTGTCCGCATCTTTCTGGTC-3’

WT IGF-IR 3’-UTR Reverse

5’-GGATCACAAACACACATTTGC-3’

Step

Temperature Time

1. Initial activation step

95°C

15 min

Denaturation:

94°C

1 min

Annealing:

55°C

1 min

Extension:

72°C

1 min

2. 3-step cycling (35 cycles)

3. Final extension: 10 min 72°C
The PCR products were run on 1.5% agarose gel, excised, and purified using the
QIAquick gel extraction kit (Qiagen). Subsequently, DNA was ligated into pCR 2.1-TOPO
vector using the TOPO TA cloning system (catalog # 451641; Invitrogen). Briefly, 4 µL of
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fresh PCR product, 1 µL of Salt Solution, 1 µL of pCR 2.1-TOPO vector, and 5 µL of
nuclease-free water were admixed and incubated for 5 min at room temperature. Thereafter,
ligated products were immediately transformed using DH5α competent cells and plated on
ampicillin resistant agar plates coated with 40 mg/mL X-gal overnight at 37°C. White
colonies were picked and amplified using ampicillin containing LB broth overnight at 37°C
with shaking at 225 rpm and subjected to miniprep using QIAprep Miniprep kit (Qiagen).
Plasmid sequence was confirmed using direct sequencing. In order to create the luciferase
reporter plasmid containing the IGF-IR 3’-UTR, the pCR 2.1-TOPO-IGF-IR-3’-UTR
plasmid and the pGL4.17 luciferase vector (Promega) were subjected to restriction enzyme
digest using Hind III and Eco RV restriction enzymes (New England Biolabs, Ipswich, MA).
Restriction enzyme digested products were run on a 1.5% agarose gel and purified using the
QIAquick gel extraction kit. Resulting DNA was ligated using the Quick Ligation kit
(Catalog # M2200S; New England Biolabs) and the following PCR conditions in Table 3:
Table 9. PCR conditions for Quick Ligation
Temperature Time
22°C

30 min

20°C

30 min

18°C

30 min

16°C

30 min

14°C

30 min

12°C

30 min

10°C

30 min

8°C

30 min

6°C

30 min

96
4°C

30 min

4°C

∞

Ligated products were subjected to transformation as described above. The WT IGF-IR
3’-UTR luciferase vector was used as a template to create mutated (MUT) IGF-IR 3’-UTR
luciferase constructs using the Quickchange II XL site-directed mutagenesis kit (Agilent
Technologies), primers and PCR conditions listed in Table 4.
Table 10. PCR conditions for mutated IGF-IR 3’-UTR construction
MUT IGF-IR 3’-UTR Forward
5’-TAGTCAGTTGACGAAGATCTGGTCAAGAACTAATTAAATGTTTCATT-3’
MUT IGF-IR 3’-UTR Reverse
5’-AATGAAACATTTAATTAGTTCTTGACCAGATCTTCGTCAACTGACTA-3’
Step

Temperature Time

1.

95°C

1 min

2.*

95°C

50 sec

60°C

50 sec

68°C

6 min

68°C

7 min

3.
*

Step 2 is repeated for a total of 18 cycles

MUT IGF-IR 3’-UTR luciferase plasmids were transformed, purified, and verified using
the above procedures.
Luciferase assay – Luciferase assay was performed with the Dual Glo Luciferase kit
(Promega) after cotransfecting R- cells with the reporter plasmids containing the wild type or
mutated IGF-IR 3’-UTR constructs along with control mimic, miR-30a or miR-30d. Cells
were washed with sterile PBS, scraped, and plated in a 96 well luminometer plate.
Thereafter, the Dual-Glo Reagent (75 μL) was added and incubated for 10 min at room
temperature for cell lysis to occur. Firefly luminescence readings were obtained using a
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luminometer. Finally, the Dual-Glo Stop & Glo reagent was added in equal volume to
original culture media volume and incubated for 10 min at room temperature. Renilla
luminescence readings were obtained using the above methods.
Western blotting – Cells were collected and lysed using lysis buffer containing 25 mM
HEPES (pH 7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM
PMSF, 2 mM DTT, phosphatase inhibitor, and protease inhibitor cocktails (Thermo
Scientific). Protein concentrations were measured using Bio-Rad protein assay and OD
values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT).
Proteins (50 μg) were electrophoresed on 8% SDS-PAGE. The proteins were transferred to
PVDF membranes and probed with specific primary antibodies and then with appropriate
horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Cardiff, UK).
Proteins were detected using chemiluminescence-based kit (Amersham Life Sciences,
Arlington Heights, IL).
Antibodies – The following antibodies were used: pIGF-IRY1131 (3021), pALKY1604 (Y664 in
NPM-ALK; 3341), pAKTS473 (4051), integrin α5 (4705), and integrin β1 (9699) (all from
Cell Signaling Technology, Danvers, MA); IRS-1 (ab40777) and AKT (ab8805) (Abcam,
Cambridge, MA); IGF-IR (396700, Life Technologies, Grand Island, NY); pIRS-1S639 (sc22300, Santa Cruz Biotechnology, Santa Cruz, CA); ALK (M719501-2, Dako, Carpinteria,
CA); and β-actin (A-5316, Sigma).
Colony formation assay – Transfected cells were resuspended to eliminate clumping and
then added in a 1:10 (v/v) ratio to 3 mL methylcellulose (MethoCult H4230 (NPM-ALK+
ALCL cells) or MammoCult 04100 (for MCF-7); Stemcell Technologies) in 15 mL tubes.
Tubes were tightly capped, and the mix was gently inverted several times. Then, 1.0 mL of
the mix was divided into 24-well plates in triplicates. Plates were placed in a humidified
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incubator at 37°C in 5% CO2 for 7 days and then p-iodonitrotetrazolium violet was added for
24 h for staining. Colonies were visualized using AlphaImager system (Santa Clara, CA).
Cell proliferation assay – Cell proliferation was measured using the 5-bromo-2′deoxyuridine (BrdU) assay kit (ExAlpha, Shirley, MA). Briefly, 2 × 105 cells/mL was plated
into a 96-well plate. The BrdU label (1:500 dilution) was added, and the plate was incubated
for 24 h at 37°C. Cells were fixed for 30 min at room temperature, incubated with anti-BrdU
antibody for 1 h after washing, followed by peroxidase goat anti-mouse IgG conjugate
(1:2000 dilution) for 30 min. Thereafter, the 3,3’,5,5’-tetramethylbenzidine peroxidase
substrate was added and incubated for 30 min at room temperature in the dark. Thereafter,
the acid Stop Solution was used to stop the reaction and the plate was read at 450 nm using
an ELISA plate reader.
Cell migration assay – Cell migration was studied using 24-well transwell plates with
polycarbonate membranes (Corning Costar, Tewksbury, MA). Briefly, treated NPM-ALK+
ALCL cells were serum-starved for 24 hours, then loaded in serum-free RPMI 1640 medium
onto the upper compartment. Simultaneously, 500 ng/mL insulin-like growth factor I (IGF-I)
(R&D Systems, Minneapolis, MN) was loaded in serum free culture medium onto the lower
compartment. For control cells, untransfected cells were incubated with or without IGF-I in
the lower compartment. Plates were incubated for 4 h at 37°C, and cells migrating through
the membrane into the lower chamber were counted using a particle counter and size
analyzer (Coulter).
5’aza-cytidine treatment – 1 × 106 NPM-ALK+ ALCL cells were plated in 24 well plates. 5
μM 5’-aza-cytidine (Catalog # A2385; Sigma Aldrich) was added to the wells and the plate

99
was incubated for 5 h. Thereafter, cells were collected by centrifugation (200× g for 5 min),
washed once with PBS, and subjected to RNA extraction.
Stable cell lines – To generate Karpas 299 tamoxifen-inducible stable cells, vectors
containing miR-30a (pEGFP/RFP-miR-30a) or miR-30d (pEGFP/RFP-miR-30d) were used
(catalog # v-0923, CelluTron, Baltimore, MD). The vector expressing Cre recombinase
(pCreER-IRES-Puro) was also used (catalog # v-0924, CelluTron). Karpas 299 cells were
transfected with empty vector or miR-30a or miR-30d expression vectors by electroporation
(as described above). Forty-eight hours post transfection, 2.5 µg/mL blasticidin was added to
culture media and the cells were incubated for 2 weeks. Thereafter, sorting by flow
cytometry was performed to isolate the GFP+ cells, which indicate that the miR vector of
interest is present. Furthermore, sorted cells were collected and expanded to become the
subsequent “host cell line.” The “host cell lines” were then transfected with the second vector
expressing Cre recombinase by electroporation. After 48 h, 0.1 µg/mL puromycin was added
for 1 week. Subsequently, stable cells expressing either empty vector or miR along with the
Cre recombinase vector were expanded and maintained in media containing 1.5 µg/mL
blasticidin and 0.05 µg/mL puromycin. Stable cell lines were first tested in vitro using 2 µM
4-hydroxytamoxifen (4-OHT; Sigma Aldrich). Images were obtained using Olympus IX70
microscope (Center Valley, PA).
In vivo studies – Mice (SCID/beige, female, 8 weeks old) were purchased from Taconic
Biosciences, Inc. (CBSCBG-F, Hudson, NY). Karpas 299 cells (2.0 × 106) expressing either
empty vector miR-30a or miR-30d were subcutaneously injected into the left flank. On the
day of injection, 2 mg/mL 4-OHT (dissolved in ethanol and corn oil in 1:9 ratio) was
administered for 21 days by i.p. injection. Tumor size was measured every 3 days using
Vernier calipers, and tumor burden was calculated using the formula: 3.14 × long axis × short
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axis2 × 0.6 cm3. Mice were euthanized when tumors reached 1.5 cm. To measure miRNA
levels, some were sacrificed at day 21.
Statistical analysis – Statistical analysis was performed using GraphPad Prism software. The
student’s t-test, Tukey’s multiple comparisons test, Log Rank Mantel-Cox test, and 2-way
ANOVA were used for statistical comparison, whenever appropriate. P < 0.05 was
considered statistically significant.
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3.3.2.2. Results
MiR-30a and miR-30d are downregulated in NPM-ALK+ ALCL cells: To examine whether
deregulated miRs exist in NPM-ALK+ ALCL cells, an miR array analysis was performed
using 5 NPM-ALK+ ALCL cell lines (Karpas 299, SR-786, SUP-M2, SU-DHL-1, DEL)
compared to normal human T lymphocytes (Figure 1A). The array generated a list of
potentially downregulated or upregulated miRs in NPM-ALK+ ALCL cells. Because of our
interest in IGF-IR, 3 web-based algorithms, TargetScan, PicTar, and miRANDA, were
utilized to explore whether any of the highly ranked miRs have potential binding sites with
the IGF-IR 3’-UTR. We identified that members of the miR-30 family of miRNAs could
potentially bind the IGF-IR 3’-UTR (Figure 16A). Although several members of this family
appeared to be deregulated based on the heat map, two of these miRs, miR-30a and miR-30d,
appeared with the highest binding probability. The low expression levels of miR-30a and
miR-30d, relative to human T lymphocytes, were confirmed by qPCR (Figure 16A).
Examination of miR-30a and miR-30d expression levels in lymphoid tumors from patients
revealed that these miRs were significantly decreased in these tissues compared to normal
lymph nodes (P<0.0001, Figure 16B).
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FIGURE 16. Array analysis of differential expression of miR in NPM-ALK+ ALCL cell
lines vs. normal human T lymphocytes. (A) MicroRNA array analysis identified numerous
miR to be downregulated (green/blue) or upregulated (yellow/orange/red) in NPM-ALK+
ALCL cell lines vs. normal human T lymphocytes. Because of our interest in whether any of
these miRs is involved in the regulation of IGF-IR expression, we used the web based
algorithms, TargetScan, MiRanda, and PicTar, to identify miRs with the potential to bind the
3’-UTR of IGF-IR. These algorithms predicted members of miR-30 family to bind with 3’UTR-IGF-IR (> 0.9). We focused on miR-30a and miR-30d because they demonstrated the
highest differential expression. The algorithms also proposed the potential binding sites of
miR-30a and miR-30d within the IGF-IR 3’-UTR (bottom panel). According to the miR
array, these miR are markedly downregulated in the lymphoma cell lines than the normal
human T-cell (upper left panel). Decreased expression of these miR was further confirmed by
qPCR (upper right panel) (T lymphocytes vs. NPM-ALK+ ALCL cell lines: * = p<0.00005).
(B) qPCR also shows that miR-30a and miR-30d are significantly downregulated in FFPE
tumor tissues from ALK+ ALCL patients compared to normal lymph nodes (* = p<0.05).
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MiR-30a and miR-30d bind IGF-IR 3’-UTR and decrease IGF-IR protein, but not IGF-IR
mRNA levels: We explored whether miR-30a and miR-30d possess the ability to bind and
regulate IGF-IR 3’-UTR by performing a luciferase assay using a wild type IGF-IR 3’-UTR
luciferase construct along with control, miR-30a or miR-30d mimics transfected into R- cells,
which lack the expression of IGF-IR. Simultaneously, a luciferase assay using mutated IGFIR 3’-UTR luciferase construct lacking binding domains to miR-30a and miR-30d was
performed after transfection of control or miR mimics. MiR-30a and miR-30d, but not the
control mimic, decreased the luciferase activity of wild type IGF-IR 3’-UTR. Furthermore,
changes were not observed in the luciferase activity of the mutated IGF-IR 3’-UTR. These
findings suggest that miR-30a and miR-30d bind and negatively regulate IGF-IR 3’-UTR
(Figure 17). Next, the effects of miR-30a and miR-30d on endogenously expressed IGF-IR
were examined by transfecting Karpas 299 and DEL cells with either control, miR-30a or
miR-30d mimic and then measuring IGF-IR protein and mRNA levels by Western blotting
and qPCR, respectively (Figure 18). Although miR-30a and miR-30d significantly decreased
IGF-IR protein, they failed to decrease IGF-IR mRNA, suggesting that these miRs induce
negative regulation of IGF-IR expression posttranscriptionally (Figure 18). We further
examined the phosphorylation levels of IGF-IR and its important downstream signaling
targets. Transfection of miR-30a and miR-30d was associated with decreased pIGF-IRTyr1131,
and also decreased pIRS-1Ser639 and pAKTSer473 levels, with no changes in total IRS-1 and
AKT. It has been previously demonstrated that IRS-1 and AKT are downstream targets of
IGF-IR signaling. MiR-30a and miR-30d also decreased pNPM-ALKTyr664 expression levels.
This finding is consistent with our previous observations that IGF-IR functions to maintain
the phosphorylation of NPM-ALK [128]. In addition, miR-30a and miR-30d also decreased
total NPM-ALK protein expression. We have previously demonstrated that IGF-IR is able to
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maintain NPM-ALK protein stability [127]. However, to rule out that these 2 miRs have
direct inhibitory effects on NPM-ALK, we searched the web-based miR target prediction
algorithms, and found that NPM-ALK does not represent a target of miR-30a or miR-30d.
These findings provide strong evidence to support that the decrease in total NPM-ALK
expression levels resulted from the decrease in IGF-IR and its effects on promoting the
stability of NPM-ALK protein. Finally, miR-30a and miR-30d decreased the expression of
important proteins involved in cell migration and adhesion and known to contribute to IGFIR oncogenic effects, namely integrin α5/β1.
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FIGURE 17. MiR-30a and miR-30d decrease IGF-IR-3’-UTR activity. A luciferase assay
in R- cells transfected with wild type IGF-IR 3’-UTR luciferase reporter construct along with
control mimic, miR-30a or miR-30d mimics revealed that miR-30a and miR-30d can bind
and regulate IGF-IR 3’-UTR. In contrast, R- cells transfected with control mimic or mutated
[MT] IGF-IR 3’-UTR failed to show similar decrease in IGF-IR 3’-UTR activity (*: p<0.05;
**: p<0.001). The results are shown as means ± SD of 3 consistent experiments.
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FIGURE 18. MiR-30a and miR-30d decrease IGF-IR protein expression, but not IGFIR mRNA expression. Forced expression of control mimic, miR-30a or miR-30d mimics in
Karpas 299 and DEL cell lines induced marked downregulation of IGF-IR protein (upper
panel), but not IGF-IR mRNA (lower panel), indicating that these miRs regulate IGF-IR
expression posttranscriptionally. The results are shown as means ± SD of 3 consistent
experiments. In addition, there were significant decreases in pIGF-IRTyr1131, pNPMALKTyr664, pIRS-1Ser639, and pAKTSer473 without any changes in total IRS-1 or total AKT. In
contrast, the basal levels of NPM-ALK were significantly reduced, which is in agreement
with our previous findings that IGF-IR sustains the stability of NPM-ALK protein.
Furthermore, there was significant decrease in the tumor cell invasion-related proteins,
integrins α5/β1. To our knowledge, which was further supported by searching the web-based
miR prediction search algorithms, integrins α5/β1 are not potential direct targets of miR-30a
or miR-30d, and therefore their downregulation most likely resulted from IGF-IR
downregulation.
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MiR-30a and miR-30d decrease cell proliferation, migration, and anchorage-independent
colony formation potential of NPM-ALK+ ALCL cells: Thereafter, we proceeded to test the
impact of miR-30a and miR-30d-mediated downregulation of IGF-IR on the neoplastic
potential of NPM-ALK+ ALCL. Transfection of Karpas 299 and DEL with either miR-30a or
miR-30d significantly decreased lymphoma cell proliferation (Figure 19A), migration in
response to IGF-I (Figure 19B), and anchorage-independent colony formation potential.
Similar effects were not observed in control cells transfected with control mimic (Figure
19C).
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FIGURE 4. MiR-30a and miR-30d decrease cell proliferation, migration, and colony
formation potential in NPM-ALK+ ALCL cells. (A) Transfection of Karpas 299 and DEL
cells with miR-30a or miR-30d, but not control mimic, resulted in significant decrease in the
proliferation of these cells after 48 h. (B) In addition, miR-30a and miR-30d decreased
significantly the migration of the lymphoma cells in response to IGF-I (500 ng/mL). (C) The
2 miRs abrogated Karpas 299 and DEL cell colony forming potential. The number of
colonies is shown on the left and representative images are shown on the right. *: p<0.05; **:
p<0.001; §: control mimic vs. miR-30a [p<0.05]; ¥: control mimic vs. miR-30d (p<0.05); †:
control mimic vs. miR-30d (p<0.001). The results are shown as means ± SD of 3 consistent
experiments.
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Methylation contributes to downregulation of miR-30a and miR-30d expression in NPMALK+ ALCL: At this point, we sought to define the mechanisms that could lead to
downregulation of miR-30a and miR-30d expression in NPM-ALK+ ALCL. To determine
whether the decrease in miR-30a and miR-30d was due to effects elicited by NPM-ALK,
Karpas 299 and DEL cells were transfected with scrambled siRNA or ALK siRNA for
various time points, and miR-30a and miR-30d levels were measured by qPCR. Even after
sufficient knockdown of NPM-ALK, there were no significant changes in miR expression,
suggesting that NPM-ALK most likely does not induce the decrease in miR-30a and miR30d (data not shown).
Several miRs have been previously shown to be decreased in cancer cells due to
epigenetic events, such as methylation of their gene promoters [187]. To test whether
methylation is suppressing expression of miR-30a and miR-30d in NPM-ALK+ ALCL,
Karpas 299 and SUP-M2 cells were treated with the demethylating agent 5’-azacytidine (5’aza) for 48 h and levels of miR-30a and miR-30d were measured by qPCR (Figure 20). 5’aza significantly increased miR-30a by 2, 2, and 3-fold in Karpas 299, DEL, and SUP-M2,
respectively. In addition, 5’-aza increased miR-30d by 2.5, 2, and 4-fold in Karpas 299, DEL,
and SUP-M2, respectively. These results suggest that methylation could represent one
possible mechanism underlying decreased expression of miR-30a and miR-30d in NPMALK+ ALCL.
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FIGURE 20. 5’-aza increases miR-30a and miR-30d expression in NPM-ALK+ ALCL
cells. Treatment of Karpas 299, DEL, and SUP-M2 with the demethylating agent 5’-azacytidine (5 µM for 48 h) resulted in increased miR-30a (2 fold, 2 fold, and 3 fold for Karpas
299, DEL, and SUP-M2, respectively) and miR-30d expression (2.5 fold, 2 fold, and 4 fold
for Karpas 299, DEL, and SUP-M2, respectively) (* = p<0.05, ** = p<0.001). The results are
shown as means ± SE of 3 consistent experiments.
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MiR-30a and miR-30d suppress NPM-ALK+ ALCL tumor progression in mice: Tamoxifeninducible stable cell line variants of Karpas 299 cells that express EV, miR-30a or miR-30d
were developed to test the effect of miR-30a and miR-30d on NPM-ALK+ ALCL in vivo. To
create these cell lines, a vector containing miR-30a or miR-30d juxtaposed to a red
fluorescent protein (RFP) coding sequence, was obtained. The vector also contained a green
fluorescent protein (GFP), which is flanked by lox P sites. The miR expressing vectors were
sequentially transfected with a second plasmid encoding Cre recombinase. With the
treatment of 4-hydroxy tamoxifen (4-OHT), the Cre recombinase was activated, which
resulted in excision of "floxed" GFP and the termination sequence allowing RFP and miR to
be expressed. Ex vivo analysis revealed that miR-30a and miR-30d were stably expressed, as
indicated by expression of RFP after the cells were treated with 4-OHT for 48 h, compared to
untreated cells that still showed GFP expression (Figure 21). In addition, cells transfected
with EV showed only GFP expression.
Stable cell lines expressing EV, miR-30a or miR-30d were subcutaneously injected into 3
different groups of SCID/beige mice. On the day of injection, 2 mg/mL 4-OHT was
administered i.p. to induce the expression of the miRs, and thereafter was administered daily
for 21 days to maintain the expression of miRs (Figure 22). Importantly, during the course of
administration of 4-OHT, mice in which miRs were induced displayed much slower tumor
establishment rate compared to control mice. By day 21, all of the mice in the control group
had already been euthanized, whereas all of the mice from the miR-30a and miR-30d groups
were alive. To measure miR levels after induction, some mice from the miR groups were
sacrificed at day 21. The level of expression of miR-30a and miR-30d were also measured in
tumors from control mice with lack of induction of miR. The remaining mice in were
monitored past day 21 without 4-OHT administration. After cessation of miR induction at
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day 21, tumors present in mice with activated miR-30a and miR-30d slowly began to
increase in size, although never reached the size of the control group. Furthermore, we
noticed that miR-30a and miR-30d groups of mice had much smaller tumors that were more
localized to the injection site relative to the control group (Figure 22A). Control mice, in
contrast, displayed larger tumors that were sometimes disseminated and spread to the dorsal
areas away from the injection site (Figure 22B). Measurement of miR-30a and miR-30d in
mouse tumors revealed both miRs to be decreased in control mice, but demonstrated high
expression in tumors from miR-induced mice. Furthermore, miR seemed to be continually
expressed at low levels after stopping 4-OHT treatment, which may account for the fact that
these tumors only gradually increased in size after 4-OHT cessation (Figure 23).
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FIGURE 21. Inducible miR-30a and miR-30d mouse model. (A) Stable Karpas 299 cell
lines were tested ex vivo before utilizing in mice. 4-OHT was added to Karpas 299 cells
expressing EV, miR-30a (pEGFP/RFP-miR-30a/pCreER-IRES-Puro) or miR-30d
(pEGFP/RFP-miR-30d/pCreER-IRES-Puro) for 48 h. Fluorescent microscopy revealed
conversion of GFP to RFP in cells transfected with miR-30a or miR-30d, indicating
expression of miRs, whereas cells expressing EV had no RFP signal, and thereby lack miR.
(B) Mice experiments scheme illustrating that 8-week old female SCID/beige mice were
injected s.c. with 2 × 106 Karpas 299 cells expressing EV, miR-30a or miR-30d. In miR-30a
and miR-30d groups, 4-OHT (2 mg/mL) was administered i.p. once daily and tumor burden
was measured every 3 days up to 21 days. After stopping 4-OHT at 21 days, some mice were
scarified to measure miRs levels in the tumors and the remainder observed until euthanized.
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FIGURE 22. MiR-30a and miR-30d suppress NPM-ALK+ ALCL tumor growth in vivo.
(A) Upper left panel; during administration of 4-OHT, mice in which miR-30a or miR-30d
was activated developed tumors substantially slower than the control mice. More
importantly, all control mice had been euthanized due to excessive tumor burden at day 21 or
before, whereas no mice from the miR-30a or miR-30d groups required to be euthanized
during this period. By day 29, tumor burden in miR-30a or miR-30d groups began to
gradually increase although for most of the tumors over 50 days their size was still
considerably less than control group tumors (overall tumor volume significance over 50 days:
control vs. miR-30; p=0.0004) Upper right panel; day 21 tumor volume only (*= p< 0.05);
Lower panel; survival for miR-30a and miR-30d groups of mice was significantly longer
relative to control groups (***= p=0.0006). (B) Representative images at day 21 (with 4OHT) or > day 21 (no 4-OHT). Control mice displayed larger tumors, including one mouse
that displayed disseminated tumors (example shown; all tumors from this example are shown
as tumor aggregate below image), whereas mice from miR-30a and miR-30d groups at 21
days displayed tumors that were smaller and localized to the site of injection. Although the
mice in the miR-30 groups in which 4-OHT treatment was stopped displayed slightly larger
tumors after 21 days, the tumor volume was still considerable less compared to controls.
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FIGURE 23. Adequate induction of miR-30a and miR-30d expression by
administration of 4-OHT in mice. miR-30a and miR-30d expression levels increased in
tumors from mice administrated 4-OHT for 21 days. High levels of miRs expression
continued even after cessation of 4-OHT, perhaps indicating that induction of miRs led to
persistent expression in the system.
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3.3.3. Posttranscriptional Regulation of IGF-IR: mRNA Stability
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3.3.3.1 Materials and Methods
Cell lines – Five NPM-ALK+ ALCL cell lines were used: Karpas 299, DEL, SUP-M2, SR786, and SU-DHL-1 (DSMZ, Germany). Normal T lymphocytes were purchased from
StemCell Technologies (Catalog # 70024, Vancouver, British Columbia). Lymphoma cell
lines and normal T lymphocytes were maintained in RPMI 1640 medium (HyClone, South
Logan, UT) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM),
penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air
chamber.
Actinomycin D treatment – Briefly, actinomycin D (Sigma) was dissolved in DMSO (final
concentration: 1 mg/mL). Human T lymphocytes or NPM-ALK+ ALCL cell lines were
treated with 1 µM actinomycin D and samples were collected at 0, 0.5, 1, 2, 4, and 8 h.
RNA extraction, cDNA synthesis and absolute quantitative real time PCR (qPCR) – Total
RNA was isolated and purified using RNAeasy Mini Kit (Qiagen, Valencia, CA). Briefly, 12 × 106 cells were collected by centrifugation at 200× g for 5 min, washed twice in sterile
PBS, and subjected to lysis and homogenization in RLT buffer using QiaShredder spin
columns. Homogenized cells were resuspended in an equal volume of 70% ethanol and
passed through provided spin columns. Two additional washing steps were performed with
appropriate buffers: Buffer RW1 and Buffer RPE. Total RNA was collected upon elution
with RNAse-free water. Optical density readings were detected using Nanodrop (Thermo
Scientific).
cDNA synthesis was performed through a two-step procedure using Superscript III RT
protocol (Invitrogen, Carlsbad, CA). Approximately 0.3 μg total RNA was used for reverse
transcription. First, total RNA, oligo (dT), and dNTP mix were added to a mixture that was
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adjusted to a final volume of 10 μL with Rnase-free water. RNA mixture and primer was
denatured by incubating at 65°C for 5 min and then placed on ice. Second, a master reaction
mix consisting of 10× cDNA synthesis buffer, 0.1 DTT, RNaseOUT, SuperscriptIII RT,
MgCl2, and RNAse-free water was prepared on ice and vortexed gently. Approximately 10
μL of reaction mix was pipetted into each reaction tube on ice bringing the final volume to 20
μL. The samples were then transferred to a thermal cycler preheated to the appropriate cDNA
synthesis temperature and incubated for 60 min at 50°C, then terminated at 85°C for 5 min. 1
μL of RNase H was added and samples were incubated at 37°C for 20 min to remove
template RNA.
Absolute Quantitation real-time PCR was used to examine levels of IGF-IR mRNA in
NPM-ALK+ ALCL cell lines and normal T lymphocytes in a 25 µL reaction using 1 µL of
the reverse transcribed cDNA, 20× IGF-IR copy number primer/probe, and Taqman
Genotyping Mastermix (Applied Biosystems). The primer/probe sets used were obtained
from Applied Biosystems (sequences not provided). To create a standard curve, serial tenfold dilutions (30, 300, 3000, 30,000, 300,000 copies) of an IGF-IR plasmid [128] were used.

127
3.3.3.2. Results
Rate of IGF-IR mRNA decay in ALK+ ALCL cell lines and normal human T lymphocytes:
Consistent with our previously published results [128], basal levels of IGF-IR were much
higher in the NPM-ALK+ ALCL cell lines than in the normal human T lymphocytes (Figure
24A, 24B). In T lymphocytes, IGF-IR mRNA decreased to 50% of its basal levels at 0.8 h
(Fig. 1A). The decay of IGF-IR mRNA varied among the 5 different NPM-ALK+ ALCL cell
lines, yet it consistently occurred at a more prolonged rate than T lymphocytes (Figure 24B),
decreasing to 50% of the basal IGF-IR mRNA at 2.62 ± 0.4 h (mean ± SE).
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FIGURE 24. IGF-IR mRNA expressed in NPM-ALK+ ALCL cells exhibits prolonged
decay time compared with IGF-IR mRNA from normal human T lymphocytes. (A) The
50% level of IGF-IR mRNA was detected at 0.8 h in normal human T lymphocytes. (B) In
contrast with T lymphocytes, the NPM-ALK+ ALCL cell lines expressed remarkably higher
basal levels of IGF-IR mRNA, with DEL and SUP-M2 cells demonstrating the highest and
lowest levels, respectively. The 50% IGF-IR mRNA level was achieved after longer periods
of time in the lymphoma cells than in normal T lymphocytes (SU-DHL-1: 3.7 h, Karpas 299:
3.4 h, SR-786: 2.6 h, SUP-M2: 1.9 h, DEL: 1.5 h). The mean of the IGF-IR mRNA decay
time in the lymphoma cells was 2.62 ± 0.4 h (SE). Results shown represent the means ± SE
of 3 experiments.
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3.4. Discussion for Aim 2
In this aim, we identified deregulated posttranscriptional mechanisms that could contribute to
the pathogenesis of NPM-ALK+ ALCL. First, we identified miR-30a and miR-30d as
potential regulators of IGF-IR expression at the posttranscriptional stage. Relative to normal
T lymphocytes and reactive human lymphoid tissues,, miR-30a and miR-30d were
significantly decreased in the NPM-ALK+ ALCL cell lines and tissues from lymphoma
patients. Binding of miR-30a and miR-30d to respective binding sites located within the IGFIR 3’-UTR decreased substantially the activity of the IGF-IR 3’-UTR. Furthermore, both
miRs decreased IGF-IR protein levels but not IGF-IR mRNA levels, suggesting that these
miRs do not cleave IGF-IR mRNA, but inhibit IGF-IR translation. Downregulation of IGFIR by miR-30a and miR-30d resulted in decreased phosphorylation of several important IGFIR interacting proteins and induced reduction in cell proliferation, migration, and colony
formation. Treatment with the demethylating agent, 5’-aza-cytidine, was associated with
increased miR-30a and miR-30d levels in NPM-ALK+ ALCL cell lines, alluding to the
possibility that these miRs are suppressed by epigenetic silencing. Importantly, the 2 miRs
hindered NPM-ALK+ ALCL tumor growth in immune-compromised mice. These results
suggest that miR-30a and miR-30d can negatively regulate the progression of NPM-ALK+
ALCL. At the posttranscriptional level, we also determined that IGF-IR mRNA turnover was
considerably slower in the NPM-ALK+ ALCL cells compared with normal T lymphocytes.
When we measured the expression levels of miR-30a and miR-30d, both miRNAs were
significantly decreased in the NPM-ALK+ ALCL cell lines and patient tumors compared to
normal T lymphocytes and reactive lymph nodes. To the best of our knowledge, the gene
from which miR-30a and miR-30d are transcribed has not been identified, and therefore, this
proved to be a limitation for us to further investigate how the expression of these miRs is
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negatively regulated. Nonetheless, there have been reports showing that certain oncogenes
can directly inhibit the expression of miRs [188-192]. Thus, we sought to examine whether
the key oncogene in NPM-ALK+ ALCL, namely NPM-ALK, is involved in the suppression
of miR-30a and miR-30d. Effective targeting NPM-ALK by siRNA did not result in
increased expression of either miR-30a or miR-30d, suggesting that NPM-ALK is not
contributing to downregulation of miR-30a and miR-30d expression (data not shown).
However, there have been a variety of other mechanisms proposed for the deregulation of
miRs in cancer such as epigenetic silencing [187]. A large proportion of tumor suppressor
miRs are located within CpG islands, and therefore, are prone to DNA hypermethylation, as
in the case of miR-127, miR-9-1, miR-34b/c cluster, and the DNMT1-derived miR-124a
[193-196]. In our study, treating the NPM-ALK+ ALCL cell lines with demethylating agent
5-aza-cytidine increased the expression of miR-30a and miR-30d, suggesting that the gene
promoter from which miR-30a and miR-30d are transcribed is methylated.
Although there are few studies that have shown that some members of the miR-30 family
possess oncogenic potential, the majority of these studies have described these miRs as tumor
suppressors [197-201]. In line with these studies, our data show that miR-30a and miR-30d
induced significant posttranscriptional decrease in IGF-IR protein expression,. To further
support this notion, both miR-30a and miR-30d decreased significantly the activity of the
IGF-IR 3’-UTR, which resulted in decreased cell proliferation, migration, and colony
formation potential of NPM-ALK+ ALCL cell lines, testifying to the tumor suppressor
properties of these miRs.
Exogenous expression of miR-30a and miR-30d in the NPM-ALK+ ALCL cells
decreased the phosphorylation of NPM-ALK as well as its basal protein levels. We have
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recently demonstrated that IGF-IR and NPM-ALK are physically associated via the Y646
and Y664 residues of NPM-ALK and Y950 residue of IGF-IR, which are located within their
respective C-terminus. Through this association, a positive feedback loop appears to sustain
their activation/phosphorylation [127, 128]. We also previously found that specific
abrogation of IGF-IR by siRNA significantly decreased NPM-ALK protein levels, further
attesting to the contribution of IGF-IR to sustaining NPM-ALK protein stability [127]. Using
the 3 web-based miR prediction algorithms, we found that miR-30a and miR-30d do not have
potential binding sites within NPM-ALK, implying that the decrease seen in NPM-ALK
protein expression levels most likely resulted from IGF-IR downregulation.
Decreased IGF-IR level after transfection with miR-30a and miR-30d was associated
with decreased phosphorylation of important IGF-IR downstream signaling partners,
including pIRS-1 and pAKT, with no changes in total IRS-1 or AKT, which further
demonstrates that miR-30a and miR-30d possess tumor suppressor properties in this
lymphoma. Previous in vitro and in vivo studies showed that members of the miR-30 family
are involved in the regulation of migration, invasion, and adhesion in a variety of cancer cells
including those of the prostate, pancreas, and breast. These effects occur through modulating
key proteins such as Ets-related gene (ERG), vimentin, integrin β3, and other epithelial-tomesenchymal transition molecules [199, 202, 203]. In the NPM-ALK+ ALCL cells, another
cellular protein involved in cell adhesion and migration, integrin α5/β1, significantly
decreased after miR-30-induced downregulation of IGF-IR. There have been previous reports
indicating that IGF-IR or its primary ligand IGF-I can promote the stability and expression of
α5/β1 to support the progression of different carcinomas, such as plasma cell myeloma,
prostate cancer, and chondosarcoma by enhancing cell motility, migration, adhesion of the
malignant cells, and contributes to therapeutic resistance [204-208]. Because α5/β1 is not a
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direct target of miR-30a or miR-30d, as indicated by the three online algorithms,
downregulation of IGF-IR by miR-30a and miR-30d most likely caused the decrease in α5/β1
and thus contributed to the inhibition of the migratory potential of the NPM-ALK+ ALCL
cells.
MiR-30a and miR-30d were able to inhibit the NPM-ALK+ ALCL tumor growth in
SCID/beige mice. Even after withdrawing the administration of 4-OHT at 21 days, miR
expression remained elevated in the mice, suggesting that although the tumor growth in some
of these mice increased gradually, the overall average of the tumors in miR-30-induced group
of mice never reached the overall average of tumor growth in control mice, perhaps due to
the persistent effects of miR-30, which continuously slowed the progression of the tumors. In
addition, some control mice displayed disseminated tumors, whereas all the miR-30a and
miR-30d groups displayed smaller tumors that were confined to site of injection. Although
these miRs can regulate different proteins involved in migration and invastion, it is possible
that in our system, this effect was due to downregulation of integrin α5/β1 and thereby
limiting the migration of these cells to other sites.
Because we found that the lack of expression of miR-30a and miR-30d is independent
from NPM-ALK, we decided to study whether these miRs are also capable of regulating the
expression of IGF-IR in other cancer types that are known to have high expression of IGF-IR
such as breast cancer and colon cancer [209, 210]. Similar to the NPM-ALK+ ALCL, miR30a and miR-30d were significantly decreased in the MCF-7 and SW480 breast cancer and
colon cancer cell lines, respectively, as well as primary tissue specimens from patients
(Figure S1). Ectopic expression of miR-30a and miR-30d in MCF-7 and SW-480 cells
induced remarkable downregulation of IGF-IR protein, but not IGF-IR mRNA (Figure S2).
Downregulation of IGF-IR decreased pIGF-IR, pAKT, pIRS-1, integrin α5/β1, and led to
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significant reduction in cell proliferation, migration, and anchorage-independent colony
formation potential (Figures S2 and S3). It has been previously shown that upregulation of
integrin α5/β1 in MCF-7 cells contribute to multidrug resistance (MDR) [205].
Downregulation of integrin α5/β1 through reduction in IGF-IR protein by miR-30a and miR30d may provide a mechanism to overcome MDR in these cells. Furthermore, both miR-30a
and miR-30d significantly hindered progression of mammary tumors in female Balb/c nude
mice (Figures S5 and S6). Recently, it has been shown that IRS-2 is a target for miR-30a in
colon cancer [211]. In addition, miR-30a has been previously documented to reduce breast
cancer by targeting vimentin, AVEN, metadherin, and Eya2 [212-215]. This further stresses
the importance of these miRs for the survival of these cancers. In our study, we provide
substantial evidence demonstrating IGF-IR as a novel target for miR-30a and miR-30d in
these cancers.
Our data also show that the posttranscriptional decay of IGF-IR mRNA in NPM-ALK+
ALCL occurs over a remarkably prolonged time compared with the decay of IGF-IR mRNA
that is physiologically expressed in human T lymphocytes, suggesting an additional
deregulated mechanism in which IGF-IR is upregulated posttranscriptionally. Very few
studies have examined the rate of IGF-IR mRNA decay in other types of cancer, but these
few studies support our findings [216-218]. For instance, when we treated the NPM-ALK+
ALCL cells with actinomycin D, the average half-life for the lymphoma cells was around 3
h. This is similar to what was observed in other types of cancer, such as in the pancreatic
cells MIA-PaCa-2 in which the half-life of IGF-IR mRNA was 4 h, compared to control cells
in which 50% of IGF-IR mRNA was decayed in as little as 20 min after actinomycin D
treatment [218]. Similar rates of decay were observed in breast cancer cells after treatment
with antiestrogen ICI 182780 in a separate study [219]. Some mechanisms have been
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proposed to explain the sustained stability of IGF-IR mRNA. For example, in one study,
treatment of the osteogenic sarcoma-derived cell line Saos-2 with TNFα, decreased
substantially IGF-IR mRNA stability relative to untreated cells [220]. It has been previously
reported that NPM-ALK+ ALCL cells lack the expression of TNFα due to DNA methylation
of the TNFα promoter [221]. Furthermore, TNFα is highly expressed in normal activated T
lymphocytes, where it is frequently involved in immune responses, especially in regards to
inflammatory and immunomodulatory processes [222-225]. The lack of expression of this
cytokine in the NPM-ALK+ ALCL cells may be one possibility why IGF-IR mRNA is able
to remain stable for longer periods of time compared to the normal T lymphocytes. In two
other separate studies, IGF-IR mRNA stability was greatly influenced by the expression of
HuR, an mRNA-binding protein involved in regulating the stability of a variety of mRNAs
[216, 217]. Whether either of these mechanisms plays a role in NPM-ALK+ ALCL is a
direction of future study.
Overall, in this aim, we have determined the tumor suppressing properties of miR-30a
and miR-30d in NPM-ALK+ ALCL through targeting IGF-IR. Negative regulation of IGF-IR
by miR-30a and miR-30d significantly reduces the oncogenic potential of these cells. In
addition, the delay in IGF-IR mRNA decay further contributes to the upregulation of IGF-IR.
Our results provide novel mechanisms in which IGF-IR is posttranscriptionally deregulated
in this lymphoma, which may be beneficial to develop new therapeutic approaches to treat
and ultimately eliminate the aggressive NPM-ALK+ ALCL.
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3.4.1. Supplemental
Stable cell lines – For MCF-7 Tet-inducible stable cell lines, miR-30a and miR-30d
sequences were first subcloned into pmRi-mCherry vector (Clontech, catalog # 631119).
Next, the pmRi-mCherry vectors expressing miR-30a or miR-30d were transfected into
MCF-7 Tet-On Advanced cell line (catalog # 631153, Clontech) along with hygromycin B
linear marker (200 ng; catalog# 631118, Clontech). Cells were cultured in DMEM media
containing 100 µg/mL hygromycin B and 200 µg/mL G418 antibiotics for 2 weeks. Positive
clones were expanded and maintained in DMEM media containing 50 µg/mL hygromycin B
and 100 µg/mL G418.
In vivo studies – For MCF-7 Tet-inducible miR in vivo experiments, mice (Balb/c nude,
catalog # BALBNU-F, 6-weeks old, female) were first primed with 2.5 µg/50 µL 17estradiol (E2) diluted in peanut oil and injected s.c. for 1 week to assist MCF-7 cell
proliferation. Then, mice were injected s.c. in the left mammary fat pad with 2 × 106 cells
expressing

MCF-7

Tet-ON,

pmRi-mCherry-miR-30a

or

pmRi-mCherry-miR-30d.

Doxycycline (2 mg/mL) plus 5% sucrose and 2.5 µg of E2 was administered starting on the
day of cell injection in the drinking water that was changed every 3 days in order to activate
the miR. Once tumors developed, tumor burden was measured every 3 days for 100 days
after cell injection. Tumor burden was calculated using the formula 3.14 × long axis × short
axis2 × 0.6. Doxycycline was administered during the entire 100 days, until mice were
sacrificed.
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FIGURE S1. MiR-30a and miR-30d are downregulated in MCF-7 and SW480 cells. (A)
qPCR analysis identified the expression of miR-30a and miR-30d to be remarkably
downregulated in MCF-7 and SW480 cells compared with normal epithelial cells (MCF10a). (B) A similar pattern of expression was identified in breast cancer patients and colon
cancer patients compared to their respective normal counterparts (* = p<0.05).
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FIGURE S2. MiR-30a and miR-30d decrease IGF-IR protein expression, but not IGFIR mRNA expression in MCF-7 and SW480 cells. Forced expression of control mimic,
miR-30a mimic or miR-30d mimic in MCF-7 and SW480 cell lines induced marked
downregulation of IGF-IR protein levels (upper panel), but not of IGF-IR mRNA levels
(lower panel). The results are shown as means ± SD of 3 consistent experiments. In addition,
as shown in upper panel, there were significant decreases in downstream signaling proteins
such as pIGF-IR1131, p-IRS-1Ser605, and pAKTSer445 without notable changes in total IRS-1
and AKT. Furthermore, miR-30a and miR-30d decreased the expression of integrin α5/β1.
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FIGURE S3. MiR-30a and miR-30d decrease cell proliferation, migration, and colony
formation potential in MCF-7 and SW480 cells. (A) Transfection of MCF-7 and SW480
cells with miR-30a and miR-30d, but not control mimic, resulted in significant decrease in
their proliferation after 48 h. (B) In addition, miR-30a and miR-30d decreased significantly
the migration of the cells in response to IGF-I (500 ng/mL). (C) The two miRs decreased
colony formation potential of MCF-7 and SW480 cells. Numbers of colonies are shown on
the left and representative images are shown on the right. *: p<0.05; **: p<0.001; §: control
mimic vs. miR-30a [p<0.05]; ¥: control mimic vs. miR-30d [p<0.05]. The results are shown
as means ± SD of 3 consistent experiments.
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FIGURE S4. Breast cancer mouse model with inducible expression of miR-30a or miR30d. Six-weeks old female Balb/c nude mice were first primed with s.c. injection of 2.5
µg/50 µL 17-estradiol (E2) diluted in peanut oil subcutaneously for 1 week before cell
injection in order to assist MCF-7 cell proliferation. Then, mice were injected s.c. in the left
mammary fat pad with 2 × 106 cells expressing MCF-7 Tet-ON, pmRi-mCherry-miR-30a or
pmRi-mCherry-miR-30d. Doxycycline (2 mg/mL) plus 5% sucrose and 2.5 µg of E2 was
administered on the day of cell implantation in the drinking water that was changed every 3
days for entire 100 days in order to activate the miR. Once tumors developed, tumor burden
was measured every 3 days for 100 days total from time of cell implantation.
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FIGURE S5. Inducible expression of miR-30a and miR-30d suppresses breast cancer
tumor growth in vivo. (A) Right panel; tumors developed in all control mice at 62 days after
MCF-7 cell s.c. implantation. In miR-30a and miR-30d groups, only 2/5 mice developed
tumors. Tumors in control mice grew significantly faster, and the average tumor volume was
greater than the miR-30a and miR-30d groups of mice, whose sizes were smaller and
stabilized over the course of the study (100 days). Left panel; at day 100, control and miR-30
groups were euthanized to collect tumors [tumor burden significance at day 100 only, ***= p
<0.0001; overall tumor burden significance: control vs. miR-30; p<0.0001]. (B) At day 100,
control mice displayed tumors of variable sizes but were generally larger with greater
average tumor volume than mice from miR-30a and miR-30d groups that displayed smaller
average tumor sizes.
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FIGURE S6. Doxycyclin increased efficiently the levels of miR-30a and miR-30d in vivo.
MiR-30a and miR-30d expression levels increased in tumors that miRs were activated by
doxycycline treatment at 100 days.
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3.5. Posttranslational Regulation of NPM-ALK & IGF-IR
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3.5.1. Introduction
Posttranslational modifications contribute to critical signaling events that occur during
neoplastic transformation. SUMOylation is a posttranslational modification that is
characterized by the covalent and reversible binding of small ubiquitin-like modifiers
(SUMO), including SUMO-1, SUMO-2/3, and SUMO-4, with their target proteins [226228]. Although SUMOylation has some similarities with ubiquitination [229, 230], it has
been shown that SUMO proteins compete with ubiquitin for substrate binding and thus
SUMOylation appears to protect target proteins from proteasomal degradation [231, 232]. In
addition to enhancing protein stability, SUMO proteins are involved in nuclear translocation
of target proteins, which affects processes essential for cellular homeostasis [233, 234]. The
SUMO family also includes the sentrin-specific proteases (SENPs): SENP1-3 and SENP5-7
[226, 235]. The roles of SENPs encompass removal of SUMO from target proteins; thus
suppressing protein stabilization induced by SUMOylation. It has been recently demonstrated
that SUMOylation plays a key role in the progression of cancer by stabilizing oncoproteins or
targeting tumor suppressors to proteosomal degradation [236-240]. SUMOylation in NPMALK+ ALCL has not been previously studied; therefore, one of our goals in this aim is to
analyze SUMOylation in this aggressive lymphoma.
Posttranslational modifications also include ligand-mediated activation of target proteins.
It has been previously shown that chimeric oncogenes, e.g., the Ewing sarcoma fusion
proteins, transcriptionally induce the expression of IGF-I [68]. The increase in secreted IGFI, as we have previously demonstrated in this lymphoma, leads to phosphorylation and
activation of IGF-IR protein through dimerization. Whether NPM-ALK upregulates IGF-I
expression and, as a result, promotes IGF-I-induced activation of IGF-IR is not known. In
this aim, we also examined the potential role of NPM-ALK in regulating IGF-I expression.
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3.5.2. Aberrant Posttranslational Mechanisms: SUMOylation
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3.5.2.1. Materials and Methods
Web-based search – To identify potential SUMOylation consensus binding sites within
NPM-ALK and IGF-IR amino acid sequences, the online algorithm SUMOplot was used:
http://www.abgent.com/SUMOplot.
Cell lines – Five characterized NPM-ALK+ ALCL cell lines were used, including Karpas
299, DEL, SUP-M2, SR-786, and SU-DHL-1 (DSMZ, Germany). The 786-O (renal
adenocarcinoma cell line; CRL-1932, ATCC) was used as a negative control for SUMO
proteins. Jurkat cells (T lymphoblastic leukemia/lymphoma; ATCC) were used as host cells
in protein degradation experiments and as a positive control. The normal human CD3+ pan-T
cells were purchased (Catalog number: 70024, StemCell Technologies, Vancouver, British
Columbia, Canada). Cells were maintained in RPMI 1640 medium (HyClone, South Logan,
UT) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin (100
U/mL), and streptomycin (100 μg/mL) at 37°C in a chamber containing humidified air with
5% CO2.
Western blotting – Western blotting was used to analyze the expression of various proteins.
Cells were collected and subjected to lysis using lysis buffer as previously described [128].
Concentrations were measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA), and
OD values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT).
Proteins (50 μg) were subjected to electrophoresis with sodium dodecyl sulfate on 8% SDSPAGE. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes and probed
with specific primary antibodies and then with appropriate horseradish peroxidase–
conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, and GE
Healthcare, Cardiff, UK). Proteins detection was performed using chemiluminescence
(Amersham Life Sciences, Arlington Heights, IL).
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Antibodies – Antibodies included SUMO-1 (4940), SUMO-2/3 (4971), Ubc9 (4786), SENP1
(11929), Ubiquitin (3933), Myc-tag (2276) (Cell Signaling Technology, Danvers, MA), ALK
(M7195; DAKO, Carpenteria, CA), and β-actin (a5316; Sigma, St. Louis, MO).
Immunoprecipitation – Cells were lysed using lysis buffer containing 25 mM HEPES (pH
7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM
phenylmethylsulfonyl fluoride (PMSF), 2 mM dithiothreitol (DTT), Halt protease and
phosphatase inhibitor cocktails 100× (Thermo Scientific), and N-Ethylmaleimide (NEM; 10
mM) (Thermo Scientific) to inhibit deSUMOylation [241]. For immunoprecipitation, protein
A/G agarose beads (Millipore, Billerca, MA) were blocked with 5% bovine serum albumin
(BSA) overnight in order to reduce non-specific binding. In addition, lysates were precleared using 2.5 µg normal IgG with rocking for 1 h at 4°C, followed by centrifugation for 1
min at 13,000 rpm and removal of supernatant. Thereafter, 800 µg of lysate was incubated
with 2.5 µg of primary antibody or mouse IgG control antibody along with the blocked
protein A/G agarose beads overnight at 4°C. The next day, immunocomplexes were spun and
supernatant was removed. The beads were washed 3 times with cold phosphate-buffered
saline solution (PBS) for 15 min each at 13,000 rpm and once with lysis buffer, and then
resuspended with 2× sample buffer (Bio-Rad). The samples were then subjected to SDSPAGE.
Recombinant proteins – The NPM-ALK recombinant protein was constructed using the TnT
T7/SP6 Coupled Rabbit Reticulocyte Lysate System (Promega, Fitchburg, WI). The template
for the TnT reaction was a plasmid previously described [128]. The following reaction
components were assembled in a 1.5 mL microcentrifuge tube: TNT Rabbit Reticulocyte
Lysate (25 µL), TNT Reaction Buffer (2 µL), TNT T7 RNA Polymerase (1 µL), Amino Acid
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Mixture Minus Leucine 1 mM (0.5 µL), Amino Acid Mixture Minus Methionine 1 mM (0.5
μl), RNasin Ribonuclease Inhibitor, 40 u/µl (1 μL), NPM-ALK plasmid template (2 µL),
Transcend Biotin-Lysyl-tRNA (1 μl), and nuclease-free water to a final volume of 50 μL.
Thereafter, the reactions were incubated at 30°C for 90 min. Aliquots of these reactions (5
µL) were analyzed by Western blotting to confirm the translation of NPM-ALK.
SUMOylation assay – The in vitro SUMOylation assay was performed by using the SUMO1 and SUMO-2/3 SUMOlink Kits (Active Motif, Carlsbad, CA). Briefly, the following
reaction components were assembled in a 1.5 mL microcentrifuge tube: protein buffer (1
µL), 5× SUMOylation buffer (1 µL), NPM-ALK recombinant protein (4 µL), E1 activating
enzyme (1 µL), E2 conjugating enzyme (1 µL), SUMO-1, -2 or -3 protein (1 µL), and
nuclease-free water to a final volume of 20 μL. For baseline mutated reactions, the SUMO
proteins were substituted with their corresponding mutated proteins, provided in the kit. The
reactions were mixed gently and incubated at 30°C for 3 h. Thereafter, the reactions were
stopped by adding an equal volume of 2× SDS-PAGE loading buffer and analyzed by
Western blotting.
Site-directed mutagenesis – NPM-ALKK24R and NPM-ALKK32R constructs were created by
using the QuickChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa
Clara, CA) and the following set of primers according to the manufacturer’s instructions:
Table 11. Primers used to create NPM-ALKK24R and NPM-ALKK32R constructs by sitedirected mutagenesis.
NPM-ALKK24R Forward
NPM-ALKK24R Reverse
NPM-ALKK32R Forward
NPM-ALKK32R Reverse

5’-TTTTCGGTTGTGAACTACGGGCCGACAAAGATTATC-3’
5’-GATAATCTTTGTCGGCCCGTAGTTCACAACCGAAAAG-3’
5’-GCCGACAAAGATTATCACTITCGCGTGGATAATGATGAAAATGAG -3’
5’-CTCATTTTCATCATTATCCACGCGAAAGTGATAATCTTTGTCGGC-3’

The polymerase chain reaction (PCR) products (5 µL) were transformed using
MaxEfficiency DH5alpha competent cells (Invitrogen), and the transformation reactions
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were plated on ampicillin-resistant plates. Colonies containing the correct insert were
confirmed by direct sequencing and amplified in ampicillin-containing LB broth overnight at
37°C with shaking at 225 rpm. The following day, the colonies were processed with the
QiaPrep Spin Miniprep Kit (Qiagen, Germantown, MD) to isolate plasmids. For in vitro
SUMOylation assays, the mutated plasmids were used as templates for the TnT reactions to
create mutated recombinant proteins.
Transfection – Transfection of NPM-ALK+ ALCL cells with the SENP1 expression plasmid
(Origene, Rockville, MD) was performed by electroporation using the Amaxa 4D
nucleofection system in 100 µL cuvettes (Solution SF, Program CA-150; Lonza, Houston,
TX); Transfection of Jurkat cells using the wild-type NPM-ALK, NPM-ALKK24R or NPMALKK32R plasmid was performed using the Nucleofector System (Solution V, Program X001; Lonza, Houston, TX); thereafter, cells were incubated for 48 h.
Protein degradation assay – Cells were transfected, using the conditions described in the
previous section, with either wild type or mutated NPM-ALK constructs for 48 h. The cells
were then treated with cyclohexamide (CHX, Sigma-Aldrich; 100 µg/mL) for another 24 or
48 h, then harvested and subjected to lysis and Western blotting.
Immunofluorescence – Cytospins were prepared from EV or myc-tagged SENP1 transfected
cells, followed by fixation with 4% paraformaldehyde (PFA) at the following timepoints: 0
min, 15 min, 30 min, 1 h, 3h, 6 h, 12 h, 24 h, and 48 h. After fixation, cells were subjected to
permeabilization with 0.2% Triton-X in PBS for 30 min at room temperature. Subsequently,
cells were blocked with 0.3% Triton-X/2% BSA in PBS solution for 1 h at room temperature.
Thereafter, Myc-tag primary antibody was added at 1:2000 dilution in order to detect
exogenous SENP1 and slides were incubated at 4°C overnight. The following day, slides
were washed 3 times in PBS and Alexa 647 fluorochrome-conjugated secondary antibody
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was added at 1:200 dilution for 1.5 h at room temperature. Thereafter, slides were washed 3
times in PBS and counterstained with DAPI. Prolong Gold Antifade Mountant (catalog #
P36934; Invitrogen) was added, slides were coverslipped, and sealed with nail polish to
prevent dehydration. Images were captured using Deltavision Image Restoration microscope
(Olympus IX71; GE Healthcare; total magnification is ×400).
Cell fractionation – Cell fractionation was performed using the Nuclear/Cytosol
Fractionation kit (BioVision, Milipitas, CA). For expression of cytoplasmic and nuclear
proteins at baseline levels as well as after transfection with EV or SENP1 expression
plasmids, cells were collected by centriguging at 600 × g for 5 min at 4°C. CEB-A buffer
(0.2 mL) containing DTT and protease inhibitors (provided in the kit) was added and samples
were spun at 500 × g for 3 min at 4°C. The supernatant was removed and the pellet was
resuspended in 0.2 mL of the CEB-A mix and subjected to vigorous vortexing at the highest
setting for 15 sec to fully resuspend the pellet. Thereafter, the samples were incubated on ice
for 10 min. Ice-cold CEB-B buffer (11 µL) was added to the tube, which was subjected to
vortexing and placed on ice for 1 min, and then spun at maximum speed for 5 min.
Immediately, the supernatant (containing the cytoplasmic extract) was transferred into a
clean, pre-chilled tube. The remaining pellet was washed 5 times in ice-cold PBS by
centrifugation at maximum speed for 1 min. Then, the pellet was resuspended in 30 µL of
ice-cold NEB buffer and subjected to vortexing for 15 sec and returned to ice for 10 min.
This step was repeated 4 times. Finally, the samples were subjected to centrifugation at
maximum speed for 15 min, and the supernatant (containing nuclear extract) was transferred
into a clean, pre-chilled tube.
Colony formation assay – Methylcellulose (3 mL; Methocult H4230) was added to 15 mL
tubes. Transfected cells were resuspended to eliminate clumping and then added in a 1:10
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(v/v) ratio to the methylcellulose. Tubes were tightly capped, and the mixtures were gently
inverted several times. Then, 1.0 mL of the mix was dispensed into 24-well plates in
triplicate. Plates were placed in a humidified incubator at 37°C in 5% CO2 for 7 days and
then p-iodonitrotetrazolium violet was added for 24 hours for staining. Colonies were
visualized using the AlphaImager system (ProteinSimple, San Jose, CA).
Cell viability assay – Cell viability was evaluated by the CellTiter 96 AQueous One Solution
Cell Proliferation Assay (MTS) kit (Promega). Cells were seeded in 96-well plates at a
concentration of 10,000 cells/well in 100 μL of RPMI medium supplemented with 10% FBS.
MTS reagent (20 μL) was added and then incubated at 37°C in a humidified chamber
containing 5% CO2 in air for approximately 4 hours. OD measurements were obtained by
using an ELISA plate reader.
BrdU assay – Cell proliferation was measured by using the 5-bromo-2′-deoxyuridine (BrdU)
assay kit (ExAlpha, Shirley, MA). Briefly, 2 × 105 cells/mL were plated into a 96-well plate.
The BrdU label (1:500 dilution) was added, and the plate was incubated at 37°C for 24 h.
Cells were fixed for 30 min at room temperature. The anti-BrdU antibody was added for 1 h
after washing, followed by peroxidase goat anti-mouse IgG conjugate (1:2000 dilution) for
30 min. Thereafter, the 3,3’,5,5’-tetramethylbenzidine peroxidase substrate was added to the
cells and the plate incubated for 30 min at room temperature in the dark. The acid Stop
Solution was then added and the plate was read at 450 nm by using an ELISA plate reader.
Protein extraction from FFPE tissues – Proteins were recovered from these sections by
using the Qiagen Qproteome FFPE Tissue Kit (Catalog # 37623). Briefly, 2 µM tissue
sections were subjected to the following sequence of deparaffinization conditions: (1) xylene
(2 × 5 min); (2) 100% ethanol (3 × 5 min); (3) 95% ethanol (3 × 5 min); and (4) 80% ethanol
(3 × 5 min). Areas of interest were excised from the slide with a needle and transferred to a
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1.5 mL collection tube. The supplied Extraction Buffer EXB Plus without β-mercaptoethanol
was provided with the kit. For each extraction procedure, 6 μL of β-mercaptoethanol was
first added to 94 μL of Extraction Buffer EXB Plus to obtain a working solution. Extraction
Buffer EXB Plus supplemented with β-mercaptoethanol (100 µL) was added into the tube
containing the excised tissue and mixed by vortexing. Each tube was sealed with a Collection
Tube Sealing Clip (supplied) and incubated on ice for 5 min, then mixed again by vortexing.
The samples were incubated on a heating block at 100°C for 20 min, and then incubated in an
oven with rotators at 80°C for 2 h with agitation at 750 rpm. Thereafter, the tubes were held
at 4°C for 1 min and the Collection Tube Sealing Clips were removed. The samples were
subjected to centrifugation for 15 min at 14,000 × g at 4°C. The supernatant containing the
extracted proteins was transferred to a new 1.5 mL tube. For quantification of protein yield,
the Bio-Rad assay was used.
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3.5.2.2. Results
SUMOylation pathway is upregulated in NPM-ALK+ ALCL cells: SUMOylation of IGF-IR
has been previously characterized in other types of cancers. In addition, we found
SUMOylation of IGF-IR in NPM-ALK+ ALCL cells (Supplemental Figures), which
supports previously published literature [238, 242-244]. Nonetheless, we decided to focus on
whether SUMOylation also contributes to NPM-ALK protein stability, which has not been
previously studied. To determine whether there are SUMO consensus motifs located within
the NPM-ALK amino acid sequence, we searched the online algorithm SUMOPlot and
identified several potential SUMO consensus motifs (Figure 25). Screening of the 5 NPMALK+ ALCL cell lines relative to normal human T lymphocytes revealed Ubc9 and SUMO-1
to be moderately overexpressed in 3/5 cell lines, whereas SUMO-2/3 demonstrated
significant overexpression in all cell lines. In contrast, SENP1 protein was substantially
decreased in all cell lines, suggesting that the SUMOylation pathway is deregulated in NPMALK+ ALCL cells (Figure 26A). A similar pattern was observed in patient samples extracted
from FFPE lymphoma tumor sections (Figure 26B).
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FIGURE 25. SUMO consensus motifs within NPM-ALK amino acid sequence. The
online software SUMOplot revealed several SUMO consensus motifs within the NPM-ALK
amino acid sequence, two of which appeared with the highest probability of conjugation with
the SUMO proteins (>0.80). Red: motifs with high probability; Green: motifs with low
probability; Blue: overlapping motifs.
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FIGURE 26. SUMO is upregulated in NPM-ALK+ ALCL. (A) Upper panel; screening of
the NPM-ALK+ ALCL cells lines Karpas 299, SR-786, DEL, SUP-M2, and SU-DHL-1 by
Western blotting revealed overexpression of Ubc9 and SUMO-1 in the majority of the cell
lines (4/5 and 3/5 cell lines, respectively) relative to normal T lymphocytes (TL). SUMO-2/3
was upregulated in the lymphoma cell lines, relative to TL. In contrast, SENP1 protease was
decreased in the lymphoma cell lines compared to TL. β-actin was used as a loading control.
Jurkat and 786-O cells were used as positive and negative controls, respectively. Lower
panel; densitometry of SUMO proteins relative to β-actin is shown. (B) Upper panel;
Western blot performed on protein extracted from FFPE tissue sections of patient specimens
(1-15) revealed a similar pattern of expression: Ubc9 and SUMO-1 was overexpressed in
7/15 and 9/15 patients, whereas SUMO-2/3 was overexpressed in all patients. In contrast,
SENP1 was decreased in 13/15 patients. β-actin was used as loading control. Lower panel;
densitometry of SUMO proteins relative to β-actin is shown. Variability in β-actin levels was
due to the poor quality of some of the FFPE tumor sections.
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SUMO proteins physically associate with NPM-ALK: To test whether the SUMO proteins
can physically associate with NPM-ALK, NPM-ALK protein was immunoprecipitated in the
Karpas 299 and SR786 cell lines and the expression of SUMO-1, SUMO-2/3, and Ubc9 was
analyzed by Western blotting. We found that all 3 of the SUMO proteins can interact with
NPM-ALK (Figure 27A). Furthermore, an in vitro SUMOylation assay showed that all
SUMO modifiers are capable of SUMOylating NPM-ALK in vitro, as indicated by the
presence of the higher molecular weight band above the baseline NPM-ALK protein levels.
In contrast, mutated SUMO-1 and SUMO-2/3 proteins failed to SUMOylate NPM-ALK
(Figure 27B).
SUMOplot showed several potential SUMO consensus motifs for NPM-ALK: K24 and
K32 were identified as having the highest probability of conjugation with SUMO proteins.
To determine whether these potential sites are indeed capable of binding the SUMO
modifiers, a second in vitro SUMOylation assay was performed using either the wild-type
NPM-ALK protein or NPM-ALK protein mutated at either K24 or K32 (Figure 28A).
SUMOylation was abolished with NPM-ALKK24R for both SUMO-1 and SUMO-3 and with
NPM-ALKK32R for SUMO-3 only (Figure 28B). This suggests that SUMO-1 and SUMO-3
are most likely the primary SUMO modifiers for NPM-ALK at K24 and K32. In contrast,
mutations at K24 and K32 failed to prevent SUMO-2 from conjugating to NPM-ALK;
SUMO-2 most likely conjugates to lysine residues found within other consensus motifs in
NPM-ALK.
Next, we sought to determine the effects of K24 and K32 mutations on NPM-ALK
protein stability. Jurkat cells, which lack NPM-ALK but contain high levels of SUMO
modifiers and Ubc9 proteins, were transfected with wild-type NPM-ALK, NPM-ALKK24R,
NPM-ALKK32R or the NPM-ALKK24R/K32R construct, and then treated with the protein
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synthesis inhibitor CHX for 24 or 48 h. While degradation of NPM-ALK protein was
minimal at 24 h, CHX inhibited protein synthesis significantly in cells expressing NPMALKK24R, NPM-ALKK32R, and most with the NPM-ALKK24R/K32R combination at 48 h. NPMALK mutated at K24 induced an increase in degradation by 42% compared to wild type
NPM-ALK. Similarly, NPM-ALK mutated at K32 led to an increase of its degradation level
by 56% vs. wild type NPM-ALK. Notably, NPM-ALK dual mutation at K24 and K32 was
associated with more pronounced increase in degradation; 67% in comparision with wild
type NPM-ALK. In contrast, CHX did not inhibit wild-type NPM-ALK at either time point
(Figure 29). These findings suggest that SUMOylation contributes to the stability of NPMALK in NPM-ALK+ ALCL cells.
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FIGURE 27. NPM-ALK is SUMOylated. (A) NPM-ALK was immunoprecipitated in
Karpas 299 and SR-786 cells, and the expression of SUMO proteins was detected by
Western blotting. These studies showed that SUMO-1 and SUMO-2/3 can interact with
NPM-ALK, as indicated by bands present in lane 1 (NPM-ALK immunoprecipition) but not
in lanes 2 and 3, where normal mouse IgG was immunoprecipitated or beads alone were used
in the IP reaction, respectively. (B) Upper panel; NPM-ALK recombinant protein was
created using the TnT coupled rabbit reticulocyte kit. Western blotting was performed to test
the expression of the NPM-ALK recombinant protein (entire membrane shown): no
expression of NPM-ALK in rabbit reticuloycte lysate only (lane 1), positive band
corresponding to NPM-ALK in the NPM-ALK recombinant protein at 80 kDa (lane 2), and
in the positive control Karpas 299 cell line (lane 3). Lower panel; recombinant NPM-ALK
protein was subjected to in vitro SUMOylation assay. Presence of a band with a molecular
weight that is ~20 kDa higher than baseline NPM-ALK molecular weight was detected in
lanes incubated with wild type SUMO-1 (lane 1), SUMO-2 (lane 3), or SUMO-3 (lane 5);
incubation with mutated SUMO forms (lanes 2, 4, and 6) did not show higher molecular
weight band.
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FIGURE 28. NPM-ALK is SUMOylated at Lys24 and Lys32. (A) Mutated NPM-ALK
recombinant proteins (NPM-ALKK24R and NPM-ALKK32R) were created using the TnT
coupled rabbit reticulocyte kit. Western blotting was performed to test NPM-ALK protein
expression of recombinant proteins: wild-type (WT) NPM-ALK recombinant protein (lane
1), NPM-ALKK24R recombinant protein (lane 2), and NPM-ALKK32R recombinant protein
(lane 3). (B) Wild type and mutated recombinant NPM-ALK proteins were subjected to an in
vitro SUMOylation assay. SUMOylation was abolished with the K24R mutation for SUMO1 and SUMO-3 and with the K32R mutation for SUMO-3. These two mutations failed to
deSUMOylate SUMO-2.
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FIGURE 29. SUMOylation promotes the stability of NPM-ALK protein. Upper panel;
Jurkat cells were transfected with wild type NPM-ALK, NPM-ALKK24R, NPM-ALKK32R or
NPM-ALKK24R/K32R for 48 h and then treated with the protein synthesis inhibitor
cyclohexamide (CHX) for an additional 0, 24, or 48 h. NPM-ALKK24R and NPM-ALKK32R
substantially decreased NPM-ALK protein expression at 48 h (42% and 50% protein
reduction, respectively), which was further enhanced with NPM-ALKK24R/K32R (67% protein
reduction). In contrast, wild type NPM-ALK protein expression did not decrease even after
48 h. Lower panel; densitometry of NPM-ALK compared to β-actin. β-actin loading was
unequal due to limited amount of protein available in some samples for Western blot after
prolonged transfection.
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Abolishment of SUMOylation prevents nuclear NPM-ALK accumulation in NPM-ALK+
ALCL cells: It is well established that NPM-ALK gains the ability to translocate to the
nucleus through the process of heterodimerization between wild type NPM and NPM-ALK
[50]. Whether other unidentified factors contribute to this phenomenon remain unclear.
SUMOylation has been shown to play important roles in the translocation of target proteins
into the nucleus [233]. We set to study whether SUMOylation contributes to the translocation
of NPM-ALK and its accumulation in the nucleus. To elucidate whether there is abundance
of NPM-ALK inside the nucleus in NPM-ALK+ ALCL cells, we fractionated Karpas 299 and
SR-786 (2 cell lines showing low expression levels of endogenous SENP1, but higher
expression of SUMO modifiers). As previously described [47], there was significantly higher
expression of NPM-ALK in the nuclear extracts than in the cytoplasmic extracts, as well as
higher expression of SUMO proteins in the nucleus (Figure 30). The strong presence of
NPM-ALK inside the nucleus may be due to the enhanced SUMOylation process in NPMALK+ ALCL cells. To further investigate this interesting observation, Karpas 299 and SR786 cells were transfected with SENP1, one of the proteases responsible for removing the
SUMO modifier from the target and thereby destabilizing the target, and cell fractionation
was performed again. Consistent with previous studies [245, 246], we found that SENP1 is
able to rapidly shuttle between the nucleus and cytoplasm in NPM-ALK+ ALCL cells
(Figure 31; upper panel). Importantly, SENP1 decreased the expression of SUMO proteins
in the nucleus. This decrease was associated with reduction of nuclear NPM-ALK levels in
both cell lines. This event further led to a decrease in the cytoplasmic expression of NPMALK, suggesting that SUMOylation contributes to the accumulation of NPM-ALK in the
nucleus in NPM-ALK+ ALCL cells, which appears to hinder its export from the nucleus to
the cytoplasm (Figure 31; lower panel).
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FIGURE 30. NPM-ALK is predominantly expressed in the nucleus. Cell fractionation
experiments in Karpas 299 and SR-786 revealed higher expression of NPM-ALK protein in
the nucleus, relative to cytoplasm. In addition, SUMO proteins were mainly nuclear. Lamin
A/C and β-actin were used as nuclear and cytoplasmic loading controls, respectively.
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FIGURE 31. SENP1 decreases NPM-ALK expression. Upper panel; Karpas 299 and SR786 cells were transfected with EV or SENP1 expression plasmid. Then,
immunofluorescence staining for the detection of SENP1 was performed at various time
points. Up to 1 h, SENP1 was predominantly localized in the cytoplasm, and then it became
predominantly nuclear at 3 to 6 h. At 24 h most of SENP1 appeared to be shuttling back to
the cytoplasm, whereas at 48 h strong levels of expression of SENP1 were detected in the
nucleus and cytoplasm. Lower panel; cellular fractionation shows that transfection of SENP1
in Karpas 299 and SR-786 cells resulted in decreased expression of SUMO-1 and SUMO-2/3
proteins at 48 h after transfection. The decrease in SUMO was associated with decreased
NPM-ALK protein expression in the nucleus and cytoplasm at 48 h after transfection. The
decrease in NPM-ALK levels appears to be more pronounced in the nucleus. Lamin A/C and
β-actin were used as nuclear and cytoplasmic loading controls, respectively.
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Downregulation of the SUMOylation pathway decreases cell proliferation, viability, and
colony formation potential in NPM-ALK+ ALCL cells, and enhances the ubiquitination of
NPM-ALK: To test the biological impact of overexpressing SENP1, we transfected DEL,
SR-786, and SU-DHL-1 (3 cell lines showing low expression levels of endogenous SENP1),
with either empty vector or SENP1 full-length expression plasmid for 48 h. SENP1
significantly decreased cell viability, cell proliferation, and colony formation potential of
lymphoma cells (Figure 32A, 32B, 32C). In addition, SENP1 increased the covalent
modification of ubiquitin on NPM-ALK, suggesting that deSUMOylation by SENP1
switches target proteins to the ubiquitination pathway (Figure 32D).
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FIGURE 32. SENP1 decreases cell viability, proliferation, and colony formation
potential in NPM-ALK+ ALCL cells. (A) Transfection of DEL, SR-786, and SU-DHL-1
cells with EV or the SENP1 protease expression plasmid in resulted in a significant decrease
in their viability after 48 h. (B) In addition, SENP1 decreased significantly the proliferation
of these cells, and (C) decreased their colony formation potential. Numbers of colonies are
shown on the left and representative images are shown on the right (*: p<0.05; **: p<0.001).
(D) SENP1 decreased NPM-ALK expression, which was simultaneously associated with
increased binding between ubiquitin and NPM-ALK, suggesting that deSUMOylation directs
NPM-ALK to the ubiquitination pathway.
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FIGURE 33. Schematic model illustrating the SUMOylation of NPM-ALK. We have
identified that SUMOylation plays an important role in stabilizing NPM-ALK protein. NPMALK is able to form heterodimers with wild type NPM, which facilitates shuttling of NPMALK between the cytoplasm and nucleus. Left panel; SUMOylation of NPM-ALK at Lys24/32
results in its stabilization in the nucleus, which leads to efficient shuttling of NPM-ALK into
the cytoplasm. Right panel; in the presence of deSUMOylating protease SENP1, the SUMO
modifier is removed from the NPM-ALK heterodimer in the nucleus which allows the
binding of ubiquitin, which mediates its degradation via 26s proteasome, as has been
previously demonstrated [247]. Degradation of the NPM-ALK heterodimer in the nucleus
decreases its nuclear accumulation and subsequently reduces its translocation and expression
in the cytoplasmic compartment.
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3.5.3. Aberrant Posttranslational Mechanisms: IGF-I
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3.5.3.1. Materials and Methods
Cell lines – Three NPM-ALK+ ALCL cell lines were used in this study: DEL, SUP-M2, and
SR-786. The cell lines were maintained in RPMI 1640 medium (HyClone, South Logan,
Utah) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin
(100 U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber.
Transfection – Transfection of the cells with scrambled or NPM-ALK siRNA (Dharmacon)
was performed by electroporation using Amaxa 4D nucleofection system in 100 µL cuvettes
(Lonza; Solution SF, Program CA-150) and, thereafter, cells were incubated for 48 h.
Western blotting – Western blotting was used to analyze the expression of IGF-I and NPMALK proteins. Cells were collected and lysed using lysis buffer containing 25 mM HEPES
(pH 7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM PMSF,
2 mM DTT, phosphatase inhibitor (20 mM B-GP, 1 mM Na3VO4, Roche), and protease
inhibitor cocktails (10 μg/ml leupeptine, 2 μg/ml pepstatin, 50 μg/ml antipain, 1x
benzamidine, 2 μg/ml chymostatin; Roche). Concentrations were measured using Bio-Rad
protein assay and OD values were obtained using an ELISA plate reader (Bio-Tek
Instruments, Winooski, VT). Proteins (50 μg) were electrophoresed on 8% SDS-PAGE. The
proteins were transferred to PVDF membranes and probed with specific primary antibodies
and then with appropriate horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz; and GE Healthcare, Cardiff, UK). Proteins were detected using chemiluminescencebased kit (Amersham Life Sciences, Arlington Heights, IL).
Antibodies – Antibodies used were ALK (M719501-2; Dako, Carpinteria, CA); IGF-I (05172; Millipore, Billerica, MA); and β-actin (A-5316; Sigma).
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ELISA – To measure the levels of IGF-I secreted in cell culture supernatant, a standard
ELISA-based approach was used. Briefly, cells were transfected with scrambled or ALK
siRNA for 48 h. Thereafter, cells were switched to serum free media for 24 h. The medium
was then collected and concentrated using Amicon Ultra-15 centrifugal tubes (UFC900308;
Millipore). ELISA assay was performed using the IGF-I cytokine kit (R&D Systems).
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3.5.3.2. Results
NPM-ALK does not affect the levels of expression of IGF-IR or IGF-I: Previous studies in
our lab demonstrated that the levels of IGF-IR as well as endogenous IGF-I and secreted
IGF-I were increased in NPM-ALK+ ALCL [128] (Figure 34). To explore whether NPMALK plays a role in the increased levels of expression of IGF-IR and IGF-I, we transfected
SR-786, DEL, and SU-DHL-1 cells with ALK siRNA for extended periods of time. Although
siRNA effectively decreased NPM-ALK levels, the levels of IGF-IR protein (Figure 35A)
and mRNA (Figure 35B) remained unchanged. In addition, decreased levels of NPM-ALK
by siRNA were not associated with decreased levels of endogenous pro-IGF-I or IGF-I
proteins (Figure 35A) or levels of secreted IGF-I (Figure 35C).
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FIGURE 34. Expression of IGF-I in NPM-ALK+ ALCL cell lines. (A) Western blotting
shows overexpression of endogenous IGF-I in 4/5 NPM-ALK+ ALCL cell lines. EJM
(plasma cell myeloma) and RSC96 (Schwann cells) cell lines were used as positive and
negative controls, respectively. (B) RT-PCR shows the presence of IGF-I mRNA in SUPM2, SR-786, DEL (low level), and EJM, and its absence in Karpas 299, SU-DHL-1, and
RSC96. (C) SUP-M2, SR-786, and DEL cell lines demonstrate the presence of secreted IGFI in cell culture supernatants. The EJM cell line was included because it expresses IGF-I
protein and mRNA. IGF-I is almost undetectable in cell culture supernatants from Karpas
299 and RSC96 cells. The experiment was repeated 3 times, and the results shown are the
mean ± SD. P<0.01 for SUP-M2, SR-786, and DEL compared with other cell lines. Adapted
by direct permission from BLOOD (Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak
LW, Ford RJ, Amin HM. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to
induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood. 2009 Jul
9;114(2):360-70.), copyright 2009.
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FIGURE 35. NPM-ALK does not affect the levels of expression of IGF-IR and IGF-I.
(A) Western blotting shows that at 48 h, downregulation of NPM-ALK by ALK siRNA was
not associated with decreased expression of IGF-IR, pro-IGF-I or IGF-I proteins in SUP-M2,
SR-786, and DEL cell lines. Analysis of IGF-IR levels after transfection of the cells with
ALK siRNA was performed at extended time points (12, 24, 48, 72, and 96 h), and also in
other cell lines including Karpas 299 and SU-DHL-1, with similar results (data not shown).
β-Actin shows equal protein loading. (B) Downregulation of NPM-ALK in the 3 cell lines
did not decrease the levels of IGF-IR mRNA. The example shown is at 48 h after transfection
of the cells with ALK siRNA. The results are shown as means ± SE of 4 consistent
experiments. In addition, analysis of IGF-IR mRNA was performed at other time points and
cell lines as described in Fig. 6A. Changes in IGF-IR mRNA levels were not detected at any
time point (data not shown). (C) An ELISA assay showing that specific downregulation of
NPM-ALK did not decrease the levels of secreted IGF-I in the 3 NPM-ALK+ ALCL cell
lines SUP-M2, SR-786, and DEL. The results represent means ± SE of 3 experiments.
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3.6. Discussion for Aim 3
In this aim we show that posttranslational defects exist and contribute to the pathogenesis of
NPM-ALK+ ALCL. Firstly, we found that there was an overall upregulation of SUMO
proteins expression in 5 NPM-ALK+ ALCL cell lines as well as in ALK+ ALCL patients’
specimens compared to normal human T lymphocytes. Specifically, the expression of
SUMO-2/3 was increased in the lymphoma cell lines and patients’ tumor samples. In
addition, the expression of SUMO-1 was increased in majority of cell lines and patients’
tumors. In contrast, expression of the SUMOylation inhibitor SENP1 was decreased in the
cell lines and patients’ tumors than the T lymphocytes. We also showed that NPM-ALK is
SUMOylated via covalent modification by SUMO proteins, which protects it from
degradation. In support of this idea, inhibition of SUMOylation through restoration of the
deSUMOylating SENP1 protease decreased SUMO protein expression, and induced a
substantial decrease in NPM-ALK protein expression in the cytoplasm and nucleus. Our data
provide strong evidence that SUMOylation contributes to the stability of NPM-ALK protein
in NPM-ALK+ ALCL. Downregulation of SUMOylation by SENP1 resulted in decreased
viability, proliferation, and colony formation potential of the lymphoma cells, suggesting that
disruption of the SUMOylation pathway induces tumor-suppressing effects in this type of
cancer. Secondly, we found that NPM-ALK does not regulate the expression of IGF-I and
IGF-IR proteins. IGF-I is the main ligand for IGF-IR and causes posttranslational
modifications of IGF-IR thorough phosphorylation and subsequent activation.
SUMOylation is a dynamic process that induces major impact on target proteins
including changing their stability, localization, and activity. Whereas SUMOylation is
important for physiological processes, it is deregulated in cancer cells [248]. In line with this
possibility, our data showed that the SUMO proteins were aberrantly overexpressed and
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SENP1 protease was decreased in NPM-ALK+ ALCL compared to normal T lymphocytes. It
has been established that an important outcome of SUMOylation is the maintenance of
protein stability by protecting targets from proteosomal degradation [237, 249-254]. We were
able to identify K24 and K32 within the NPM domain as targets for SUMOylation in NPMALK oncogenic protein. Indeed, all SUMO modifiers were capable of modifying NPM-ALK
at these lysine residues. Mutations induced at K24 and K32 in the SUMO consensus motifs
of NPM-ALK prevented SUMO-1 and SUMO-3 from modifying NPM-ALK as well as
resulted in significant degradation of NPM-ALK protein, testifying to the stabilizing effect of
SUMOylation on NPM-ALK. Moreover, both SUMO-1 and SUMO-3 were required to
induce substantial degradation, in contrast to the level of degradation achieved individually
by these modifiers. This observation suggests that this dual mutation that prevents both
SUMO modifiers from modifying NPM-ALK is required for NPM-ALK to undergo
degradation. Also, the finding that NPM-ALK double mutant was not degraded entirely
because NPM-ALK double mutant maintained its ability to bind with SUMO-2. Therefore,
we cannot completely exclude that other SUMO binding motifs may encompass potential
binding sites for other SUMO modifiers, such as SUMO-2, which also conveys protection of
NPM-ALK from degradation.
We elected to study SENP1 because of its ability to deSUMOylate all 3 SUMO modifiers,
unlike other SENPs that have preferential deSUMOylation activities [255-257]. SENPs have
2 primary functions: 1) the conversion of SUMO precursors to mature SUMO via removal of
a portion of the C-terminus; and 2) the removal of SUMO from target proteins. These SENPcontrolled processes contribute to the dynamic nature of SUMOylation. In fact, using
immunofluorescence staining we found that SENP1 moves from the nucleus to cytoplasm in
only 15 min. This is in line with previous studies which showed the very short time required
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by SENP1 to shuttle between the nucleus and cytoplasm, and how this mechanism allows
SENP1 to elicit different functions in multiple compartments within the cell [245, 246, 258260]. It has been shown that amino acid residues located at positions 171-177, within the Nterminal region of SENP1, are essential for SENP1 nuclear targeting. This was directly
demonstrated through substitution experiments in which the basic residues within this short
motif hindered significantly SENP1 nuclear accumulation and restricted its expression in the
cytoplasm. Although this motif is does not fit the classical consensus NLS sequence, these
results provided evidence that this region can be classified as a nonconesus NLS and more
importantly, is required for SENP1 nuclear import as well as modulating SENP1 activity
[260]. Reestablishment of SENP1 in NPM-ALK+ ALCL cells resulted in increased
deSUMOylation activity, which was associated with decreased expression of the SUMO
proteins and NPM-ALK protein levels. As a result, downregulation of the SUMOylation
pathway by SENP1 decreased cell viability, proliferation, and colony formation.
NPM is inherently capable of moving between the nucleus and cytoplasm [50]. The
nuclear localization signal (NLS) of NPM is present within its C-terminus [17]. Nonetheless,
the NPM segment that associates with ALK to form the NPM-ALK chimera is derived from
the more proximal N-terminus that lacks the NLS, explaining why NPM-ALK lacks the
ability to move to the nucleus [50]. However, nuclear translocation of NPM-ALK still occurs
primarily because of the formation of heterodimers between wild type NPM and NPM-ALK.
Our experiments showed that the expression of NPM-ALK in the nucleus, as well as
cytoplasm, was significantly reduced after SENP1 transfection. This may be explained by: 1)
SENP1 activity increased in the nucleus upon transfection with SENP1 plasmid, allowing for
deSUMOylation to simultaneously increase in the nucleus leading to NPM-ALK
destabilization; and 2) SENP1-mediated degradation of NPM-ALK heterodimers in the
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nucleus makes them less available for nuclear export into the cytoplasm. Our results suggest
a model in which SUMOylation provides stabilization of NPM-ALK protein, which appears
to further sustain NPM-ALK expression and accumulation in the nucleus and cytoplasm.
SUMOylation can lead to alteration of protein surfaces, which greatly affects interactions
of the target protein with other molecules that can also indirectly influence the target’s
stability. For instance, it has been shown that SUMOylation can promote protein-protein
interactions [261-265]; however, in many cases, SUMOylation leads to protein-protein
interaction interference [266-268]. For instance, SUMOylated E2-25K prevents interaction
with the ubiquitin E1 activating enzyme [268]. Similarly, there have been studies indicating
that disruption of SUMOylation reveals ubiquitin-acceptor lysine residues located elsewhere
in the protein, whose subsequent ubiquitination will promote protein degradation [250, 251,
269]. In NPM-ALK+ ALCL cells, deSUMOylation of NPM-ALK by SENP1 led to an
increase in the association of ubiquitin and NPM-ALK, suggesting that SUMOylation may
be able to prevent NPM-ALK from entering the proteosomal degradation pathway. NPMALK has been previously shown to be ubiquitinated through hsp70-mediated proteosomal
degradation, although a specific lysine residue for ubiquitination has not been identified
[247]. Our data suggest that transfection of SENP1 resulted in the removal of the SUMO
modifiers, which unmasked lysine residues in NPM-ALK and made them available for
modification by ubiquitin for proteosomal degradation. To this end, there is no direct
evidence that ubiquitin binds to and modifies K24 and K32 that we identified as sites of
modification by SUMO proteins, however, we cannot completely rule out that at least one of
these residues possess ability to modified by ubiquitin. Indeed, entering the amino acid
sequence

in

a

web-based

ubiquitination

prediction

search

algorithm

(UbPred;

www.ubpred.org) revealed that NPM-ALK contains potential ubiquitination site at K32
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(intermediate statistical confidence of p=0.71). Importantly, we have provided evidence that
ubiquitin and NPM-ALK are physically associated after SENP1 transfection, and it is likely
that deSUMOyaltion triggers the ubiquitination pathway.
It has been previously shown that IGF-IR undergoes ligand-dependent SUMOylation,
which appears to be a prerequisite for its nuclear translocation [238, 270]. It has also been
shown that this nuclear translocation requires the phosphorylation of IGF-IR [271]. In our
lymphoma cells, IGF-I stimulation induced nuclear expression of pIGF-IR (Figure S7). We
also determined that IGF-IR is capable of interacting with SUMO proteins in NPM-ALK+
ALCL cells (Figure S8), and that transfection of SENP1 leads to decreased expression of
IGF-IR in the cytoplasm as well as decreased pIGF-IR nuclear expression (Figure S9). We
have recently demonstrated that the physical association between NPM-ALK and IGF-IR
proteins enhances the stability of NPM-ALK [127]. In support of this idea, specific targeting
of IGF-IR by siRNA significantly decreased NPM-ALK protein levels, attesting to the
contribution of IGF-IR to maintaining NPM-ALK protein stability [127]. In contrast, NPMALK has no effect on IGF-IR protein stability (Figure 35 in section 3.5.3.2.). Therefore, it
can be postulated that deSUMOylation of IGF-IR by SENP1 perhaps causes interference of
its association with NPM-ALK, which would lead to NPM-ALK protein instability.
However, futher studies need to be performed to establish such a claim. Jointly, these
alternative mechanisms also provide novel evidence in which SUMOylation contributes to
NPM-ALK protein stability.
It was previously demonstrated that chimeric oncogenes such as the Ewing sarcoma
oncogenic fusion proteins induce the expression of IGF-I, the primary ligand of IGF-IR,
which enhances the phosphorylation/activation of IGF-IR though dimerization [68]. In this
aim, we tested whether NPM-ALK induces effects similar to Ewing sarcoma fusion proteins
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on IGF-I levels. Specific abrogation of NPM-ALK by siRNA failed to reduce pro-IGF-I or
IGF-I protein levels, which suggests that NPM-ALK lacks ability to upregulate IGF-I
expression, and therefore does not possess a posttranslational effect on IGF-IR, at least from
this aspect.
In this aim, we identified for the first time that SUMOylation contributes to maintaining
NPM-ALK protein stability, and hinders its proteosomal degradation. In contrast, SENP1mediated disruption of SUMOylation causes degradation of NPM-ALK, which thereby
reduces the oncogenic potential of this oncogenic protein. At the other hand, we found that
NPM-ALK does not regulate IGF-I-mediated posttranslational modulation of IGF-IR.
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3.6.1. Supplemental
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FIGURE S7. IGF-IR is SUMOylated. IGF-IR was immunoprecipitated in Karpas 299 and
SR-786 cells, and expression of SUMO proteins was evaluated by Western blotting. These
studies revealed SUMO-1 and SUMO-2/3 are associated with IGF-IR, as indicated by bands
present in lane 1 (IGF-IR immunoprecipitation) and not in lanes 2 and 3, where mouse IgG
was immunoprecipitated or beads alone, respectively.
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FIGURE S8. IGF-IR and pIGF-IR are expressed in the cytoplasm, whereas pIGF-IR is
expressed in the cytoplasm and nucleus after IGF-I stimulation. Cell fractionation
experiments in Karpas 299 and SR-786 cells reveals expression of IGF-IR protein in the
cytoplasm, with no expression in the nucleus with or without IGF-I stimulation. In contrast,
pIGF-IR is predominantly located in the cytoplasm under non-stimulated conditions. After
IGF-I stimulation, however, pIGF-IR is expressed in the cytoplasm and nucleus. In addition,
SUMO proteins predominantly showed nuclear expression. Lamin A/C and β-actin were used
as nuclear and cytoplasmic loading controls, respectively.
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FIGURE S9. SENP1 decreases IGF-IR nuclear and cytoplasmic expression. Transfection
of empty vector or SENP1 expression plasmid in Karpas 299 and SR-786 cells decreased the
expression of SUMO proteins after 48 h. Subsequently, IGF-IR and pIGF-IR expression
decreased in the cytoplasm. In addition, pIGF-IR expression decreased significantly in the
nucleus as well. Lamin A/C and β-actin were used as nuclear and cytoplasmic loading
controls, respectively.
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Conclusions
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In this work, we identified novel dregulated mechanisms that determine the pathogenic
expression of IGF-IR and NPM-ALK, two potent oncogenic proteins that play important
roles in the survival of NPM-ALK+ ALCL; an aggressive type of cancer that predominantly
affects children and young adults.
At the transcriptional level, we found that two transcription factors, namely Ik-1 and
MZF1, are markedly decreased in NPM-ALK+ ALCL cell lines and patients lymphoma
tissues. Importantly, we provided evidence that Ik-1 and MZF1 negatively regulate the IGFIR gene promoter, which leads to a significant decrease in the expression of IGF-IR mRNA
and protein. We also used FISH analysis and found no evidence to support amplification of
the IGF-IR gene in this lymphoma. It is important to note that although we performed FISH
analysis in 5 established NPM-ALK+ ALCL cell lines and obtained consistent findings, it
cannot be ruled out that if a large cohort of patient samples were analyzed, rare cases with
IGF-IR gene amplification might have been discovered.
At the posttranscriptional level, we found that the time required for the decay of IGF-IR
mRNA is significantly longer in the NPM-ALK+ ALCL cell lines than normal human T
lymphocytes, which supports the idea that more IGF-IR mRNA transcripts are available for
translation into IGF-IR protein, resulting in the overexpression of IGF-IR in this lymphoma.
Also at the posttranscriptional levels, we showed that miR-30a and miR-30d are substantially
decreased in NPM-ALK+ ALCL cell lines and human lymphoma tissues. Importantly, we
demonstrated that miR-30a and miR-30d are capable of binding and inhibiting the IGF-IR3’UTR to decrease IGF-IR protein expression.
At the posttranslational level, we identified for the first time that SUMOylation, a
posttranslational modification mechanism, is deregulated in NPM-ALK+ ALCL. In this
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regard, SUMOylation appears to sustain the stability of NPM-ALK protein and facilitates its
nuclear and cytoplasmic accumulation. Although it has been demonstrated in other types of
cancer, herein our data support that SUMOylation sustains IGF-IR protein stability also in
NPM-ALK+ ALCL. On the other hand, there was no evidence to support that NPM-ALK is
involved in the regulation of IGF-I expression, and hence doesn’t impact IGF-I-mediated
phosphorylation/activation of IGF-IR.
Intriguingly, our data support that increased expression of IGF-IR protein and decreased
expression of miR-30a and miR-30d appear not to be directly resulting from the expression
of NPM-ALK. Although NPM-ALK has significant oncogenic potential and its expression is
considered the mainstay feature in NPM-ALK+ ALCL, most likely NPM-ALK is not the only
factor that governs the clinicopathological and the immunophenotypic features of NPMALK+ ALCL as known in human patients. Evidence suggests the oncogenic effects of NPMALK stem from its ability to collaborate with other survival-promoting proteins within the
lymphoma cells. Although the lymphomagenic potential of NPM-ALK has been
demonstrated in chimeric as well as transgenic (Tg) mice models, mice typically developed
significant B-cell lymphoma and plasma cell tumors with a smaller proportion developing Tcell neoplasms. [272]. For instance, it has been shown that in an NPM-ALK Tg mouse model
under the control of a murine CD4 promoter, mice developed lymphoma tumors of B-cell
origin [56]. In addition, the lymphoma tumors found in some these mice were exclusively
plasmablastic [56]. In another model, NPM-ALK transgenic mice under the control of the
Vav-promoter also gave rise almost exclusively to tumors of a B-cell origin [273]. This is
particularly interesting because the Vav-promoter is directly involved in the development and
expression of all the types of hematopoietic lineages. Furthermore, in a transgenic mouse
model in which NPM-ALK was under the control of the lck promoter, the developed tumors
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were of immature T lymphoblastic type [274]. While the lck promoter model is more suitable
for studying T-cell lineage tumors (lck promoter is active in T cells), the authors concluded
that this animal model does not reflect the classic human NPM-ALK+ ALCL development.
Lastly, in a chimeric animal model, irradiated mice transplanted with bone marrow cells
infected with a retroviral construct, pSRαMSVtkneo–NPM-ALK that contains the
human NPM-ALK cDNA, developed lymphomas that were composed of immunoblast-like Bcells [53]. Collectively, these observations indicate that NPM-ALK may be inclined to
transform B-cell lineages in mice, in contrast to tumors of T-cell origin such as those of
human NPM-ALK+ ALCL [275]. More importantly, these data are inline with our results that
failed to show that NPM-ALK, despite being a very important survival molecule in NPMALK+ T-cell lymphoma, does not necessarily regulate all factors contributing to the survival
of these cells, e.g., the increase in IGF-IR or the decrease in miR-30a/miR-30d expressions.
The evidence provided by the animal studies supporting how NPM-ALK is very
important for development of lymphoma tumors yet, these tumors are not necessarily similar
to NPM-ALK+ ALCL in humans further strengthens the argument that the multilevel
deregulation identified in our experiments carry important potential in the pathogenesis of
this aggressive disease. However, there are limitations to in vitro studies including that this
experimental system lacks essential components that affect the cells under physiological
conditions such as the microenvironment that includes surrounding stromal tissue and blood
vessels. These elements are not found in a purely in vitro system, and can influence the
outcome of the result. In vivo experiments, although more closely related to human
conditions,

also

have

their limitations. While animal

models

do

contain

the

microenvironment, they do not represent human conditions exactly. Differences in species,
even subtly, can produce different outcomes. Therefore, perhaps the ideal way to examine if
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truly a specific oncogenic mechanism is deregulated is by directly analyzing this mechanism
in a large cohort of patients with correlation to clinicopathological features and response to
therapy and survival data. In our study, we analyzed the expression of Ik-1, MZF1, miR-30,
and SUMO proteins in relatively small patient populations. Although such analysis supports
that these aberrancies indeed exist in patients, more extensive analysis in a larger cohort of
patients is expected to help to provide concrete conclusions.
It has been shown that NPM-ALK interacts with several molecules known to regulate
cellular survival. In preliminary studies conducted in our lab, we found that NPM-ALK
interacts with IGF-IR to maintain the latter’s phosphorylation status. Reciprocally, our data
suggested that IGF-IR not only maintains NPM-ALK phosphorylation, but also sustains its
stability. In the current study, we have further demonstrated using several experimental
approaches

in

which

modifications

of

transcriptional,

posttranscriptional,

and

posttranslational pathways resulted in abrogation of IGF-IR signaling system was associated
with a remarkable decrease in NPM-ALK protein expression attesting that IGF-IR sustains
the stability of NPM-ALK. At least from these data, IGF-IR could represent a unique
oncogenic entity in this lymphoma.
The aberrant expression/function of key molecules at each regulatory stage, beginning at
the “gene level” and ending at the “protein level”, allows IGF-IR to escape tight regulatory
systems in this lymphoma; in contrast to normal human T lymphocytes, in which these
systems keep IGF-IR expression at low physiologic levels. This observation further
emphasizes the contributions of every single system. It also suggests that the failure of one
mechanism to maintain overexpression of IGF-IR might result in alternative pathways that
rescue IGF-IR expression and maintain it at very high levels for it to continue to elicit
oncogenic effects. Targeting IGF-IR not only provides opportunities to decrease the
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oncogenic effects mediated by IGF-IR alone, but could also affect significantly the
oncogenic potential of NPM-ALK due to IGF-IR’s regulatory effects on the stability of the
fusion protein. Exploring how these individual mechanisms are themselves deregulated could
be an important direction for future studies (Figure 36).
Our model supports the multifaceted nature of NPM-ALK+ lymphoma, and that
disturbances in more than one regulatory mechanism exist, which reflects the complex
survival network in these lymphoma cells in particular as well as in cancer cells in general.
Even though this lymphoma is driven by a major oncogene such as NPM-ALK, our data
strongly suggest that the regulation of the expression of IGF-I/IGF-IR molecules is largely
independent from NPM-ALK. Despite the fact that this lymphoma, similar to few other types
of cancer, is driven by a major oncogene, numerous epithelial, mesenchymal, neural, and
hematological cancers are instead driven by several oncogenic molecules that work in
harmony to promote cell survival. Notably, upregulation of IGF-IR is a common feature
among the majority of these tumors. Thus, the findings in our lymphoma model could be
applied to other types of cancer. In support of this idea, our data show that miR-30a and miR30d can negatively regulate IGF-IR posttranscriptionally; not only in NPM-ALK+ ALCL but
also in breast and colon cancers as well. Our study also demonstrates that upregulation of
IGF-IR gene expression results from aberrancies in transcriptional regulatory mechanisms,
namely Ik-1 and MZF1 transcription factors, resembling what was found before with other
transcription factors that regulate IGF-IR in epithelial and mesenchymal tumors. In a similar
fashion, our data support that aberrant SUMOylation of IGF-IR occurs in NPM-ALK+
ALCL, and these findings are in line with previously established findings in other types of
cancer where SUMOylation of IGF-IR plays important roles in their pathogenesis.
Furthermore, our current study supports that SUMOylation plays an additional important role
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via maintaining the stability of NPM-ALK. These observations highlight that although
different types of cancer exhibit remarkably heterogeneous clinical and pathological features,
certain molecular characteristics are still common among them.
Overall, we provide novel evidence that multilevel deregulation of survival mechanisms
contributes to the pathogenesis of NPM-ALK+ ALCL. We hope that our findings will further
current knowledge of the pathobiology of NPM-ALK+ ALCL and provide a framework for
the tailoring of novel therapeutic strategies to eradicate this lymphoma.
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FIGURE 36. Mechanisms contributing to deregulated survival mechanisms in NPMALK+ ALCL. Ik-1 and MZF1 expression levels are significantly decreased, preventing them
from transcriptionally inhibiting IGF-IR gene expression and allowing IGF-IR mRNA to be
transcribed. MiR-30a and miR-30d are markedly decreased in NPM-ALK+ ALCL. Lack of
suppression of the IGF-IR-3’UTR by these miRs allows IGF-IR protein to stabilize.
Furthermore, slower decay of IGF-IR mRNA increases its bioavailability for protein
translation. Fully translated IGF-IR is further stabilized by the posttranslational modification
SUMOylation. SUMOylated IGF-IR can indirectly stabilize NPM-ALK, which is itself is
capable of being SUMOylated. How these mechanisms are regulated (indicated by “?”) is a
direction of future study.
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Future Directions
Apart from the future studies mentioned in the individual discussion sections, identifying
whether each of our identified mechanisms have regulatory effects on each other as well as
determining how these aberrant mechanisms are deregulated would be worth pursuing, as
illustrated in Figure 36. Some of the important mechanisms that require further analysis
include:
1. Determining whether NPM-ALK contributes to the decreased expression levels of Ik-1
and MZF1 in these lymphoma cells. Preliminary experiment: Transfect NPM-ALK+
ALCL cells with scrambled siRNA or ALK siRNA, and check Ik-1 and MZF1 expression
levels by qPCR and Western blotting.
2. Identifying the host genes of miR-30a and miR-30d may lead to better understanding of
how these microRNAs are deregulated, not only in NPM-ALK+ ALCL but also in any
other type of cancer. It is possible that Ik-1 and MZF1 help support the transcription of
miR-30 by regulating its host gene. Preliminary experiment: Identify miR-30 genes. In
addition, overexpression of Ik-1 and MZF1 in NPM-ALK+ ALCL cells by transfection,
and measure miR-30 expression levels by qPCR.
3. It has been previously shown that miR-30 directly targets the SUMO conjugating enzyme
Ubc9, and that restoration of a previously decreased miR-30 expression level inhibits
Ubc9 expression. Exploring whether the aberrantly decreased expression of miR-30 in
NPM-ALK+ ALCL cells contributes to upregulation of SUMOylation would also support
IGF-IR and NPM-ALK protein stability. Preliminary experiment: Overexpress miR-30a
and miR-30d in NPM-ALK+ ALCL cells, and measure Ubc9 and SUMO expression by
qPCR and Western blotting.
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